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High mortality rates of bacterial pneumonia and increased antibiotic resistance are major reasons 
to develop novel vaccine strategies against Streptococcus pneumoniae. S. pneumoniae serotype 3 
(ST3) is one of the most frequent serotypes isolated from patients with invasive pneumococcal 
diseases, even though it is included in the routine immunization schedule. To improve 
immunogenic properties of ST3, synthetic antigenic tetrasaccharide based on capsular 
polysaccharide repeating units have been conjugated to a carrier protein and used as a vaccine 
candidate. The study illustrates the principle of proper optimization of variable aspects of 
vaccine formulation, such as dosage, adjuvant, and carrier protein. 
Use of highly pure and well-characterized synthetic oligosaccharide allowed to significantly 
decreased the dosage of antigen while maintaining sufficient protection shown by in-vitro 
opsonoph gocytic killing  ss y. In  efi nce of the gener l notion “the more, the better”, the 
higher dose did not improve the protective effect of immunization but could even diminish the 
final success of the vaccination. 
In order to improve the immunogenicity of semi-synthetic ST3-glycoconjugates, several 
commercially available adjuvants were used and incorporated into biodegradable poly-lactic-acid 
(PLA) microparticles. Screening experiments in mice yielded promising results for agonists of 
TLR7/8, namely resimiquimod (R848) and bacterial RNA, as well as MPLA, a TRIF-biased 
TLR4 agonist used in several commercial vaccines. 
The carrier protein derived from S.pneumoanie c n serve  s “ ouble-action bullet”, being both   
carrier essential for glycan presentation and an additional vaccine antigen providing broader 
protection, so-called "additional valency". Hence, ST3-tetrasaccharide was conjugated to 
pneumolysin and PspA protein and vaccine was evaluated in-vivo in the mouse and swine model. 
The mouse study showed that ST3-tetrasaccharide pneumolysin conjugates decrease the bacteria 
load in blood and lungs as well as reduce the disease severity in mice challenged with 
S.pneumoniae serotype 3. Additionally, the synthetic oligosaccharide conjugated to pneumolysin 
and PspA inhibited colonization of the nasopharynx after infection with bacteria. The 
immunization of piglets provides the first evidence for the immunogenicity of the synthetic 
glycoconjugate vaccine in a swine model. The generated antibodies were able to kill 
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pneumococci and neutralize the toxic effect of pneumolysin in-vitro. However, the protective 
activity of the glycoconjugate vaccines in the swine in-vivo infection model has to be further 
investigated. 
The study presented in the thesis combined a series of innovations, which enhance the efficacy 
and applicability of glycoconjugate vaccines and help to further clarify the principles of anti-






Hohe Sterblichkeitsr ten bei b kteriellen Lungenentzün ungen un  eine erhöhte 
 ntibiotik resistenz sin  wichtige Grün e für  ie Entwicklung neuer Impfstr tegien gegen 
Streptococcus pneumoniae. S. pneumoni e Serotyp 3 (ST3) ist einer  er häufigsten Serotypen, 
die bei Patienten mit invasiven Pneumokokkenerkrankungen isoliert wurden, obwohl er in den 
routinemäßigen Impfpl n  ufgenommen wur e. Um  ie immunogenen Eigensch ften von ST3 
zu verbessern, wurden synthetische antigene Tetrasaccharide, die auf sich wiederholenden 
Polysaccharid-K pseleinheiten b sieren,  n ein Trägerprotein konjugiert un   ls 
Impfstoffkandidat verwendet. Die Studie veranschaulicht das Prinzip der richtigen Optimierung 
verschiedener Aspekte der Impfstoffformulierung, wie Dosierung,   juv ns un  Trägerprotein. 
Die Verwendung von einem hochreinen und gut charakterisierten synthetischen Oligosaccharid 
ermöglichte eine signifik nte Verringerung  er  ntigen osis unter  ufrechterh ltung eines 
ausreichenden Schutzes, belegt durch einen in-vitro-Opsonoph gozytentötungstest. Entgegen 
 em Sprichtwort „Viel hilft viel“ verbesserte  ie höhere Dosis  ie Schutzwirkung  er 
Immunisierung nicht, son ern konnte  en en gültigen Erfolg  er Impfung sog r beeinträchtigen. 
Um  ie Immunogenität von h lbsynthetischen ST3-Glykokonjugaten zu verbessern, wurden 
mehrere im H n el erhältliche   juv ntien verwen et un  in biologisch  bb ub re 
Polymilchsäure (PL ) -Mikropartikel eingearbeitet. Screening-E perimente  n Mäusen erg ben 
vielversprechende Ergebnisse für TLR7/8- gonisten, nämlich Resimiquimo  (R848) un  
bakterielle RNA, sowie MPLA, einen TRIF-voreingenommenen TLR4-Agonisten, der in 
mehreren kommerziellen Impfstoffen verwendet wird. 
D s von S.pneumo nie  bgeleitete Trägerprotein k nn  ls "Mehrzweckwaffe" dienen, da es ein 
für  ie Glyk npräsent tion wesentlicher Träger, un  gleichzeitig  uch ein zusätzliches 
Impfstoff ntigen ist,   s einen breiteren Schutz,  uch "zusätzliche Wertigkeit" gen nnt, bietet. 
Folglich wurde ST3-Tetrasaccharid an Pneumolysin und PspA-Protein konjugiert und der 
Impfstoff in-vivo im Maus- und Schweine-Modell bewertet. Die Mausstudie zeigte, dass ST3-
Tetrasaccharid-Pneumolysin-Konjugate die Bakterienbelastung in Blut und Lunge reduzieren 
sowie  ie Schwere  er Erkr nkung bei Mäusen, die mit S. pneumoniae Serotyp 3 in Kontakt 
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gebr cht wur en, verringern. Zusätzlich inhibierte   s synthetische Oligos cch ri ,   s  n 
Pneumolysin und PspA konjugiert war, die Kolonisierung des Nasopharynx nach Infektion mit 
Bakterien. Die Immunisierung von Ferkeln liefert  en ersten N chweis für  ie Immunogenität 
des synthetischen Glykokonjugat-Impfstoffs in einem Schweinemodell. Die erzeugten 
 ntikörper konnten Pneumokokken  btöten un   ie to ische Wirkung von Pneumolysin in-vitro 
neutralisieren. Die Schutzwirkung der Glykokonjugat-Impfstoffe im In-vivo-Infektionsmodell 
für Schweine muss je och weiter untersucht wer en. 
Die in der Dissertation vorgestellte Studie kombinierte eine Reihe von Innovationen, die die 
Wirksamkeit und Anwendbarkeit von Glykokonjugat-Impfstoffen verbessern und zur weiteren 






1.1 Streptococcus pneumoniae  
S. pneumoniae is the leading source of life-threatening diseases like pneumonia, septicemia, and 
meningitis (1), as well as a major cause of death in children under five years old in developing 
countries (2-4). According to a UNICEF report from 2017, pneumonia globally kills 5.6 million 
children every year (16%). More than 95% of cases occur in emerging nations (5). In the US, 
pneumonia is less often fatal for children, but it is still the most common reason for them to be 
hospitalized. According to the American Thoracic Society debriefing, among American adults, 
pneumonia is the most common cause of hospital admissions other than women giving birth. 
About 1 million adults in the US seek care in a hospital due to pneumonia every year, and 50,000 
die from this disease (6). Pneumococcus is also the leading cause of bacterial meningitis in older 
adults, causing substantial morbidity and mortality (7). 
Although the clinical significance of community-acquired pneumonia (CAP) is very high, a 
clinical disease with the pneumococcus is rare compared to bacteria colonization. Up to 10% of 
the adolescent population, and more than 40% young infants, mainly those exposed in daycare 
settings, are colonized (8). Thus, in order to protect most individuals against clinical syndromes 
such as pneumonia and invasive pneumococcal disease, an effective immune response must 
already have been developed in them (9). 
S.pneumoniae enter the nasal cavity and attach to the nasopharyngeal epithelial cells. Bacteria 
may either stay as a colonizer or spread to other organs, such as the ears, sinuses, or via bronchi 
down to the lungs. The initiation of pneumonia requires bacteria to escape from mucous defenses 
by the interaction of bacterial components with the alveolar epithelium (inhibiting the 
mucociliary beat of respiratory cells and separating epithelial cell tight junctions). From the lung, 
it can penetrate the mucosal barrier to enter the bloodstream and cross the blood-brain barrier to 
cause meningitis. Lack of innate defenses in cerebrospinal fluid (CSF) allows bacteria to 
multiply easily. Pneumolysin and hydrogen peroxide, produced by bacteria cause the toxin-
mediated neuronal death. Pneumococcal infections spread from person to person via 




Figure 1. Pathogenic route for S. pneumoniae infection.  
Adapted from Bogaert et al., 2004 (8). 
 
At least 98 S. pneumoniae serotypes can be distinguished based on their CPS (11, 12). Currently 
available CPS-based pneumococcal vaccines contain the serotypes most frequently associated 
with invasive pneumococcal diseases (IPDs). Although the licensed 23-valent polysaccharide 
vaccine (Pneumovax 23
®





cover thirteen and ten serotypes respectively and are highly successful 
in all age groups (14). Nevertheless, the plasticity of the pneumococcal genome means that the 
pathogen has the potential to adapt to the selective pressure of vaccines (9). The serotype 
replacement due to vaccination and regional differences in dominant serotypes necessitate the 
expansion of existing vaccines to include additional serotypes. New strains, e.g., serotype 19A 




1.1.1 Biology of S. pneumoniae  and virulence factors 
Streptococcus pneumoniae is a gram-positive facultatively anaerobic organism. Its growth is 
enhanced in 5% carbon dioxide or anaerobic conditions. On blood agar, colonies  re α hemolytic 
and can be identified as lancet-shaped short chains diplococci. The specific pneumococcal types 
based on polysaccharide capsule can be identified using typing serum, microscopic examination, 
and molecular techniques (16). 
1.1.1.1 The capsular polysaccharide of S. pneumoniae  
S.pneumoniae has a capacity to produce a capsule, which is structurally distinct for each of the 
98 recognize serotypes and is the dominant surface structure of the organism. In 1881, Louis 
Pasteur observed that colony variants of a pneumococcal strain react with the serotype-specific 
protective ser , which w s  escribe   s  n “ ureole (h lo)”. The stu ies of pneumococc l culture 
supernatants containing materials reacting with serotyping sera revealed a polysaccharide (PS) 
nature of the capsule (17). Capsular polysaccharide (CPS) plays a critical role in virulence of  
S. pneumoniae and all fresh clinical isolates are encapsulated. CPS appears to act as a safeguard, 
preventing activation of the complement pathway and also an interaction between the pathogen 
and receptors on phagocytic cells. The spontaneous nonencapsulated (rough) derivatives of the 
bacteria are almost avirulent. Most pneumococcal capsules are anionic, except 7A, 7F, 14, 33F, 
33A, and 37 that are not charged. The negative charge helps to inhibit clearance by mucus and 
prevent phagocytes through electrostatic repulsion (16, 18). However, antibodies to CPS are 
highly protective and result in opsonization as well as rapid removal of the invading 
pneumococci by the host opsonophagocytic clearance mechanisms. 
The genes necessary for capsular synthesis are present in a cassette-like arrangement. Genes, 
named wzg, wzh, wzd, and wze (more commonly known as cpsA, cpsB, cpsC, and cpsD, 
respectively) are widely conserved. The cps loci are transcribed as a single operon. CPSs are 
generally synthesized by the Wzx/Wzy-dependent pathway. The locus begins with conserved, or 
“common,” genes whose pro ucts  re involve  in the regul tion of capsule: cpsA, cpsB, cpsC, 
and cpsD (Figure 2a). The cps locus encodes the enzymes to build the repeat units, including 
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glycosyl phosphate transferase, and additional transferases responsible for the formation of the 
linkages and addition of sugars, as well as a repeat-unit flippase and polymerase (19). 
CPSs are synthesized by transfer of an initial monosaccharide phosphate from a nucleotide 
diphosphate sugar to a membrane-associated lipid carrier and the sequential transfer of further 
monosaccharides to produce the lipid-linked repeating unit. The lipid-repeating unit is 
transferred to the outer face of the cytoplasmic membrane by the repeat-unit transporter or 
flippase, polymerized to form the mature CPS, and then attached to the peptidoglycan (Figure 
2b) (19).  
 
Figure 2. Genetic and biochemical bases of S.pneumoniae serotype 3 capsular synthesis.  
a) The serotype 3 cps locus b) Synthesis of serotype 3 PS by Cps3S synthase, which initiates a 
transfer of glucose (Glc) from UDP-glucose to a phosphatidylglycerol (PG) acceptor (1). 
Glucuronic acid (GlcUA) is transferred from UDP-GlcUA to the PG-linked Glc (2), and the 
capsule is extended to approximately an octa-saccharide (3). Cps3S translocates the PS chain to 
the outer face of the membrane (4) and increases chain length by a processive capsular synthesis 
mechanism (5). (Adapted from Geno K.A. et al., 2015) 
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The PSs of different serotypes are built of structurally varying repeating units, which include 
recognized saccharide residues, their order, and linkages. The repeating units contain from two 
to eight saccharides and are very often substituted with O-acetyl, phosphoglycerol, and pyruvyl 
acetal, and other groups. The substitutions are located at various sites with various degrees of 
substitution. (18). Monosaccharide composition can be determined with a gas-liquid 
chromatography, a mass spectrometry method, the size of repeating units can be solved. Modern 






P, and two-dimensional (2D) 
NMR) can reveal structural details of intact capsular PS with minimal degradation (20).  
1.1.2 Virulence factors of S. pneumoniae  
S.pnuemoniae virulence factors are classified based on different functions during in vivo 
infection: (a) surface adhesins (b) enzymes involved in the invasion of host tissues (invasins) and 
(c) enzymes destabilizing and suppressing the host defense. Most of the pneumococcal virulence 
factors are cell surface located proteins. They can either be the classical cell wall proteins or 
house-keeping cytosolic enzymes that are secreted and attached to the bacterial cell wall (21). 
Multiple virulence factors have been identified and considered for use as vaccine candidates, 
such as pneumolysin, neuraminidases, hyaluronidase, choline-binding proteins (e.g. autolysin, 
pneumococcal surface protein A (PspA) and choline-binding protein A (CbpA)), lipoprotein 
(pneumococcal surface antigen A (PsaA)) and the immune subverting factor Immunoglobulin A1 
(IgA1) protease. 
1.1.2.1.1 Pneumolysin 
Pneumolysin (Ply) is a 53 kDa protein that belongs to the family of cholesterol-dependent 
cytolysin (CDC). Ply is not actively secreted from the bacterium as it lacks a typical signal 
secretion leader sequence but escapes from the cell by either autolysis or the action of lytic 
antibiotics. However, there have been some reports of active secretion of the protein. Ply forms 
pores in the cell membrane by oligomerization and conformational change in the structure. The 
pores formed can be up to 350 Å in  i meter with e ch pore up to 50 Ply monomers. The 
formation of pores results in a cell membrane disintegration which helps the bacteria to spread in 
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a body as well as increase the host cells death and disease manifestation. Pneumolysin is a 
relatively conserved protein across all serotypes of S. pneumoniae. However, at least 16 different 
naturally-occurring variants of Ply are expressed in specific strains of serotypes 1, and 8 
pneumococci have been identified (22, 23).  
Pneumolysin is a multifunctional toxin with distinct activities such as: 
 Complement activation - Ply plays a central role in protecting the pneumococcus from 
complement attack and helps the spread of the bacteria to other tissues/organs. The 
secreted protein can activate the classical complement pathway, even in the absence of 
Ply specific antibody. This mechanism results in depletion of complement in the host and 
decreases inflammation (24). Patients with an active pneumococcal infection have 
reduced serum complement levels, while Ply-treated serum has reduced opsonic activity 
(25). 
 Lysis of red blood cells (hemolysis) – it was proved that Ply forms pores in the 
membrane of red blood cells and cause the hemoglobin release. The toxin  has lectin 
activity and binds glycans, including the Lewis histo-blood group antigens (26) 
 Production of immune regulatory molecules - Ply has highly pro-inflammatory properties 
and stimulates the production of cytokines including TNFα, IL-1, and IL-6. The 
production of these cytokines may play a role in pro-inflammatory disease as well as in 
the regulation of the immune response to pneumococcus (27).   
 Impact neutrophil activity and neutrophil extracellular traps formation (NETs) - it has 
been proven that Ply reduces the killing of pneumococci by neutrophils in vitro (28). 
Other studies showed the toxin induces vital NETosis in human neutrophils, which 
depends on the intensity of the inflammatory response during pneumococcal infection 
and may either contribute to host defense or worsen disease severity (29). 
 Helps to spread bacteria –  Ply breaks the tight epithelial junctions (by reducing stable 
and dynamic microtubule content and by modulating VE-cadherin expression), increases 
alveolar permeability and inflammation, thus allows bacteria spread in the blood 
(bacteremia). The toxin also damages the blood-brain barrier allowing for the bacteria to 
reach the brain and cause meningitis (30). 
 Influences cell-signaling, cytoskeletal rearrangement and induces DNA damage (31). 
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 Colonization of the host - studies using S.pneumoniae PLY-deficient mutants revealed 
decreased colonization of the nasopharynx, increased bacterial clearance from the lung 
and prolonged survival of animals following the infection (32).  
 Play a role in pneumonia pathogenesis by, causing the endothelial hyper-permeability 
(pulmonary permeability edema), a major complication of pneumonia (33).  
 
The evidence from animal infection studies points clearly to an integral role of pneumolysin in 
invasive pneumococcal diseases. Neutralization of the toxin seems to be a potentially valuable 
approach to treat pneumococcal diseases as well as an exciting vaccine candidate. 
1.1.2.1.2 Pneumococcal surface antigen A – PspA 
PsaA is a very well conserved 37-kDa lipoprotein composed of 309 amino acid residues directly 
attached to the lipid of the cytoplasmic membrane. The flexible nature of the PsaA structure 
enables its dual functions of metal ion transport and adhesion to the epithelial cells (34). PspA is 
composed of four different distinct regions (1) the C-terminal anchoring the protein to the 
pneumococcal surface, (2) a stretch of ten highly conserved 20-amino-acid repeats, (3) a proline-
rich region which acts as a tether and allows greater flexibility and movement of the amino-
terminus, and (4) a highly charged amino-terminus (23, 35). The amino-terminal end extends 
from the cell wall and sticks outside the capsule (36). Based on amino acid sequence ahead of 
the proline-rich region, PspA is classified into three families and six clades (Family 1, clades 1 
and 2; Family 2, clades 3, 4 and 5; and the rarely isolated Family 3, clade 6) (21). The interaction 
of PspA through helix 3 and helix 4 of the N-terminal domain with the iron-saturated lactoferrin 
helps bacteria to adhere on the surface of the host (35). A highly polar electrostatic charge of 
PspA increase the capsule charge stabilization and the predominant part of protein prevents C3-
mediated binding of the host complement to pneumococci by competing with the C-reactive 
protein (23, 37).  
The multifunctional immune evasive properties of PspA are essential for pneumococcal 
nasopharyngeal colonization and invasion of S.pneumoniae (38). Many studies show that PsaA
−
 
mutants of S. pneumoniae were significantly less virulent than the parent strains. This may be 
due to their impaired growth in an Mn
2+
 deficient environment, reduced capacity to adhere to 
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lung cells, or hypersensitivity to oxidative stress (34). Active immunization with PspA in animal 
models protects against the nasopharyngeal carriage and invasive disease. Intranasal 
immunization of mice with the cholera toxin B subunit-PsaA was shown to protect them against 
pneumococcal colonization without changing their healthy flora (39).  
PsaA is immunogenic and induces both the humoral (antibody production) and cellular 
(activation of phagocytes, cytotoxic T-lymphocytes, and the release of various cytokine) immune 
response. Asymptomatic or symptomatic pneumococcus carriage results in robust production of 
antibodies to PsaA and inhibits colonization and disease. The protein has a high potential to be 





Vaccines are one of the most successful medical advances in modern times and one of the 
greatest success stories within the health sector. The eradication of several life-threatening 
diseases, such as smallpox, whooping cough, mumps, and polio, has put vaccines on one of the 
highest pedestals in disease prevention (40, 41). Unfortunately, political instability, conflict and 
not a transparent strategy of pharma industries has posed a challenge for public trust in vaccines. 
(42). Vaccine hesitancy has been stated as one of the ten main issues that demand attention from 
WHO and health partners in 2019 (43). Another problem facing world health is antimicrobial 
resistance (AMR). Overuse or inappropriate consumption of antimicrobials in people and 
animals has led to the rapid development of AMR. It is estimated that AMR currently causes 
700,000 deaths annually. Use of vaccines can prevent antibiotic-resistant infections directly by 
reducing or eliminating the risk of infection. The secondary effect of vaccines decrease viral 
infections such as influenza and measles, concomitantly reduces the risk of secondary infections 
that are often a result of the use of antibiotics (44).  
1.2.1 History of vaccines 
Recognition of the pathogens (mostly viruses or bacteria) as a cause of the infectious disease was 
already made in 400 b.c by Hippocrates. He was the first to recognize infections such as mumps 
and diphtheria in neonates and children and combine the knowledge with the occurrence of 
deadly diseases. At that point, the disease could not be prevented but only treated by herbal 
medicine with a very high rate of mortality.  Many decades later, around the 12
th
 century, the 
first vaccine-like related procedures were described in China and India. Healthy people were 
inoculated with ground smallpox scabs by blowing them into the nostril or applying onto the 
scratched skin (45, 46). However, the title of “the father of vaccination and immunology” 
belongs to Edward Jenner, who in 1796 successfully introduced the Cowpox immunization in 
humans. He transferred a cowpox sore from an infected milkmaid to a healthy boy and then 
challenged him with a human virus. With the experiment, Jenner proved that when a cowpox 
sample is transferred from one person to the other, it has a protective effect.  
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The new era of vaccinology began in the 19
th
 century, when scientists, such as Louis Pasteur, 
Robert Koch, and Paul Ehrlich discovered and developed essential knowledge related to 
pathogens and immunization. Their achievements led to the expansion of research in 
vaccinology and paved the way for the production of new vaccines around the world.  The 
milestones in the field of vaccinology are summarized in Table 1.  
 
Table 1. Milestones in vaccinology research.  
Table prepared based on (45, 46). 




















 1759 Heberden described how parents could inoculate their children 
against smallpox 








1885 Rabies attenuated vaccine used in human (Pasteur) 
1890 Serological treatment by Emil Von Behring and Paul Ehrlich; 
tetanus toxoid was introduced 
1896 Typhoid Fever (Salmonella typhi) vaccine 
Cholera (Vibrio cholerae ) vaccinee 








1915 Pertussis - whooping cough (Bordetella pertussis) vaccine 
1927 BCG (Bacillus Calmette–Guérin) vaccine against tuberculosis 
1936 Yellow Fever (Yellow fever virus) vaccine 
1945 The first influenza vaccine approved (Influenza virus A  
and B) 
1948 Pertussis, Tetanus, Diphtheria (DTP) combined vaccine  
1960 Polio (Enterovirus) vaccine 
1963 Measles (Paramyxovirus) vaccine 
1964 Use of adjuvant was recommended 
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1967 Mumps (Rubulavirus) vaccine licensed (Mumpsvax
®
) 
1969 First Rubella (Rubivirus) vaccine licensed 
1971 Combined MMR vaccine (measles, mumps, and rubella) 
1974 
WHO Expanded Program of Immunization for BCG, Polio, DTP, 
measles, yellow fever, and hepatitis B. 
First meningococcal B polysaccharide vaccine 
1977 First pneumococcal vaccine (14 different strains) 
1980 Rabies: HDCV (human diploid cell) vaccine 
1981 Hepatitis B first subunit viral vaccine 
1983 Expanded pneumococcal vaccine PCV23 (Pneumovax23
®
) 









2000 Pneumococcal conjugated 7-valent vaccine (Prevnar7
®
) 
2008 Rotavirus vaccine licensed (Rotarix
TM
) 
2010 Cconjugate pneuomococcal 13-valent vaccine (Prevnar13
®
) 




1.2.2 Vaccine types 
Vaccines, one of the best defenses against infectious diseases, can exert a protective effect 
against various invading pathogens. With time, significant effort has been made to improve and 
control vaccine-safety as well as efficacy. Vaccines are classified into different categories, based 
on specific characteristics and the spectrum of protection (46). The first most traditional 
generation of vaccines includes live attenuated (e.g., MMR vaccine, Yellow Fever, Influenza) 
and inactivated (e.g., Rabies, Pertussis, Hepatitis B) vaccines, which can be produced easily. 
Both types contain whole pathogens, respectively weaken through several cells passages or 
inactivated by heat, radiation, or chemical methods. Nevertheless, the pathogens are able to 
return to an infective form. The second generation of vaccines offers a safer solution and are 
made by utilizing the specific microbial elements of the microbes or recombinant antigens that 
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can elicit a protective response. The subunit vaccines might contain one on more immunogenic 
compounds; either protein/peptide or a polysaccharide; for example tetanus, diphtheria, and 
pertussis toxoid vaccines are non-toxic forms of a main pathogenic factor of the respective 
bacteria. Another example of the second generation of vaccines is the use of the polysaccharide 
capsule of the bacteria as an antigen. It can be conjugated to the carrier protein to increase the 
more robust immune response or used alone as in the case of  Pneumoniae, Meningococcus or 
H.influenza. The recombinant antigens of hepatitis B virus, herpes simplex virus, or rotavirus 
respectively also belong to this family. Since there are no genetic components involved with this 
method, these highly immunogenic particles are not able to cause the disease anymore (46-48). 
The third generation of vaccines utilizes the genetic material of pathogens as antigens. Either 
liner DNA and RNA or plasmid can be employed. Many ongoing clinical trials are based on the 
use of the most modern type of vaccines for cancer, HIV, influenza or Ebola prevention as well 
as for immunotherapy. So far, DNA vaccines have been licensed only for animal use (49).  
1.2.3 Immunology of antigen recognition 
The main goal of vaccination is to induce the long‐lasting protective immune memory, so that 
upon exposure to the pathogen, a quick and forceful response will be generated. Vaccination 
induces both the evolutionarily ancient and immediate, innate response and the highly specific, 
but temporally delayed, adaptive immune response. However, the quality, the intensity, and the 
duration of the final adaptive response are greatly influenced by the innate arm (50, 51).  
The immunological mechanism of immunization has been studied for many years, and the 
understanding of the processes occurring after the injection of antigen is very well established. 
The main impact into the field was made by Charles Janeway, who described the mechanism of 
T cells recognition of cognate antigen, the interactions between the T cell receptor and antigen 
presented by Major Histocompatibility Complex (MHC) molecule, the role of “co-receptor” for 
activation of T cells, mechanism of pattern recognition by the mammalian Toll-like receptor 
family, as well as connection between innate signals and adaptive immunity (52).   
The innate immune system can recognize invariant features, characteristic for different classes of 
microbes, so-called pathogen-associated molecular patterns (PAMPs), by using germ-line 
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encoded receptors (pattern recognition receptors - PRRs). The mechanism is highly specific and 
efficient in distinguishing self and non-self antigens, classes of pathogens, and most importantly, 
determining the need for either immediate or future defense (51). Numerous classes of PRRs, 
such as Toll-like Receptors (TLRs), Nucleotide-binding Oligomerization Domain (NOD)-like 
Receptor (NLRs), C-type Lectin Receptors (CLRs) and Retinoic Acid-Inducible Gene (RIG)-I-
like Receptors (RLRs) have been identified. Physical association between antigen and PRR on 
antigen-presenting cells, such as dendritic cells and macrophages, initiates a cascade of various 
signaling pathways. The most critical molecules included in the cascades are Myeloid 
Differentiation primary response gene 88 (MyD88), Toll-interleukin-1 Receptor Adaptor Protein 
(TIR P) in ucing interferon β,  n  TRIF-related adaptor molecule (TRAM). Their activation 
results in the initiation of the mitogen-activated protein kinases (MAPKs), followed by the 
transcription of a nuclear factor (NF)-κB  n  interferon regul tory factor (IRF)-responsive genes 
which finally lead to the regulation of the phagocytosis of the pathogen as well as the cytokines 
production by antigen-presenting cells (APCs) (53). The uptake of intact microbes into the 
endocytic pathway may occur by receptor-mediated endocytosis, phagocytosis, or nonspecific 
fluid-phase endocytosis. It has been hypothesized that TLR signaling may regulate the 
phagocytic pathway to improve antigen presentation and host defense (53). TLRs are also able to 
recognize PAMPs in the extracellular space and endosomes (54). 
The signals from TLRs via the signaling adaptor protein MyD88 and the MAPK p38) activate 
fusion of nascent phagosomes with endosomes and lysosomes. The low pH of the 
phagolysosome, created after fusion of the phagosome with the lysosome, causes the 
fragmentation of the bacteria into small pieces (proteolysis). The phagolysosome containing 
pathogen-derived proteins fuse with the MHC bearing endosome allowing bacterial peptides to 
bind to the groove of the MHC class II molecule. MHC-II-peptide loaded endocytic 
compartments change morphology from vacuolar to tubular, and is transported to the area of the 
plasma membrane where contact with the TCR on CD4
+
 T cells occurs. Only phagosomes 
containing TLR ligand can mediate the presentation of antigens. Apoptotic cells which do not 
involve TLR signaling (their phagosomes mature into different compartments) are not receptive 
to MHC-II presentation. This mechanism allows APCs to distinguish between phagosomes with 
self (non-stimulating) antigens and non-self (stimulating) antigens (53, 55). 
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APCs activated by microbial components via pattern-recognition receptors such as TLRs secrete 
a precise set of cytokines that attract T cells and induce a specific T cell response (T helper type 
1 (Th1), T helper type 2 (Th2), T follicular helper (TFH)). Thus, APCs are a bridge between innate 
and adaptive immunity (56). The antigen is taken up by dendritic cells at the site of 
immunization and, within a few days, is transported to the peripheral lymphoid organs such as 
spleen or lymph nodes. The activation of the B cell receptor (BCR) by a T cell-dependent 
antigen provides further activation signals triggering the formation of the germinal centers (GC) 
within lymph nodes and the spleen. The maturation, proliferation, and differentiation of B cells 
occurs within GCs (57). 
T cells develop in the thymus by undergoing positive and negative selection which results in 
n ïve CD4  n  CD8 T cells popul tion  ispl ying  istinctive T-cell surface receptor (TCR). The 
TCR is composed of two membrane- nchore  polypepti es (α  n  β),  n  e ch cont ins one 
constant (C) and one variable (V) domain. The variable domain-containing complementarity 
determining regions (CDRs) recognizes the peptide:MHC complex and delivers activation 
signals to the B cell. However, first, T cells by themselves require antigen-induced three-step 
activation (Figure 3). The initial binding between a TCR and the antigen-MHC is called the first 
signal. The second signal comes from co-stimulatory molecules, e.g., in a case of T helper, CD28 
costimulatory ligand which binds to one of two receptors on the APC – B7.1 (CD80) or B7.2 
(CD86. The third signal comes from released cytokines, which determine the functional 
subclasses of T cells, like TFH or Th1, Th2, or Th17 with different cytokine profiles and functions. 
Activated T cells synthesize both cell-bound and secreted effector molecules that synergize in 




Figure 3. Naïve T cell activation. 
The activation of a naive T cell requires communication with a professional APC which 
provides multiple signals. CD40L, CD40 ligand; DAMP, damage-associated molecular pattern; 
IL-12, interleukin-12; IL-12R, IL-12 receptor; PAMP, pathogen-associated molecular pattern; 
PRR, pattern recognition receptor. Adopted from Kambayashi et.al., 2104 (59)  
 
B cell development and rearrangement of B cell immunoglobulin genes occurs in the bone 
marrow. The immature B cells with the surface-bound B cell receptor (BCR) of the IgM isotype 
first go through negative selection. The self-antigen recognizing B cells are removed from the 
cell's repertoire by apoptosis. The immature B cells continue to differentiate into transitional and 
mature B cells before and after they travel to the spleen (60). In a light zone of the spleen 
positive selection takes place. B cells that are able to interact with an antigen carry by TFH cells 
are positively selected into the peripheral B cell compartment (57).  
The BCR on a surface of the B cell can recognize both soluble and membrane-bound antigens, 
and this interaction provides the first signal for cell activation. The second co-stimulation signal 
is typically provided by TFH cells in germinal centers of the spleen, where the B cells are 
clustered. CD40 ligand on TFH interacts with the CD40 receptor on the B cell, which 
subsequently activates immature B cells. This contact induces polyclonal B cell proliferation, 
antibody affinity maturation, IgG class switching, and formation of memory B cells (61). 
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Activated B cells leave the GCs as high-affinity plasma and memory B cells. Plasma B cells are 
able to secrete antigen-binding antibodies for several weeks after activation. Memory B cells 
circulate throughout the body with high-affinity BCRs ready for quick response to the antigen 
and stopping the infection (62). 
1.2.4 T cell-independent (TI) carbohydrate antigens 
Activation of B cells without the assistance of helper T cells is called T cell-independent 
activation (TI) and occurs when BCRs interact with T-independent antigens, such as a 
polysaccharide of high molecular weight (TI-2) or lipopolysaccharide (TI-1). TI-1, in comparison 
to TI-2, can induce neonatal B cells and low-affinity antibody production in children below two 
years of age (3, 63). It was shown that CPSs are taken up by APC, engulfed into endosomes and 
fragmented into smaller carbohydrates by oxidative agents such as reactive oxygen species 
(ROS) and reactive nitrogen species. T cells are not able to respond to carbohydrates due to 
failure of these molecules to bind MHC class II, not to T cell inability to recognize presented 
glycans (64). Carbohydrates induce low- affinity IgM response. The lack of antibody class 
switching (from IgM to IgG), booster antibody response (no rapid increase in IgG titer after 
repeated contact with the antigen) and formation of memory T cells are typical features of the T 
cell-independent immune response (65, 66). The structure of capsular polysaccharides that 
contain many repeating units allows for cross-linking of multiple BCRs, providing the first 
signal for B cell activation.  The second signal usually comes from other sources, such as 
interactions of Toll-like receptors with PAMPs, without the involvement of T cells (Figure 4a). 
1.2.5 T cell-dependent (TD) carbohydrate antigen  
Zwitterionic polysaccharides (ZPS), containing both positive and negative charges in each 
repeating unit, are unique carbohydrates that can activate the T cell-dependent immune response. 
They are produced by Bacteroides fragilis, Streptococcus pneumoniae serotype 1, or 
Staphylococcus aureus type 5 and 8 (67). After the recognition of the antigen by APCs, ZPS is 
processed into smaller fragments and displayed on MHC class II through the electrostatic 
interaction with the peptide-binding groove. Thereby, a synapse with TCR on CD4+ T cells is 
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formed, leading to their activation and cytokine production (Figure 4b) (65, 66, 68). ZPS can 
activate adaptive immune responses in the absence of a carrier protein (69), leading to the 
possibility of carbohydrate only vaccines (70). 
1.2.6 T cell-dependent recognition of glycoconjugate vaccines  
Glycoconjugate vaccines contain bacterial capsular polysaccharide (CPS) chemically coupled to 
the T cell-dependent carrier protein or peptide. The concept was first described by Avery and 
Goebel in the early 1930s. This standard practice was finally introduced in the mid-1970 after 
the realization that Hib and meningococcus C vaccines are not effective in young children (57, 
71). The development of technology for glycoconjugate production is considered one of the 
major milestones in vaccinology in recent decades. Polysaccharide protein conjugate vaccines, 
based on isolated CPS antigens attached to carrier proteins, also protect young children and the 
elderly, from deadly bacterial pathogens including Haemophilus influenza type b (Hib), 
Neisseria meningitides, and the encapsulated Gram-positive bacterium Streptococcus 
pneumoniae (Table 2). The covalent linkage of a carbohydrate antigen to a protein enables to 
evoke a longlasting T-cell memory response and polysaccharide specific plasma cells. After the 
boosting with a polysaccharide conjugate vaccine or contact with the bacteria, the plasma cells 
rapidly proliferate, maturate and produce high-affinity antibodies that can eliminate the pathogen 





Figure 4. T cell-dependent and T cell-independent immune response to the polysaccharide. 
a) Bacterial polysaccharides are classic T cell-independent antigens. Interaction between the 
polysaccharide and the BCR induce the clonal expansion of B cells and the production of low-
affinity IgM antibody but no immunological memory is generated. b) Zwitterionic 
polysaccharides are known to be a T cell-dependent antigen in a manner similar to protein 
antigens. These specific type of polysaccharides are presented to T cells, leading to their 
activation. Zwitterionic polysaccharides elicit high-affinity IgG production and B cell memory 





Table 2. Licensed glycoconjugate vaccines. 
Adapted from Berti & Adamo (71). TT - tetanus toxoid; OMPC - Outer membrane porin C; DT - 












TT Native PS 
Hiberix/GSK TT Size-reduced PS 
Quinvaxem/GSK CRM197 Depolymerized PS 
PedvaxHIB/Merck OMPC Native PS 
Neisseria meningitidis 
serotype C 




Menjugate/GSK CRM197 Depolymerized PS 
Menitorix/GSK  
(with Hib) 








Menactra/Sanofi Pasteur DT Depolymerized PS 
Menveo/GSK CRM197 Depolymerized PS 
Nimenrix/Pfizer TT Size-reduced PS 
Streptococcus pneumoniae  
(serotypes 4, 6B, 9V, 14, 
18C, 19F, 23F) 
Prevnar/Pfizer CRM197 Native PS 
Streptococcus pneumoniae  
(serotypes 1, 4, 5, 6B, 7F, 
9V, 14, 18C, 19F, 23F) 
Synflorix/GSK 
NTHi PD, DT, 
TT 
Size-reduced PS 
Streptococcus pneumoniae  
(serotypes 1, 3, 4, 5, 6A, 
6B, 7F, 9V, 14, 18C, 19A, 
19F, 23F) 
Prevnar13/Pfizer CRM197 Native PS 
 
The classical hypothesis of immune activation by glycoconjugate states that the protein portion 
of the conjugate activates protein-specific CD4+ T cells to help carbohydrate specific B cells 
produce long-lasting IgG antibodies. Activation can be cytokine-mediated or through cognate 
interactions (73), suggesting that only peptide is presented to the T cells, ignoring the fact that 
glycan is chemically attached via a strong covalent linkage. However, the current theory strongly 
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indicates the contribution of glycan-specific CD4+ T cells, called Tcarb. The glycoconjugate is 
uptaken by APCs and depolymerized inside the endosome to the short glycan (size ~10kDa) still 
covalently linked to the peptide. Antigenic fragment of the polysaccharide is presented to the 
CD4 T cells in a context of MHC class II by the anchoring peptide from the carrier protein 
(Figure 5). The covalent linkage of carbohydrates to proteins in glycoconjugate vaccines is 
unlikely to be broken within the endosome (64, 72). It was shown that carbohydrate specific 
antibody levels were comparable when different carrier proteins conjugated to the glycan were 
used for priming and boosting. This observation suggests a similar level of B cell activation 
independent of the carrier (72). The glycoconjugate induces the Tcarbs that recognize the 
carbohydrate portion of the vaccine. However, the structure of the polysaccharide is critical for 
the final presentation of the antigen to CD4
+
 T cells. Some oligosaccharides might be 
depolymerized into fragments too small or fragments not recognizable by TCRs and not able to 
trigger T cell-dependent immune response (74). A better understanding of differences in 
carbohydrate antigen processing, presentation, and recognition are essential factors in the design 
and optimization of glycoconjugate vaccines. 
 
 
Figure 5. Processing and presentation of a carbohydrate vaccine by immune cells. 
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Glycoconjugate vaccine antigens allow for the glycan-specific B cell to present carrier protein 
peptides on MHCII to T cells, thus confers a stronger, T cell-dependent immune response, Avci 
et. al. (64). 
1.2.7 Antibody production and their way of protection 
Significant variations of response to glycoconjugate vaccines and following protection against 
bacteria have been observed between age groups (Figure 6). The antibody response of small 
children, which are in a high-risk infection group, fall rapidly after primary vaccination, raising 
the need to introduce booster immunization to maintain antibody levels. In young adults, natural 
nasopharyngeal colonization of encapsulated bacteria such as S. pneumoniae, H.influenza B and 
N. meningitis boost the memory immune response and play a significant role in sustaining 
immunity (75). This indicates that reactive memory, by itself is insufficient to protect against 
infection (57, 76). 
In the absence of specific antibodies, capsular polysaccharide allows bacteria to evade innate 
host defenses by preventing complement deposition (no access to the regulators of complement 
activation (RCA) which are crucial determinants for complement function on self and non-self 
cells) on their surfaces and PRR activation (77).  
Protection against encapsulated bacteria is mediated by antibodies via complement‐mediated 
killing or opsonophagocytosis. The complement system can be activated mainly through three 
distinct ways: the classical pathway (C1qr2s2, C4 and C2), the alternative pathway (C3, factor B, 
factor D, and properdin), and the lectin pathway (MBL or ficolins /MASPs, C4 and C2). All of 
them finally lead to the ultimate goal – elimination of the target bacteria either by lysis or 
phagocytosis. Each of the three activation pathways leads to the formation of a C3 convertase, 
following the formation of the principal phagocytosis stimulating opsonins C3b and iC3b. The 
classical pathway requires immunoglobulins IgM and IgG for its activation. The antigen-
antibody complexes containing IgG or IgM are formed, and they can be recognized by the first 
component of the complement system C1q. Shortly afterward, C1q triggers autoactivation of 
C1r, which then cleaves C1s. Active C1s cleaves C4 and C2 to a vital complex known as C3 
convertase C4bC2a. The C3 convertase cleaves C3, the major complement protein in serum (78). 
Efficient phagocytosis of opsonized target cells is highly dependent on the recognition of the 
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target cell by IgG/IgM and complement components generated from C3. C3b2–IgG/IgM 
complexes are significantly more effective than IgG antibody alone in inducing phagocytosis by 
professional phagocytes (neutrophils, monocytes, macrophages, DCs, osteoclasts, and 
eosinophils) (79, 80). Complement activation might continue with the terminal complement 
components (C5-C9) that accumulate and form a cell lysing membrane attack complex which 
kills gram-negative bacteria (e.g., N. meningitidis or H.influenza type b). However, gram-
positive bacteria as S.pneumoniae resist the bactericidal action of C5-C9 (78, 81, 82). 
Antibody-mediated opsonophagocytosis is the basic protection mechanism of the CPS-based 
vaccines. However, a high IgG titer is not the only factor to consider in potential vaccine 
efficacy. The epitope specificity, antibody affinity, avidity, subclass, and functionality have to be 





Figure 6. Mechanism of the immune response to polysaccharide and glycoconjugate 
vaccines in infants and adults.  
Immune response to glycoconjugate differ in infants (a) and adults (c) and at least one additional 
boosting in children above the age of two is necessary to achieve the antibody titer equivalent to 
one immunization in adults. Polysaccharides in infants do not initiate proliferation of B cells but 
their apoptosis (b). The preexisting low-affinity memory B cells in adolescents are responsible 
for a rapid immune response to polysaccharide already after one immunization (d). (Adapted 
from Rappuoli 2018, (57)). 
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1.3 How To Improve Vaccine - Rational Vaccine Design 
1.3.1 Commercial vaccines against S.pneumoniae 
Immunization is the only method for preventing bacterial infections. Due to the high impact of S. 
pneumoniae on morbidity and mortality in adults and children, great efforts have been invested 
in reducing the rate of pneumococcal disease by vaccination over the past 30 years. The 
polysaccharide capsule is an essential factor responsible for pneumococcal colonization and 
virulence. Therefore, it is a perfect target as a vaccine antigen.  
The vaccines against S. pneumoniae contained purified polysaccharide capsules as antigens. A 
first pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23
®
) has been developed in 
1983 by an American physician Robert Austrian. PPSV23 protects against the following capsular 
serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 
23F, and 33F. Capsular polysaccharides are purified from bacteria culture, and 25 µg of each  
CPS is formulated together into a polyvalent vaccine. It is recommended that all adults older 
than 65 years receive one dose of PPSV23. The vaccine contains T-cell independent antigen 
(unconjugated polysaccharide), that is why the Centers for Disease Control and Prevention 
(CDC) recommends immunization at least eight weeks after PCV13 administration (83). The 
vaccine did not generate an immune response in the group with the highest rate of pneumococcal 
disease burden and children younger than two years of age (84) 
To protect the pneumococcal infection high-risk group and stimulate their protective immune 
response, vaccines containing the capsular polysaccharide conjugated to carrier proteins were 
developed. The first polysaccharide conjugate vaccine against  S. pneumoniae was developed in 
2000 and manufactured by Wyeth (later acquired by Pfizer) and covered 7 CPS from serotypes 
4, 6B, 9V, 14, 18C, 19F and 23. Ten years later, additional serotypes 1, 3, 5, 6A, 7F, and 19A, 
were included to form 13- valent pneumococcal vaccine (PCV13, Prevnar13
®
). PCV13 is a 
mixture of  2.2 µg of each isolated CPS, except serotype 6B which is in the amount of 4.4 µg, 
conjugated to the CRM197 carrier protein. The vaccine is adsorbed onto 0.125 mg of Alum 
(Aluminium Phosphate). Currently, the CDC recommends that all children younger than two 
years of age undergo a series of Prevnar13
® 
immunizations. All infants should be given the first 
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series of PCV13, at ages 2, 4, and 6 months with a booster at age 12 to 15 months (83). The 
WHO report from 2017 vendors all countries to adopt PCV and implement a schedule containing 
a minimum of three doses, which may be administered either as 3 primary doses without a 
booster (3p + 0) or as 2 primary doses with one booster (2p + 1). Some national immunization 
programs use a 3p + 1 schedule (85). Implementation of PCV13 into vaccination schedule has 
provided a substantial reduction of the incidence of invasive pneumococcal disease. Multisite 
population-based surveillance analyses revealed an overall reduction of 64% in invasive 
pneumococcal disease in children younger than five years of age (86). Synflorix
®
 is another 
license conjugated polysaccharide vaccine. It contains ten CPS isolated from the same serotype 
as Prevnar13
®
 except for serotype 3, 6A and 19A in an amount 1 µg or 3 µg. The CPSs are 
conjugated to either protein D from H.influenzae, tetanus toxoid or diphtheria toxoid and 
adsorbed onto 0.5 mg of Alum (Aluminium phosphate).  
1.3.2 Synthetic carbohydrate vaccines 
The procurement of polysaccharides for conjugate-vaccine production by the isolation of CPS 
from cultured bacteria is conceptionally simple but operationally challenging. Antigen 
heterogeneity, batch-to-batch variation, and poorly-defined conjugation to carrier proteins can be 
overcome when synthetic oligosaccharides are employed (87). The effective glycoconjugate 
vaccine QuimiHib, licensed in several countries to protect against Haemophilus influenza type b, 
is based on a synthetic oligosaccharide resulting from chemical polymerization (88). The 
medicinal chemistry approach to glycoconjugate vaccine development offers an alternative to 
CPS isolation for a variety of glycan antigens, including those for the hospital-acquired 
infection-causing bacteria Clostridium difficile and Klebsiella pneumoniae (89-92). Recent 
advances in the chemical synthesis of complex glycans including automated glycan assembly 
(AGA) have enabled the synthesis of a variety of diverse oligosaccharides resembling the CPS of 
different serotypes (93, 94). Active immunization of mice and rabbits with CRM197 conjugated 
with ST2 (95), ST3 (96), ST5 (97), ST8 (98) and ST14 (99, 100) elicited opsonophagocytic 
antibodies that were shown to be protective in infection models of the disease.  
The production of effective semi-synthetic oligosaccharide-based glycoconjugate vaccines relies 
on the identification and synthesis of well-defined glycotopes. Glycan microarrays containing 
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isolated CPS as well as synthetic glycans enable the rapid screening and identification of 
protective glycotopes as a basis for the development of highly effective next-generation synthetic 
glycoconjugate vaccines. The medicinal chemistry approach has identified fragments containing 
disaccharides to tetrasaccharides as potential vaccine candidates (87). The immunogenicity of 
the CPS depends, among other factors, on rare sugars and labile functional groups (95, 97, 98). 
Stable synthetic oligosaccharide analogs can fix production problems such as those encountered 
for ST5 CPS due to the labile ketone present in the repeating unit (97).  
The specific vaccine modification used here, such as synthetic antigen conjugated to the 
alternative carrier proteins, various adjuvant formulations and delivery system, as well as animal 
models, are investigated to generate relevant vaccines for clinical use. A key issue is whether the 
same adaptive immune response to these polysaccharides can be expected in humans (17).  
1.3.3 S.pneumoniae serotype 3 (ST3) as an important vaccine target 
S.pneumoniae serotype 3 (ST3) is an important cause of invasive pneumococcal disease, 
particularly pneumonia, in both children and adults (86). Serotype 3 conjugate was added to the 
formulation of 13-valent pneumococcal vaccine (PCV13) and is now included in the routine 
immunization schedule. However, this particular serotype remains a prominent cause of the 
invasive pneumococcal disease (IPD) in all age groups in most countries using PCV13. Many 
studies show no change in the incidence rate of serotype 3 after the introduction of PCV13 
(Figure 7). S. pneumoniae serotype 3 produces a very thick mucoid capsule (101) which protects 
the bacteria from phagocytosis, inhibits opsonization by complement,  helps to escape the 
neutrophil extracellular traps and prevents macrophage killing. Lack of clinical efficacy against 
serotype 3 after pneumococcal conjugate vaccination may be a result of reduced induction of 
immune memory (102). It was found that the levels of pre-existing ST3-specific antibody are 
negatively correlated with the B cell memory response to a booster dose of PCV13 containing 
ST3 glycoconjugate (103). Improvement by alternative approaches is needed to advance 




Figure 7. Changes in the incidence of invasive pneumococcal disease (IPD) caused by 
various S.pneumoniae serotypes among all ages. 
The orange line represents the IPD rate caused by serotypes included in PCV13 (1, 3, 4, 5, 6A, 
6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F); green line represents the IPD rate for the five most 
common non-PCV13 serotypes; purple line the rate for serotype 3 only;. Rates of IPD expressed 
as cases per 100,000. (Based on Active Bacterial Core (ABC) surveillance data reported by the 
CDC. Adapted from Moor et al., 2015. 
 
Synthetic oligosaccharides based on ST3 CPS repeating units have been shown to protect mice 
against lethal systemic challenge with ST3 pneumococci (104). A highly immunogenic 
tetrasaccharide glycotope based on the disaccharide repeating unit of S.pneumoniae serotype 3 
was synthesized (Figure 8). The semi-synthetic oligosaccharide-based glycoconjugate vaccine 
candidate shows an immunoprotective effect against experimental pneumonia caused by 
transnasal infection with ST3 strain PN36. However, the vaccine needs further enhancement to 
achieve long-lived immune memory (105).  
 
 
Figure 8. The synthetic repeating unit of S.pneumoniae serotype 3 (ST3-tetrasaccharide) 
conjugated to CRM197 carrier protein used as a vaccine candidate. 
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1.3.4 Alternative carrier proteins from S.pneumoniae  
It is a general rule that organisms with overlapping ecological niches, such as different serotypes 
of S.pneumoniae, compete with each other for resources, resulting in multifaceted interactions 
and dynamics. Replacement of specific serotypes included in the vaccines by the serotypes not 
included occurs frequently and is called serotype replacement. Development of non-vaccine 
serotypes is a major challenge in controlling of pneumococcal diseases. This problem has been a 
m jor re son for intensive rese rch in the  irection of  eveloping   ‘univers l’ pneumococc l 
vaccine immunogenic in all age groups and broadly cross-protective against all serotypes. 
Several studies reported a protein-based serotype-independent vaccine to prevent pneumococcal 
infections (36). Targeting multiple membrane proteins based on their roles in bacterial 
pathogenicity and physiology seems to be a promising approach to achieve additive protection 
against pneumococci in mice (106). 
The nature of the carrier protein is critical in defining the magnitude and quality of 
vaccine‐induced immune responses, and the duration of protection. Different aspects, such as 
competition with anti‐carrier antibodies elicited by related vaccination against tetanus and 
diphtheria, an overload of carrier protein or carrier‐mediated epitope suppression, may influence 
both T‐ and B‐cell responses to glycoconjugate vaccines. Additionally, differences in extent and 
persistence of protective antibodies triggered by primary vaccination with bacterial 
polysaccharides conjugated to various carrier proteins have been observed in infants (50, 107). 
Polysaccharides conjugated to a synthetic multi- or hybrid protein carrier (multiple T‐cell 
epitopes) might be capable of broad binding to different types of MHC class II molecules 
resulting in the faster and stronger immune response to polysaccharides compared with licensed 
glycoconjugate vaccines (107). Many studies utilize highly conserved S.pneumoniae proteins 
such as pneumolysin toxoid (Ply) (108, 109) or Pneumococcal surface protein A (PspA) (110, 
111) to provide broader protection against pneumococcal disease. 
1.3.5 Adjuvants influence vaccine immunogenicity  
Adjuvants are substances that modulate or strengthen an effective immune response against the 
vaccine antigens in different ways (Figure 9). They can support antigen immunogenicity by 
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increasing local inflammation and antigen recognition by PRR, antigen uptake by APCs, and cell 
migration to lymph nodes. Adjuvants select or modulate cell-mediated and humoral immunity, 
moderate antibody isotype, subclasses, quantity, and specificity as well as broad antibody cross-
reactivity. Additionally, adjuvants can reduce the amount of antigen or the number of 
immunizations needed for vaccination, so-called antigen dose sparing (112-114). Modern 
vaccines that use better defined, or even synthetic antigens, are generally less immunogenic than 
crude, whole organism vaccines. Research is ongoing in advancing the efficacy of adjuvant 
systems for vaccines (112). Different modes of action of antigen are summarized in Table 3. 
 
 
Figure 9. Mechanisms through which adjuvants mediate their activity. 
Many adjuvants can act as ligands for PRRs that activate an innate immune response. Receptor 
signaling trigger transcription factors that induce the production of cytokines. The cytokines help 
to direct a specific Th1 or Th2 type immune response, as well as influence the immune cells that 
are recruited to the site of injection. Some adjuvants also influence antigen presentation by MHC 
molecules (MHC class I or II), affect antigen uptake, PRR signaling, inflammasome activation 
and recruitment of immune cells. Adapted from Reed et al. 2013 (115) 
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Table 3. Modes of action of adjuvants. 
 
Antigen uptake 
 Recruitment of APCs 
 The antigen recognition through pathogen recognition 
receptors (PRRS) 
 APCs maturation 
 Local inflammation at sites of injection (creating  the local 
environment) 
Activation of immune 
cells 
 Efficient antigen presentation 
 The antigen protection 
Co-stimulation  Cytokines production 
Effector messages  Downstream modulations 
 Differentiation of T helper cells 
1.3.5.1 Aluminum-based adjuvants 
Aluminum-based mineral salts (Alum) have served as the only adjuvants for human vaccines for 
many years (116). They are used for a wide range of vaccines that predominantly aim to induce 
antibody-mediated immune responses (117). Despite its universal use, research on its mechanism 
of action is not completely clear (118). The antigen adsorbs onto Alum particles based on 
electrostatic attraction, ligand exchange (depending on substitution of surface hydroxyl group) 
and other mechanisms such as Van der Waals interaction or hydrophilic interaction. Several 
Aluminium compounds have been investigated as adjuvants, but the most popular are 
Aluminium Phosphate (AlPO4) and Aluminium Hydroxide (Al(OH)3) gels. AlPO4 and Al(OH)3 
particles have negative and positive charges respectively so different antigens (based on their 
overall charge) preferentially get adsorbed onto them (119).   
Several mechanisms of action of aluminum adjuvants have been proposed, such as delay in 
clearance from the injection site, attraction, and stimulation of cells of innate immune (through 
Toll-like receptors), presentation of   sorbe  soluble proteins  s ”p rticul te”  ntigens or 
improving antigen targeting towards APCs (108-110). Aluminium-based adjuvants also 
modulate the production of co-stimulatory molecules of Th-2 associated cytokines (IL-4, IL-10, 
IL-13, and possibly others), increased Ag-specific CD4+ T cell proliferation, stimulate Th2 
associated antibodies/isotypes (IgG1 and IgE) as well as the NALP3 inflammasome leading to 
the release of IL-1ß  n  IL-18 (120-122).   
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1.3.5.2 Oil-in-water emulsion 
Oil-in-water (O/W) emulsions have been utilized to vaccinate animals for many decades. 
Mineral (paraffin) oil combine  with mycob cteri l cells, known  s Freun ’s   juv nt, is very 
well known but not approved for human purposes. MF59
TM 
(Novartis) is a new licensed O/W 
emulsion adjuvant already used in over 20 million individuals as a part of the influenza vaccine 
(123). It contains squalene, the naturally occurring triterpene hydrocarbon with a simple 
composition (C30H50) but a complex structure, found in many plants and animals, including 
humans. MF59
TM
 also contains two plants-derived nonionic surfactants, Tween 80 and Span 85, 
which are commonly used in a range of pharmaceutical products. (124). Two other well-known 
O/W licensed adjuvants are AS03 (GSK) containing squalene, Tween 80 and tocopherol, as well 
as AF03 (Sanofi Pasteur) with squalene, cetostearyl ether and sorbitan oleate (125). 
O/W adjuvants induce a transient NF‐κB, cytokine and chemokine response, increase 
recruitment of innate immune cells to the site of injection, as well as activate APCs loaded with 
the antigen and their migration to draining lymph nodes. The adjuvants also enhance recruitment 
of innate immune cells at the local draining lymph nodes and activate CD4+ T cells interacting 
with antigen‐specific B cells, inducing high numbers of memory cells (126, 127). MF59TM 
induced a vast expansion of vaccine-specific CD4 T cells but did not modify the cytokine profile 
of the stimulated T cells (characterized by the production of IL-2 and TNF-α). Thus, MF59
TM
 
does not bias the response toward either Th1 or Th2 (128, 129). 
1.3.5.3 Toll-like Receptors (TLRs) Ligands (TLRLs) 
Toll-Like Receptors Ligands (TLRLs) are natural or synthetic molecules that bind TLRs and 
stimulate innate immune responses (by the production of inflammatory cytokines and type I or II 
interferons) which further influence the shape of adaptative B- and T-cell response. The first 
attenuated vaccines, a Rabies vaccine invented by Pasteur in 1885, already contained TLRL, e.g., 
ssRNA in Rabies vaccine activates TLR7/8; LPS and DNA in Typhoid vaccine trigger TLR4, 




1.3.5.3.1 Monophosphoryl lipid A (MPLA) – TLR4 ligand 
Monophosphoryl lipid A (MPLA) is a derivative of lipopolysaccharide (LPS), the component of 
Gram-negative bacterial cell membranes and a strong activator of TLR4 (Figure 10). It was 
discovered the 1970s by Edgar Ribi who chemically modified LPS to exclude the endotoxic 
effect. He noticed that the product maintained desirable immunostimulatory activities and could 
be used as an immunomodulator. The less cytotoxic effect of MPLA was achieved by successive 
acid-base hydrolysis of LPS. Additionally, the number, structure, position of lipids and the 
degree of phosphorylation are important factors influencing the bioactivity of lipid A (131). 
MPLA is currently approved for use as an adjuvant in a pollen vaccine (Pollinex
®
) and in 
combination with Al(OH)3  s ( S04) in hum n p pillom virus v ccine Cer vi ™  n  hep titis 
B virus Fen ri ™ v ccines (132). In the shingles vaccine (Shingrix
®
) MPLA is formulated 
together with purified fat-like substance and QS-21 from the bark of the Quillaja Saponaria tree 
(133). 
MPLA is an effective stimulator of Th1 cells and antibody responses. Administration of the 
adjuvant stimulates high serum titers of both IgG2 and IgG3 antibodies isotypes and increasing 
the surface expression of MHC and the co-stimulatory molecules on the APCs thus increasing 
the stimulatory properties of DCs, macrophages, and B lymphocytes (134). MPLA induced 
tumor necrosis factor (TNF) and  interleukin-1β (IL-1β) (135). 
 
Figure 10. Monophosphoryl lipid A (MPLA) structure. 
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1.3.5.3.2 TLR-7/8 agonist - Resiquimod 
TLR7/8 are predominantly expressed by important antigen-presenting cells, e.g., plasmacytoid 
DCs (pDCs) and are involved in the robust expression of IL-6, IL-12, TNF-α,  n  IFN-α both in 
humans and mice (136). It has been proven that the stimulation of IFN-α secretion is  n essenti l 
driving force of TLR-mediated Th1 immune responses and IFN-γ-dependent production of Th1-
specific IgG2/IgG3 (137). TLR7 and TLR8 recognize single-stranded RNA molecules (ssRNA) 
and are also activated by synthetic agonists, such as imidazoquinoline derivatives: Imiquimod 
and Resiquimod. Imiquimod was the first commercially available imidazoquinoline used for 
anogenital warts, actinic keratosis, and superficial basal cell carcinoma (138).  
Resiquimod (RQ-848), 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinolin-1-
ethanol, is a more potent and soluble analog of imiquimod (Figure 11). R-848 produces a 50- to 
100-fold cytokine response compared to imiquimod by induction of immune cells to produce 
cell-mediated or Th1 cytokines (138). Resiquimod has been known as a powerful 
immunostimulator for the treatment of cutaneous cancers in various clinical trials (139). 
 
Figure 11. The structure of Resiquimod (R-848). 
 
1.3.5.3.3 Bacterial RNA – vita-PAMP 
The innate immune system can discriminate between selves and non-self components via 
recognition of pathogen-associated molecular patterns (PAMPs). The additional differentiation 
between live and dead microorganisms occurs through a uniquely associated with live 
microorganisms sets of PAMPs called vita-PAMPs. Bacterial messenger RNA (mRNA) has been 
recognized as one of the vita-PAMPs. Innate recognition of bacterial RNA occurs through 
endosomal TLR8 on human monocytes while both human and murine plasmacytoid DC do so 
through TLR7 (140). Detection of live bacteria caused the activation of the NLRP3 
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inflammasome complex and the subsequent release of IL-1β  n  incre se  pro uction of type-I 
Interferons (IFN) (141). The idea to incorporate vita-PAMPs into vaccine formulations combines 
the excellent protection of live vaccines with the safety of synthetic vaccines (142). 
1.3.5.3.4 TLR synergy 
Pathogens express various PAMPs, and in natural infections, immune responses are amplified by 
multiple PAMPs presented all together on particulate pathogens (e.g., viruses or bacteria) (143). 
The experience with live attenuated vaccines, such as BCG, confirm the use of vaccines 
containing several compounds activating multiple innate pathways (50). Combining multiple 
PAMPs and triggering multiple PRRs at the same time,  has been an essential strategy for 
adjuvant design in modern vaccine research. Synergic activation and TLR-TLR cross-talk can 
lead to enhanced cytokine secretion, more efficient T cell activation, and better antibody 
response (143). 
Numerous studies have documented the importance of simultaneous stimulation of different 
PAMPs, such as TLR4 and TLR9 ligands (formulation of MPLA and CpG (130, 144)) or TLR4 
and TLR7 (a nanoparticle-based vaccine combining antigen, MPL + Imiquimod (145)); which 
gives a much better immune response. The levels of TNF production are much greater than that 
observed for each of the ligands alone. In a mouse model, analysis of neonatal innate immune 
responses proved that the simultaneous activation of multiple TLR improves pro‐inflammatory 
signaling and triggers DC maturation, comparable to an adult‐like antigen presentation capability 
(50). However, PRRs may also negatively regulate each other, especially when different types of 
pathogens are involved (146). 
1.3.6 Formulation: vaccine delivery systems  
Optimal vaccine design requires both the antigen and the adjuvant to be delivered together to the 
appropriate immune cells. The biochemical properties of some antigens and adjuvants do not 
allow for their direct chemical conjugation. The co-administration of antigen and adjuvant on 
delivery vehicles such as nanoparticles have been intensively studied for their feasibility, varying 
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from sutures to bone reconstruction, and in implants as well as particles for sustained drug 
delivery and vaccine formulations.   
There are already four vaccines in the market using delivery vehicles such as virus-like particles 
(VLPs) with the major immunogenic antigens on the surface. Those are two anti-hepatitis B 
vaccines: Engerix-B
®
 (GSK) and RECOMBIVAX HB
®
 (Merck) and two papillomavirus 
vaccines: Cervarix
®
 (GSK) and GARDASIL
®
 (Merck) (147). 
Polylactic acid (PLA) and poly(lactic-co-glycolic acid) (PLGA) are copolymers of hydroxy acid 
monomers, D-lactic, L-lactic, and/or glycolic acid can entrap antigens for their efficient delivery 
to cells (148). PLGA or PLA have been used for encapsulation of antigens due to their 
homogenous distribution on the matrix (149). They form biodegradable and biocompatible 
platforms and have been widely approved by the US Food and Drug Administration (FDA) and 
European Medicines Agency (EMEA) for humans and veterinary use. The slow release of 
antigen and adjuvant molecules for several weeks to months prolongs and enhances antibody 
response to the antigen and overall stimulation of the immune system by cytokine production 
(147). For the formulation of particles, mostly amorphous d,l-PLGA is used, which differ in L-
lactic: glycolic acid monomer ratio, molecular mass, and end-group chemistry. These parameters 
determine the hydrophobicity and degradation kinetics of the materials, equivalent to the 
microencapsulation efficiency and release rate of drugs and antigen. The hydrophobicity has a 
high impact on the degradation of the polymer by hydrolysis (149). 
PLA/PLGA particles have been used to deliver antigens from various pathogens, such as 
hepatitis B virus (HBV) (150, 151), malaria protein (152), HIV antigens (153) or tumor-
associated antigens (154). Additionally, the vehicles system also allows for the simultaneous use 
of multiple co-stimulants (137). Particles promote immunogenicity through (1) stabilization and 
protection of the antigen from chemical or enzymatic degradation; (2) controlled antigen release 
which increases antigen exposure to the professional APCs and prolong antigen presentation; (3) 
facilitating the antigen uptake by DCs by mimicking the size and shape of the pathogen; (4) 
targeted delivery through additional costimulatory molecules; (5) parallel delivery of multiple 
components and (6) regulation of the type of immune response (by particles size, charge and 
costimulatory molecules) (155-158). In general, the use of particles in the vaccine formulations 
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1.4  Objectives of this thesis 
High mortality rates of bacterial pneumonia and increased antibiotic resistance are major reasons 
to develop novel vaccine strategies against Streptococcus pneumoniae. An ideal vaccine has to 
be affordable, broadly available, easy to administer and induces long-lived protection. This 
requires activation of both innate and adaptive immunity. Vaccine efficiency depends on the 
quality and way of recognition of the antigen, which is in the case of carbohydrate vaccines 
associated with the antigen characteristic, carrier protein, or proper adjuvant formulation. 
S. pneumoniae serotype 3 (ST3) is one of the most frequent serotypes isolated from patients with 
invasive pneumococcal diseases, even though it is included in the routine immunization 
schedule. Preliminary results from our group showed protective effects of a vaccine candidate 
composed of ST3-tetrasaccharide the synthetic repeating unit of the S. pneumoniae serotype 3 
capsular polysaccharide conjugated to the CRM197 carrier protein in mice. However, induction 
of long-term immunity required optimization (105).  
The first step taken to improve the semisynthetic ST3-tetrasaccharide conjugated vaccine was to 
optimize the dose of antigen. The previous study from Seeberger group immunized mice with a 
dose of conjugate equivalent to 5 μg of tetrasaccharide (96) while dosing for the human is 2.2 µg 
of CPS. Taking into account the size of the human and mouse model and the high purity of the 
oligosaccharide, the antigen dose was extremely high. To avoid vaccine overload and weakening 
the immune system, the ST3-tetrasaccharide amount was profoundly decreased.  
The immunization against pneumococcal polysaccharides can lead to the replacement of 
vaccine-type pneumococcal serotypes with new pathogenic serotypes (159). Due to the large 
serotype diversity and serotype-replacement, efforts have been undertaken to develop alternative 
pneumococcal vaccine candidates. Membrane proteins originating from the same pathogen can 
induce an additional response, so-c lle  “   ition l v lency”. Conserve  among all 
S.pneumoaniae serotypes pneumolysin and PspA were chosen as a proof-of-concept to broaden 
the spectrum of protection of the pneumococcal vaccine.  
It was proven that an adjuvant can significantly change the immune response induced by the 
vaccine. The selective activation of cell-mediated/humoral and Th1/Th2 immunity is possible by 
the adjustment of the adjuvant formulation. In the thesis, different adjuvant formulations were 
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used to improve the efficiency of the semisynthetic ST3-tetrasaccharide conjugate vaccine. The 
aluminum-based adjuvant used in Prevnar13
®
 induces Th2-balanced response. Comparison of 
Th2 adjuvants Alum and water-in-oil squalene-based emulsion MF59
TM
 was investigated. A 
separate group of TLR ligands-based adjuvants selectively induce innate signals that promote 
Th1 and TFH differentiation and humoral immunity. Encapsulation of Toll-like receptors (TLRs) 
ligands, such as MPLA, Reiquimod, and PAMPs (bacterial mRNA) in poly(lactic acid) particles 
(PLGA), are used to improve the immunoprotective effect of the vaccine. The particles might 
also serve as a delivery system for the vaccine. The in-vivo mouse model (C57BL/6 mice) was 
employed to study different formulations of ST3-tetrasaccharide vaccine and long term 
immunity directed against bacterial pneumonia. 
The mouse model has been unquestionably the most widely used animal model for research 
mostly due to easy handling and simple genetic manipulation of rodents. However, the suitability 
of the models to actually human physiology and disease is not optimal. Substantial analogies 
between human and porcine physiology and especially a strong overlap in the immune system 
including expression and function of TLR makes domestic pigs an increasingly interesting model 
animal to obtain reliable pre-clinical data. Drastically increasing rates of antibiotic resistance and 
frequent emergence of veterinary pathogens in industrial animal farming further add to the 
relevancy of this animal model as a relevant target population for vaccine studies. In this work, 
for the first time, the swine model has been employed in the field of the synthetic carbohydrate 
vaccine development. 
Work presented in this thesis follows the pipeline of vaccine development (Figure 12). Glycan 
arrays containing well-defined synthetic glycans are used as the main platform for the high 













2 Experimental Section 
2.1 Immunization  
Mice were treated according to German (Tierschutz-Versuchstierverordnung) and European Law 
(Directive 2010/63/EU). Recommendations of the Society for Laboratory Animal Science (GV-
SOLAS) and of the Federation of European Laboratory Animal Science Associations (FELASA) 
were followed. The permits used in the study (Permit Number: G0135/14, A0103/12, H0184/09) 
were approved by the Office for Health and Social Affairs Berlin (LAGeSo). Animal suffering 
was minimized, and mice were euthanized as necessary according to humane experimental 
endpoints.  
Mice were housed in individually-ventilated cages under specific pathogen-free conditions in the 
animal facility of the Federal Institute for Risk Assessment (BfR, Berlin, Germany). Mice were 
provided with food and water ad libitum. Mice used for immunizations were female C57BL/6. 
Mice were either from in-breed strains at the BfR animal facility or sourced from Janvier Labs 
(Saint-Berthevin, France) and Charles River (Sulzfeld, Germany).  
Mice were immunized subcutaneously (s.c.) with an amount of conjugate corresponding to a 
particular amount of glycan antigen per injection. The glycoconjugates, together with an 
  juv nt, were  ilute  in sterile PBS to   fin l volume of 100 μL per  ose (formul tion  epen s 
on adjuvant used). The animals were immunized on day 0 (primary immunization) and boosted 
with the same formulation on days 14, 28, and final boosting depending on the character of an 






Figure 13. General immunization regime for glycoconjugate vaccine development study. 
Six to eight week old female C57Bl/6 mice were s.c. immunize  with   fin l volume of 100 µL 
of glycoconjugate vaccine in PBS according to the prime + boost + boost + final boost schedule. 
2.2 Sera collection  
To obtain sera, blood was collected either by cutting the tail-tip or through mandibular bleeding 
via facial vein puncture with 4-5 mm lancet (Goldenrod Animal Lancet) according to the general 
schedule (shown in Table 4). Three to four drops of blood (a total of about 60-80 μL) were 
collected, and the puncture site was immediately compressed with a cotton swab for a few 
seconds. The blood was left to coagulate for at least 30 min at RT and then centrifuged for 15 
minutes at 2000 rcf to pellet the blood cells and separate the serum. The serum was aspirated, 
transferred to the sterile Eppendorf vials and an additional centrifugation step was repeated to 
clean the serum from remaining blood cells. The serum was frozen at -20°C until further use. 
Table 4. A general timeline of the immunization regime. 
Week Procedure 










6-20 Bleeding every 2-4 weeks 
22 Bleeding, final boosting 
23 Bleeding 
25 Experiment termination: final bleeding/dissection 
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2.3 Antigen  
2.3.1 ST3-tetrasaccharide conjugation to a CRM197 carrier protein 
S.pneumoniae tetrasaccharide (ST3-tetrasaccharide) (1) and bis (4-nitrophenyl) adipate (2) were 
combined at 1 to 6.5 equivalent in DMSO and pyridine in v/v ratio 1.6 (Figure 13). Then 180 
equivalents of triethylamine were added, and the solution was stirred for three hours at room 
temperature. The resulting solution was frozen in liquid nitrogen and subsequently lyophilized to 
give a crude white solid. Excess bis (4-nitrophenyl) adipate was removed by washing the crude 
solid with chloroform (3 x 1 mL) and dichloromethane (3 x 1 mL) until no more bis (4-
nitrophenyl) adipate was observed by the Thin-layer Chromatography (TLC). The resulting 
compound (3) was taken forward to the next reaction without additional purification. To a pre-
weighed vial of CRM197 (4; Pfenex, California, USA) was added  utocl ve  w ter (750 µL). 
The solution was transferred to an Amicon 10K filter and centrifuged for 8 min at 10,000 rpm. 
The filtrate was discarded, and the remaining solution was added to the filter and centrifuged for 
8 min at 10,000 rpm. The CRM197 vial w s w she  with  utocl ve  w ter (~350 µL), 
transferred to the filter and centrifuged for 8 min at 10,000 rpm. The CRM197 vial was washed 
with phosph te buffer (350 µL, pH 8) (4), transferred to the filter and centrifuged for 8 min at 
10,000 rpm. Subsequently, the filter was removed, turned upside down into a clean vial and 
centrifuged for 2 min at 1,000 rpm, giving a colorless filtrate containing CRM197. The filtrate 
was added to a vial containing the tetrasaccharide-linker construct (3). The resulting solution (5) 
was stirred for 18 h, after which the solution was transferred to an Amicon 10K filter and washed 
with so ium phosph te buffer pH 8 (2   400 μL). The sample was centrifuged for 8 min at 
10,000 rpm, followed by additional washing with autoclaved water (3 x 400 μL). Prior to the 
thir  w sh,  utocl ve  w ter (200 µL) w s    e  to the filter with thorough mi ing.   sm ll 
s mple (10 µL) w s t ken for M LDI-TOF-MS  n lysis.  utocl ve  w ter (200 µL) w s    e  
to the filter and centrifuged for 8 min at 10,000 rpm. The sample was washed with PBS (400 
µL).  fterw r , the filter w s remove   n  turne  upsi e  own into   cle n vi l  n  centrifuge  





Figure 14. The ST3-tetrasaccharide and CRM197 conjugation reaction.  
ST3-tetrasaccharide was covalently conjugated with CRM197 using the p-nitrophenyl adipate 
ester as a coupling reagent. 
2.3.2 Conjugate characterization 
2.3.2.1 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Polyacrylamide gel electrophoresis of glycoconjugates was performed according to the standard 
protocol. Discontinuous SDS-P GE w s prep re   ccor ing to Lämmli’s protocol, using a 
MiniProtean system (Bio-Rad, Hercules, USA). An alkaline separating gel (375 mM Tris/HCl 
pH 8.8, 10 to 12% (w/v) of a 29:1 acrylamide/N,N’-methylenebisacrylamide mixture) and an 
acidic stacking gel (100 mM Tris/HCl pH 6.8, 4.5% (w/v) of a 29:1 acrylamide/N,N’-
methylenebisacrylamide mixture), polymerized by the addition of TEMED and 10% (w/v) 
ammonium peroxodisulfate, were used. The glycoconjugates samples were dissolved in SDS-
PAGE loading buffer (200 mM Tris-Cl (pH 6.8), 400 mM DTT, 8% SDS, 0.4% bromophenol 
blue, 40% (v/v) glycerol). An amount of 1-2 μg of glycoconjug te  n  CRM197 ( s   positive 
control) was loaded per lane and PageRuler Plus Prestained Protein Ladder 10 to 250 kDa 
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(Thermo Scientific) w s use   s   size m rker (2 μL per l ne).  ll s mples were run  t 120 V 
and 25 mA for 90 min and stained with 0.5 % (w/v) Coomassie Brilliant Blue R-250 in 50 % 
(v/v) methanol and 10 % (v/v) acetic acid for 30 min. Stained gels were destained with 50 % 
(v/v) methanol and 10 % (v/v) acetic acid.  
2.3.2.2 Matrix-assisted laser desorption/ionization with time-of-flight detection mass 
spectrometry MALDI-TOF MS.  
Mass spectra were acquired with an Autoflex Speed MALDI-TOF system (Bruker Daltonics; 
Bremen, Germany). Samples were spotted using the dried droplet technique with 2,5-
dihydroxyacetophenone (DHAP) as matrix on MTP 384 ground steel target plates (Bruker 
Daltonics). Samples were prepared by mixing protein sample with DHAP matrix and 2% (v/v) 
trifluoroacetic acid (TFA) before spotting. The mass spectrometer was operated in linear positive 
mode. Mass spectra were acquired over an m/z range from 30,000 to 210,000 and data was 




2.4 Dose-dependent study  
2.4.1  Vaccine preparation and immunization 
An amount of conjugate corresponding to a dose of ST3-tetrasaccharide antigen from 2.2 g to 
0.01 g per injection was mixed with 125 g Aluminum Hydroxide (Al(OH)3) from Alum gel  
(Alhydrogel, Brenntag, Denmark) in total volume of 100 L of phosphate buffer (PBS pH 7.4, 
PAN-Biotech, Germany). The ST3-tetrasaccharide CRM197 conjugate was provided by 
Vaxxilon (Vaxxilon Deutschland GmbH, Berlin, Germany). Different antigen doses were 
calculated based on a glycan:protein ratio evaluated by MALDI-TOF-MS (Figure 15).  The 
v ccine w s rot te  overnight  t 4°C. The conjugates were filter sterilized using 0.22 µm small 
volume syringe filters. Prior to the formulation, the adjuvant was aliquoted and kept sterile, 
every time a fresh aliquot was used. 
 
Figure 15. Calculation of glycan loading ration per protein base on the mass of compound 





Mice (six animals per group) were immunized with 100 µL of glycoconjugate vaccines 
containing different amounts of SP3-tetrasaccharide antigen listed in Table 5. A total of four 
injections, prime + boost + boost + final boost regime, were administered s.c. in order to 
generate the antigen-specific antibody response.  
Table 5. Experimental groups for the dose-dependent study. 
 
2.4.2 Determination of non-adsorbed antigen on Alum particles - the Bicinchoninic 
acid assay (BCA assay) 
The adsorption of antigen was evaluated by determination of the free glycoprotein level in the 
supernatant by the Bicinchoninic Acid assay (BCA assay)  performed according to the 
instruction included into Micro BCA Protein Assay Kit (Thermo Fisher Scientific GmbH, Berlin, 
Germany).  The vaccines were prepared as mentioned above (2.4.1)  n  rot te  overnight  t 4°C 
to allow adsorption of the antigen on alum. The samples were centrifuged for 10 mins at 3000 x 
g, and non-adsorbed supernatants were carefully transferred to new Eppendorf tubes. No-
absorbed protein concentrations in the supernatants and control samples without adjuvant were 
analyzed immediately by BCA assay. Briefly, the round bottom non-treated 96 wells plate 
(Costar 3788, Sigma Aldrich, St. Luis, USA) was used for the assay. Samples and a calibration 
curve (CRM197 or Albumin standard at concentration of 1 mg/mL, 0.8 mg/mL, 0.6 mg/mL, 0.4 









1 2.2 µg 125 μg 
Adjuvant/glycoconjugate preparation just before 
injection, 4°C, rot tion O/N 
2 0.4 µg 125 μg 
Adjuvant/glycoconjugate preparation just before 
injection, 4°C, rot tion O/N 
3 0.1 µg 125 μg 
Adjuvant/glycoconjugate preparation just before 
injection, 4°C, rotation O/N 
4 0.1 µg 125 μg 
Adjuvant/glycoconjugate – the same batch for all 
injections, 4°C, rot tion O/N, aliquots were stored at 
4°C 
5 0.05 µg 125 μg 
Adjuvant/antigen preparation just before injection, 
4°C, rot tion O/N 
6 0.01 µg 125 μg 
Adjuvant/antigen preparation just before injection, 
4°C, rot tion O/N 
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(WR) containing reagent B + C + A in ratio 24:1:25 was prepared and mixed with each control 
or samples well at ratio 1: 20 (sample to WR). The pl te w s incub te   t 37°C for 30 min in the 
dark while shaking. The absorbance was measured at 562 nm. The percentage of non-adsorbed 
protein was calculated relative to control without adjuvant, as % adsorbed = 100% − % non-
adsorbed. All samples were measured in triplicates.  
2.4.3 Glycan array serum screening 
Individual synthetic oligosaccharide fragments of S.pneumoniae CPS, native CPS and related 
proteins were dissolved in sterile printing buffer (50 mM sodium phosphate buffer, NaPi, pH 
8.5) to the final concentration of 100 – 200 μM (volume  roun  20-50 µL). Compounds were 
spotted onto CodeLink N-hydroxysuccinimide-activated glass slides (SurModics Inc., Eden 
Prairie, USA) in two or three replicates using a contact-free piezoelectric microarray spotter 
(Scienion, Berlin, Germany). After the spotting was finished, slides were incubated for 16 to 24h 
in a humidity box at room temperature to allow the completion of the coupling reaction and 
quenched for 1 h at room temperature (using 100 mM ethanolamine in 0.1 M NaPi pH 9) to 
suppress the free reactive groups on the microarray surface. The slide was washed with water 
ddH2O, dried by centrifugation (5 min at 300x g)  n  store  in  t 4°C until use. 
Directly before the assay, the slide was blocked with the blocking buffer (1% (w/v) BSA in PBS) 
for one hour  t room temper ture or overnight  t 4°C.   Fle Well gri  (FlexWell 64, Grace Bio-
Labs, Bend, US) was attached and 20-40 μL of the serum s mples were  pplie  into wells. The 
sli e with serum s mples w s incub te  for 1h  t 37°C in   light-protected humidified box. The 
micro rr y w s w she  three times by  pplying 50 µL of w shing buffer (PBS + 0.1% Tween-
20) into every well. The secondary fluorescently labeled antibodies diluted in sample buffer (1% 








)  n  incub te  for 1h  t 37°C. The sli e w s w she  three times with 50 μL PBS + 0.1% 
Tween-20 and ddH2O and dried by centrifugation (5 min at 300x g)  
The fluorescence read-out was performed using an Axon GenePix 4300A microarray scanner 
and GenePix Pro 7 software (Molecular Devices, Sunnyvale, CA, USA). Image analysis was 
carried out with the GenePix Pro 8 software (Graphpad Software Inc., La Jolla, USA). The 
photomultiplier tube (PMT) voltage was adjusted such that scans were free of saturation signals.  
 





Anti-mouse IgG (H+L) FITC 
Life Technologies, Carlsbad, 
CA, USA 
A-31574 1:400 
Anti-mouse IgG1 Alexa 
Fluor® 594 
Life Technologies, Carlsbad, 
CA, USA 
A-21125 1:400 
Anti-mouse IgG2  (ƴ2 ) 
 le   Fluor® 647 
Life Technologies, Carlsbad, 
CA, USA 
A-21241 1:400 
Anti-mouse IgG3 (ƴ3)  le   
Fluor® 488 
Life Technologies, Carlsbad, 
CA, USA 
A-21151 1:200 
Anti-mouse IgM (µ ch in) 
 le   Fluor® 546 
Life Technologies, Carlsbad, 
CA, USA 
A-21045 1:200 
2.4.4 Enzyme-Linked Immunosorbent Assay - ELISA 
ELISA was performed using high-binding 96-well polystyrene microtiter plates (Corning, USA) 
coated with different CPSs (SSI Diagnostica, Kopenhagen) at a concentr tion 10 μg/mL (50 µL 
per well) in PBS (overnight incub tion  t 4°C). The pl tes were w she  three times with PBS + 
0.1% Tween-20 and blocked with 1% BSA-PBS at RT for 1 h. After three washing steps with 
PBS + 0.1% Tween-20, plates were incubated with serial dilutions of serum in duplicate or 
triplic te for 1 h  t 37°C. The pl tes were w she  with PBS + 0.1% Tween-20 and treated with 
horseradish peroxidase (HRP)-labeled secondary antibody diluted accordingly to Table 7 in 1% 
BSA-PBS followe  by incub tion for 1 h  t 37°C. The pl tes were washed three times with PBS 
+ 0.1% Tween-20 and the color was  evelope  using HRP substr te 3,3’,5,5’-
tetramethylbenzidine (TMB substrate; BD Biosciences, San Jose, USA). The reaction was 
stopped by quenching with 2% H2SO4. The absorbance was recorded at 450 nm using a standard 
ELISA plate reader. 
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Anti-mouse IgG  
(Fc-specyfic) HRP 
Dianova, Hamburg, Germany 115-035-164 1:10,000 
Anti-mouse IgM (µ ch in) 
HRP 
Life Technologies, Carlsbad, 
CA, USA 
M-31507 1:3000 
2.4.5 In-Vitro Opsonophagocytic Killing Assay – OPKA 
The in-vitro opsonophagocytic killing assay was performed as described previously by Romero-
Steiner et al. (160). Briefly, the effector HL-60 cells (a human origin leukemia cell line) at the 
concentr tion of  ppro im tely 4×10
5 
cells/mL in a complete RPMI cell culture medium (90% 
RPMI 1640, 10% FCS, 1 mM L-glutamine and penicillin-streptomycin solution; PAN Biotech, 
Germany) were differentiated with 0.8% Dimethylformamide (DMF; 99.8% purity; Fisher 
Scientific, Fair Lawn, N.J., USA) for 5-6   ys  t 37°C in the presence of 5% CO2. After 
differentiation, the cells were h rveste  by centrifug tion (300 × g, 5 min)  n  then vi ble cells 





, 0.1% gelatin, and 10% FBS; HyClone) at a density of 1x10
7
 
cells/mL directly before use.  
The frozen stock of Streptococcus pneumoniae previously grown to mid-log phase (in a growth 
medium  t 37°C / 5% CO2 to log phase OD600= 0.3 – 0.4) was diluted in the opsonophagocytic 
buffer to a final density of 10
6
 CFU/ml (1000 CFU in 20 µL). Individual or pooled sera samples 
(10 µL per well) were heat-in ctiv te  (56°C, 30 min) and aliquoted in round bottom non-treated 
96-well plates at four-fold dilution intervals (native serum follow by 1:8 to 1:8192 dilutions) and 
tre te  with the b cteri l suspensions (20 µL per well) to initi te opsoniz tion (incub tion for 15 
min  t 37°C).  fter preopsoniz tion, 10 µL of e tern l complement source (b by r bbit 
complement, Ce  rL ne, Ont rio, C n   )  s well  s 4×10
5
 differentiated HL-60 cells in a 
volume of 40 µL were    e  to e ch well (ph gocyte/b cteri  r tio 400:1)  n  pl tes were 
incub te  for 45 min  t 37°C in 5% CO2 environment (preferably with shaking at 220 rpm). The 
phagocytic reaction was stopped by putting the plate on ice for 20 min. Viable extracellular 
pneumococci were  etermine  by pl ting  liquots (5 µL) from e ch well on Columbi   g r 
plates with 5% (v/v) sheep blood (BD, New Jersey, US )  n  incub ting  t 37°C in 5% CO2. for 
63 
 
several hours to allow bacteria growing (6-8 in case of S.pneumoniae serotype 3). Visible colony 
forming units (CFU) were counted. Negative controls lacking either antibody, HL-60 or 
complement, as well as standard control WHO 007sp typing serum (Human Anti-Pneumococcal 
capsule Reference Serum, NIBSC, Herts, UK) were used. The assay was repeated two to three 
times independently. Percentage killing of bacteria was calculated as CFU reduction relative to 
negative control wells. Serum dilution responsible for 50% killing of bacteria was estimated 
through non-linear interpolation of the dilution-killing OPKA data.  
2.5 Carrier proteins 
2.5.1 Pneumolysin (Ply) as an alternative carrier protein 
2.5.1.1 Transformation of BL21 cells with Ply plasmid  
BL21 competent E. coli cells were used for transformation with the plasmid expression vectors 
for the S. pneumoniae Ply mutants based on the pET101/D-TOPO backbone containing 
Polyhistidine-tag (PlyW460E, PlyW433E – Trp460/433-->Phe mutation received from L.S. 
McDaniel, University of Mississippi Medical Center, USA). BL21 cells were slowly thawed on 
ice and gently mixed to ensure the even suspension. The purified plasmid (1 μL, in a 
concentration range 1-10 ng/μL) was added directly to the BL21 cells, stirred and incubated on 
ice for 5 min. Next, the tubes were heated for precisely 30 s in   42°C w ter b th ( voi  sh king) 
and place on ice for 2 min. The room temperature SOC medium (Super Optimal broth with 
Catabolite repression, Merck, Darmstadt, Germany) in 250 μL volume was added to each tube 
and incubated for 60 min  t 37°C while shaking (250 rpm). Cells were plated on selective media 
(LB agar; 50mg/mL filter-sterilized carbenicillin). 
2.5.1.2 Protein expression 
A single clone of Ply transformed BL21 cells were picked and grown in selective LB medium 
(10 g/L Tryptone, 5 g/L Yeast Extract, 5 g/L NaCl plus, 50 mg/mL carbenicillin to an OD600 = 
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0.5. Isopropyl-b-D-thiogalactopyranoside (IPTG) was added to the culture to a final 
concentration of 1 mM to induce protein expression. The culture was grown for an additional 4 – 
5 hours and bacteri l cells were collecte  by centrifug tion for 10 min  t 8,000   g in 4°C. Cells 
pellet was resuspended in PBS with 1 mg/mL of lysozyme  n  incub te  for 1 hour  t 30°C. The 
cells were cooled for 30 mins, lysed by sonication (10 intervals; 30s per interval, with alternating 
30s rest periods) and centrifuged for 20 min at 20,000 x g in 4°C. The supernatant containing 
protein was collected. 
2.5.1.3 The Pneumolysin (Ply) purification 
The recombinant Ply protein with Polyhistidine-tag (His-tag) was purified using the Protino
®
 Ni-
NTA Column (Macherey-N gel, Germ ny)  n  ÄKTA pure chromatography system (GE 
Healthcare Life Science, Chicago, USA). The column was equilibrated with equilibration buffer 
and cell lysate with recovered recombinant Ply was loaded onto a 1 mL prepacked Ni-NTA 
column (1mL/min flow rate, 0.3 MPa pressure limit). The column was extensively washed with 
washing buffer (PBS, 25mM imidazole pH 7.4). Next, the His-tagged Ply protein was eluted 
with elution buffer (PBS, 250mM imidazole, pH 7.4) and subsequently dialyzed against PBS 
(pH 7.4). Before using for biological assays, the protein was concentrated using Amicon
®
 Ultra 
10K filters (Merck Millipore, Massachusetts, USA). A summary of all buffers used for the 
purification is shown in Table 8.  
Table 8. Buffers used for affinity chromatography purification. 
 
Extraction buffer (PBS) 
50mM Sodium phosphate 
300mM Sodium chloride 
Equilibration buffer (pH 7.4) 
PBS 
10mM Imidazole 
Washing buffer (pH 7.4) 
PBS 
25mM Imidazole 
Elution buffer (pH 7.4) 
PBS 
250mM Imidazole 
Pneumolysin purity was checked by Coomassie Blue staining of SDS-polyacrylamide gels and a 
concentration was determined by NanoDrop 1000 Spectrophotometer (A280 absorbance was 
automatically translated to protein concentration based on an intrinsic standard). 
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2.5.1.4 Protein conjugation to the synthetic oligosaccharide 
Pneumolysin PlyW433E was conjugated to S. pneumoniae serotype 3 tetrasaccharide (ST3) 
using the standardized protocol described previously (see section 2.3.1). The conjugation 
conditions were optimized by using PBS pH 7.4 as a washing solution and the sugar amount 
corresponding to the 1:70 equivalents (m/m protein: sugar). 
2.5.1.5 Mouse immunization and serum collection 
C57BL/6 six to eight week old female mice were immunized subcutaneously (s.c.) with the dose 
of conjug te correspon ing to 0.4 μg of SP3-tetrasaccharide and Aluminium hydroxide as an 
  juv nt (0.125 μg of  lum,  lhydrogel, Brenntag, Denmark) in a total volume of 100 uL of 
PBS. The immunization followed the standard schedule of prime + boost + boost as showed in 
Figure 16. Blood was collected via the tail-tip bleeding method and processed as described in 
paragraph 2.2 
. 
                      
Figure 16. Short-term prime + boost + boost immunization schedule. 
2.5.1.6 Evaluation of antibody response  
The carbohydrate- and protein-specific antibody response was measured by glycan array and 
ELISA  (as described previously in section 2.4.3 ad 2.4.4). ELISA plates were coated with 
purified Pneumolysin (PlyW433E) and CPS of S.pneumoniae serotype 3 (SSI Diagnostica, 
Kopenhagen) at concentration 10 μg/mL in PBS (volume of 50 µL per well). 
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2.5.1.7 Red blood cell (RBC) lysis assay 
The neutralizing ability of Pneumolysin-specific antibodies was tested using the red blood cell 
lysis assay. A 96-well non-treated round-bottom plate was used for the test. Serum samples were 
serially diluted in 1% BSA/PBS to a final volume of 25 μL. The full-length native pneumolysin 
w s  ilute  to the concentr tion of 1 μg/mL and added to each well in a volume of 25 μL. The 
plate was incubated for 30 min  t 37°C with shaking. Human red blood cells (hRBC) were 
prepared at 1% concentration in PBS and distributed to each well in a volume of 50 μL. The 
pl te w s incub te  for 60 min  t 37°C without shaking and centrifuged for 10 min at 1,000 rpm. 
80 μL of supernatants from each well were transferred to a new 96-well flat-bottom plate. The 
absorbance was measured at 414 nm using an ELISA plate reader. Control wells containing 
nonlysed 1% hRBC were used to determine the average maximum absorbance value at A414. The 
hemolytic titer was defined as the reciprocal dilution of serum that corresponded to a 50% 
decrease in the maximum absorbance value at A414. 
2.5.1.8 RBC lysis assay with a whole bacteria cells lysates 
Bacterial culture (2 mL of S.pneumoniae serotype 3 (ST3), S.pneumoniae serotype  2 (ST2) and 
S.pneumoniae serotype 8  (ST8)), were cultured in brain heart infusion broth (at 37°C in 5% CO2 
environment) to log phase (OD600 = 0.6). Cells were centrifuged, washed with PBS and re-
suspen e  in 100 μL of cell wall digestion buffer (10 mM Tris pH 7.5, 30% Sucrose, 1x protease 
inhibitor, 1 mg/mL lysozyme) for 3 h  t 37 °C. The protopl sts were    ition lly lyse  by 
sonication (samples on ice, sonication output control 4, 40W, 5 min). The lysates were 
centrifuged, and the supernatants were filter sterilized. Samples were filled to 1 mL a volume 
with F-12 K medium (Ham's F-12K (Kaighn's) Medium, Thermo Fisher Scientific, 
Massachusetts, USA). The supernatant was plated at blood agar plates to confirm the absence of 
bacterial colonies. 
2.5.1.9 Electric Cell-substrate Impedance Sensing - ECIS 
The A549 adenocarcinomic human alveolar basal epithelial cell line (received from Sander 
Group, Department of Infectious Diseases and Respir tory Me icine  t Ch rité 
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Universitätsme izin Berlin) was maintained in complete DMEM (Dulbecco Mo ifie  E gle 
Me ium , PAN Biotech, Germany) with 20% FCS (PAN Biotech, Germany) at a cell 
concentration between 6 x 10
3







 Zθ  rr y st tion ( pplie  Biophysics Inc, New York, US ) was used for the assay. 
1 x 10
5
 A549 cells in a volume of 400 µL of complete DMEM with 20% FCS were added to 
each well of 8W10E ECIS Culturew re™ Dispos ble Electro e  rr y ( pplie  Biophysics Inc, 
New York, USA) and cultured for 24h  t 37°C/5% CO2. On the next day, the medium was 
exchanged to DMEM without FSC (100 µL), and the control resistance was measured for one 
hour. The whole bacteria cell lysates of S.pneumoanie serotype 2, 3 and 8 were pre-incubated for 
1h in 37°C on   sh ker with serum from mice immunized with ST3-tetrasaccharide pneumolysin 
conjugate (see 0) collected on day 35. Pre-incubated bacteria lysate and serum samples were 
added to the respective wells (see an example in Figure 17). The assay was performed overnight. 
The electrode system measured the resulting voltage (V) across the electrodes. The impedance 
(Z) was given by the AC equivalent of Ohm's law: Z=V/I, where I was corresponding to a 
current. The pure resistive (R), as well as the capacitive portions (C) of the impedance, were also 




Figure 17. The exemplary setting of the Electric Cell-substrate Impedance Sensing assay. 
The whole bacteria cell lysates of S.pneumoanie serotype 2, 3 and 8 with and without serum 
samples were added to the wells containing A549 adenocarcinomic human alveolar basal 
epithelial cell line. The ECIS
®
 Zθ  rr y Station measured the resulting voltage (V), impedance 




2.6 Pneumolysin challenge study 
2.6.1 Immunization 
Six to eight week old female C57BL/6 mice (purchased from Charles River; Sulzfeld, Germany) 
were immunized according to the prime + boost + boost schedule as shown in Figure 16. In total, 
64 animals were divided into two infection group accordingly with S.pneumoniae serotype 2 (32 
mice) and S.pneumoniae serotype 3 (32 mice). Each infection group was vaccinated s.c. with: (1) 
conjugate of S.pneumoniae serotype 3 tetrasaccharides and PlyW433E (ST3-Ply); (2) conjugate 
of S.pneumoniae serotype 3 tetrasaccharide and CRM197 (ST3-CRM197); (3) positive control of 
Prevn r®13  n  (4) neg tive control  s PBS only (see Table 9).  
Table 9. Experimental groups used for SP3-tetrasaccharide Pneumolysin conjugate 





Infection with  
S.pneumoniae serotype 2 
(ST2) 
Infection with  
S.pneumoniae serotype 3 
(ST3) 
1 ST3-Ply 8 8 
2 ST3-CRM197 8 8 
3 Prevnar13
®
 8 8 
4 PBS 8 8 
 In total 32 32 
                   Ʃ64 animals 
The vaccines were prepared as described previously (2.4.1). Briefly, groups 1 and 2 containing 
an amount of conjugates (both SP3-Ply and SP3-CRM197) correspon ing to    ose of 0.4 µg of 
SP3-tetrasacch ri e in formul tion with 0.125 µg of  lum ( luminium hy ro i e;  lhy rogen, 
Brentage, Denmark) in a total volume of 100 µL PBS. Group 3 cont ins 100 µL of Prevnar13
® 
and group 4, 100 uL of PBS. 
2.6.2 S.pneumoniae serotype 2 (ST2) and serotype 3 (ST3) challenge model 
S.pneumoniae serotype 2 and serotype 3 were plated from frozen stocks on Columbia Agar 
pl tes with 5% (v/v) sheep bloo , grown for  ppro im tely nine hours  t 37 °C/5% CO2 and 
inoculated as single colonies in Todd Hewitt Broth with 0.5% (w/v) yeast extract (growth 
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medium). Cultures were culture   t 37 °C/5% CO2 to mid-log growth phase (OD600 = 0.3 – 0.4) 
and harvested by centrifugation (5000 rpm / 10 min).  
Mice were anesthetized by intraperitoneal (i.p) administration of ketamine (80 mg/kg, Ketavet
®
, 
Pfizer, Berlin, Germany) and xylazine (25 mg/kg, Rompun
®
, Bayer, Leverkusen, Germany). 
Infection with S. pneumoniae serotype 2 (5 x 10
7
 CFU) and S. pneumoniae serotype 3 (5 x 10
6 
CFU) w s performe  intr n s lly in   tot l volume of 20 μL b cteri   ilute  in PBS. Dise se 
severity was evaluated at 12-hour intervals (more often if animals were severely ill) for 36 - 48 h 
after bacterial infection to assess appearance, behavior, grooming, respiration and body weight. 
Measurement of rectal temperature was made at every time point (BAT-12 Microprobe 
Thermometer, Physitemp Instruments, Clifton, USA).  
Mice were sacrificed 36h (ST2 infection) and 48h (ST3 infection) after bacteria inoculation or 
when they reached at least one of the predefined human endpoints criteria (body temperature 
<30°C; bo yweight loss >20%; cumbersome bre thing;  cceler te  bre thing in combin tion 
with staggering, pain or paleness) by exsanguination via the caudal Vena cava after i.p. injection 
of ketamine (160 mg/kg body weight) and xylazine (75 mg/kg). Blood was drawn from the Vena 
cava caudalis, and lungs as well as spleen were removed. 
After blood collection, serial dilutions of blood were plated on Columbia agar plates with 5% 
(v/v) sheep bloo   n  incub te  overnight  t 37°C in 5% CO2 environment to estimate bacteria 
recovery (number of CFU in the blood). Blood antibody levels were monitored by glycan 
microarray and ELISA analysis. Lungs were homogenized by passage through a cell strainer 
(100 μm pores, BD Bioscience, Hei elberg, Germ ny) to  ssess the resi u l b cteri l bur en. 




2.6.3 S.pneumoniae serotype 2 challenge study 
2.6.3.1 Conjugation of ST2-hexasaccharide and ST3-tetrasaccharide to Pneumolysin and PspA 
carrier proteins and conjugates characterization. 
S. pneumoniae serotype 3 tetrasaccharide (ST3) and serotype 2 hexasaccharide (ST2) were 
conjugated to pneumolysin PlyW433E (Ply), and PspA using the standardized protocol described 
previously (see section 2.3). Proteins were received from Dr. Thomas Kohler from the 
Department of Molecular Genetics and Infection Biology, Universität Greifsw l . The 
conjugation conditions were optimized by using PBS pH 7.4 as a washing solution for proteins 
and the sugar amount corresponding to the 1:70 equivalents (m/m protein: sugar). Conjugates 
were characterized by Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) and matrix-assisted laser desorption/ionization with time-of-flight detection mass 
spectrometry MALDI-TOF MS.  
2.6.3.2 Immunization 
The animal experiment was conducted in accordance to the guideline of the ethic committee at 
the University of Greifswald, the German regulations of the Society for Laboratory Animal 
Science (GV-SOLAS) and the European Health Law of the Federation of Laboratory Animal 
Science  ssoci tions (FEL S ). The tri l w s  pprove  by the L n es mt für L ndwirtschaft, 
Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern (LALLF M-V, Rostock, 
Germany) and the LALLF M-V ethical board (LALLF M-V permit no. 7221.3-1-061/17). All 
efforts were made to minimize the discomfort of the animals and ensure the highest ethical 
standards.  
Six to eight week old female inbred C57BL/6 mice (n = 12, Charles River Laboratories, 
Sulzfeld, Germany) were immunized intranasally a two-week interval according to the prime + 
boost + boost regime. Conjugates of ST2-hexasaccharide and ST3-tetrasaccharide with PspA and 
Pneumolysin ( ose equ l to 2.5 µg of protein) were formul te  with 4 μg Choler  to in subunit 
B (CTB; Sigma-Aldrich, Missouri, United States)  s  n   juv nt in   tot l volume of 10 µL. PBS 
and ST3-tetrasaccharide CRM197 conjugate with CTB were administered as a negative control. 
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Blood samples were taken before each immunization step (n = 6) and two weeks after the last 
immunization (n = 6) for antibody measurements. Therefore, mice were punctured in the facial 
vein following gentle anesthesia with 2.5% isoflurane/oxygen mixture (Baxter, Illinois, United 
States). 
2.6.3.3 Intranasal infection of mice with S.pneumoniae serotype 2  
Three weeks after the final immunization, mice were intranasally infected with S. pneumoniae 
D39 (serotype 2). Pneumococci were cultured in advance in liquid Todd Hewitt Broth (THY, 
Sigma Aldrich, Missouri, USA) supplemented with 10% heat-inactivated (h.i.) FCS until mid-
log growth phase (OD600nm 0.35) and stored as glycerol-supplemented aliquots at -80 °C. 
Appropriate amounts of aliquots were thawed on the day of infection followed by adjustment of 
the infection  ose to 3.5 × 10
6
 CFU in 5 µL of PBS per mouse, verifie  by pl ting on bloo   g r 
plates. For the intranasal application, mice were anesthetized by intraperitoneal injection of 
ketamine/xylazine (50 mg/kg weight of mouse ketamine (KetanestS, Pfizer Pharmaceuticals; 
Provet AG, Berlin, Germany) + 5 mg/kg weight of mouse xylazine (Rompun, Provet AG)). 
Three days post-infection, mice were euthanized, followed by a collection of nasal tissue, 
bronchoalveolar lavage (BAL), blood and spleens. BAL samples and homogenates of nasal 
tissue were serially diluted to determine the bacterial recovery (Log10 CFU/mL). Remaining 
BAL and the nasal homogenate were snap-frozen and stored at -80 °C for further  n lyses. Post-
challenge blood samples were collected from the heart by puncture of the Ventriculus cordis 
dexter followed by centrifugation at 1000 × g for 20 min and storage of the collected sera at -20 
°C. Isolated spleens (n = 6) were transferred to a culture medium (RPMI 1640 + 10% h.i. FCS + 
1% Pen/Strep) and kept on ice until further processing. Single-cell suspensions of harvested 
spleens were prepared in 15 mL cell culture medium (RPMI 1640 + 10% h.i. FCS + 1% 
Pen/Strep) followed by the removal of red blood cells (RBC) by incubation with 5 mL RBC lysis 
buffer for 5 min. The reaction was stopped by the addition of 10 m cell culture medium. After 
centrifugation, the cells were resuspended in a 1 mL storage medium (h.i. FCS + 10% DMSO) 




2.7 Adjuvants  
2.7.1 Vaccine formulation and immunization 
Six to eight week old female C57BL/6 mice (purchased from Janvier Labs, Saint-Berthevin, 
Fr nce) were immunize  s.c. with 100 µL volume of ST3-tetrasaccharide CRM197 conjugate 
vaccines in a different adjuvant formulation, according to the long-term prime + boost + boost + 
final boost vaccination regime (as shown in Figure 13 and Table 4). In total, 60 animals were 
divided into eight experimental groups (Table 10). 
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All groups contained an amount of S.pneumoniae serotype 3 tetrasaccharide CRM197 conjugate 
correspon ing to    ose of 0.4 µg of ST3-tetrasaccharide (conjugate prepared as described 
previously in the chapter 2.3.1).  
The ST3-tetrasaccharide formulated with Aluminium hydroxide was prepared as described 
previously in method 2.4.1. Group 2 – ST3-tetrasaccharide - MF59 was formed by 
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emulsification of the ST3-tetrasaccharide CRM197 conjugate with MF59 AddaVax™ 
(InvivoGen, San Diego, USA) in 1:1 volume ratio. The water-in-oil emulsion was created by the 
“two-syringe” technique  irectly before injection. Briefly, two gl ss syringes cont ining  ntigen 
and adjuvant were connected with a double-ended syringe connector. The emulsion was formed 
by forcing a mixture of oil-in-water adjuvant and the antigen back and forth until the material 
became homogeneous and viscous. The syringes were carefully disconnected, and the antigen-
adjuvant emulsion was transferred to the plastic immunization syringe. 
The preparation of the vaccines in the form of PLGA particles is described in the next paragraph. 
2.7.2 Particle preparation 
Polylactic acid particles (PLA) were fabricated using a water/oil/water (W1 /O / W2) double 
emulsion solvent evaporation technique. A two-step  ppro ch w s employe  while 100 μL of the 
internal aqueous phase containing cargo (IAP or W1) was emulsified into 2 mL of the organic 
phase (OP or O; 50 mg/mL PLA-PDL 50, 0.49 dL/g in Dichloromethane) in a 10 mL glass vial 
using a sonicator fitted with a microtip (output control 4, 40 W, 1 minute), resulting in the 
primary emulsion (W1 / O). Microparticles were fabricated by emulsifying the primary 
emulsion, to the external aqueous phase (EAP or W2 8 mL (2% Polyvinylalcohol-PVA, Mw. 31 
- 50K, 98-99 % hydrolysis in 10% sucrose) by using a homogenizer with S 18 N-10G probe 
(10000 rpm, 8 min) resulting in the secondary emulsion (W1 /O / W2). The resulting secondary 
emulsion was poured into a glass beaker, covered with an aluminum foil punched with holes and 
stirred overnight at 400 rpm under a sterile bench to allow solvent evaporation and particle 
precipitation. The particles were collected by centrifugation at 13000 x g for 15 min, washed 
with nanopure water and lyophilized for 48 - 72 hours to obtain a fine powder. The vials were 
hermetic lly se le   n  store   t 4°C until further use. The supern t nt from w shing steps w s 




2.7.3 Particle characterization 
2.7.3.1 Flow cytometry analysis (FACS) of antigen-loaded PLA particles 
Lyophilized particles were re-suspended in PBS and washed by centrifugation (3000 x g, 5 min, 
4°C). Monoclon l  ntibo ies recognizing SP3-tetrasaccharide (7A9 and 5F6 received from 
Pirofski’s group, New York, US )  n  CRM197 (pro uce  in-house) diluted in 1% BSA/PBS 
were added to the particles and incubated overnight at 4°C while rot ting. The p rticles were 
washed three times with PBS and stained with anti-mouse IgG FITC (BD Biosciences, 
Heidelberg, Germany) and IgM- FITC (BioLegend, California, USA) diluted 1:100 in PBS for 
one hour. After three washing steps with PBS, the particles were subjected to flow cytometry 
using a FACS Canto II instrument (BD Biosciences, Heidelberg, Germany). 2,000 events were 
counted for each measurement. 
2.7.3.2 Confocal microscopy analysis of antigen-loaded PLA particles 
The encapsulation of antigen on the PLGA particles was checked by confocal microscopy 
analysis. Briefly, 10 mg of the particles were washed three times with PBS and incubated with 
the corresponding primary and secondary antibody as described in the chapter above (2.7.3.1). 
The samples were washed three times with PBS, placed onto a glass microscope slide and 
covered with a coverslip. Images were acquired using a confocal microscope (LSM-700 Carl 
Zeiss AG). 
2.7.3.3 Estimation of encapsulated antigens onto PLA particles  
The supernatant collected after washing the particles with PBS was used to evaluate the 




2.7.3.4 Transmission Electron Microscopy (TEM) of particles containing ST3-tetrasaccharide 
CRM197 conjugate and different adjuvants 
High-resolution imaging was performed using a Tecnai F20 X-Twin transmission electron 
microscope at GFZ Potsdam. The TEM is equipped with a field emission gun as an electron 
emitter. TEM bright-field images were acquired as energy-filtered images using a Gatan imaging 
filter GIF. A 20 eV window was applied to the zero-loss peak. Data were evaluated with the 
Gatan Digital Micrograph software package. 
2.7.3.5 Dynamic Light Scattering (DLS) Analysis 
The size distribution of nanoparticles was analyzed by dynamic light scattering (DLS) 
measurement technique using the Zetasizer μV N no (M lvern). Vesicles (10 μL) or 1 mg/mL 
n nop rticle suspension (10 μL) w s  ilute  in 1 mL PBS or w ter,  n  three me surements 
were performed at 25° C, each measurement comprising of 15 scans for 14 min. Microparticle 
size distribution was analyzed using a Mastersizer with each measurement performed in 
triplicates with a size range of 0.02-2000 μm. 
2.7.4 Analysis of the immune response of mice immunized with different adjuvant 
formulations 
2.7.4.1  FACS analysis of spleen and bone marrow 
Mice were sacrificed two weeks after the final boost. Blood was collected by cardiac puncture 
and spleen and bone marrow from the tibiae and femurs were isolated. Spleen was cut into four 
pieces and preserved in: (1) 4% formalin for immunohistochemistry staining; (2) 4% formalin 
for an immunofluorescence staining; (3) dry ice for an immunofluorescence staining; and (4) 
PBS for FACS analysis.  
The last piece of each spleen was weight; splenocytes cell suspension was prepared by pressing 
the org n through   40 μm cell str iner using   10 mL syringe plunger  n  w she  with PBS. 
Splenocytes were pellete   t 1300 rpm, 4°C for 10 min  n  resuspen e  in 3 mL of RBC lysis 
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buffer (0.01M KHCO3, 0.155M NH4Cl, 0.1 mM EDTA) for 10 min at RT. The reaction was 
stopped by adding 10 mL of PBS, and the pellet was washed twice with PBS. The splenocytes 
were counted using Trypan blue to exclude the dead cells.  
The tibiae and femurs were flushed with complete PBS and pipetted vigorously to disentangle 
the cells. The cell suspension was filtered with a 70 µm cell str iner, centrifuge   t 1300 rpm,  
4 
o
C for 5 minutes, resuspended in PBS and counted.  
Finally, both spleen and bone marrow cells were resuspended in 3 mL of PBS and divide into 
FACS tubes for the following staining: All antibodies used for staining were listed in Table 11, 
Table 12, and Table 13. 
2.7.4.1.1 Surface staining (B cells) 
The surface block master mix (0.5 mg/mL of αCD16/32, clone 93; Biolegend, San Diego, USA) 
was added to each tube and incubated for 5-10 minutes on ice. Cells were centrifuged at 1300 
rpm, 4 
o
C for 5 minutes and incubated with a surface stain master mix for 30 minutes at 4
o
C in 
the dark. Cells were washed once with PBS and analyzed on CANTO II (BD Bioscience 
FACSCanto™) 
2.7.4.1.2 Surface staining (T follicular (Tfh) cells) 
The surface block master mix (0.5 mg/mL of aCD16/32, clone 93; Biolegend, San Diego, USA) 
was added to each tube and incubated for 5-10 minutes on ice. Cells were centrifuged at 1300 
rpm, 4 
o
C for 5 minutes and incubated with CXCR5-Bio/buffer for 45 minutes to 1 hour on ice. 




2.7.4.1.3 Intracellular Cytokine Staining (ICS) and Intranuclear Staining (IS) 
 Stimulation 
Cells were resuspended at a concentration of 1 - 5 x 10
6
/mL in T cell medium + PMA (phorbol. 
12-myristate 13-acetate; ThermoFisher, Waltham, USA) + Ionomycin (calcium ionophore, 
ThermoFisher, Waltham, USA) to stimulate the intracellular production of the cytokines. Cells in 
200 µL volume were added to the 96-well round plate and incubated for 5 hours at 37
o
C. 
Brefeldin A (10 µL)  n  Monensin (fin l volume of 210 µL per well) were    e  to block 
extracellular proteins 2.5 hours post-stimulation transport and incubated for remaining 2.5 hours. 
 Surface staining 
Cells were centrifuged at 1300 rpm, 4
o
C for 5 minutes, resuspended in Surface Block Master 
Mix (50 µL) and incubated 5 - 10 minutes on ice. 50 µL of   Surface Staining Intra Antibody 
Mix (surface) was added to each well and incubated 10 to 15 minutes on ice in the dark. Cells 
were centrifuged at 1300 rpm, 4
o
C for 5 minutes and supernatant was discarded.  
 Fixation (the FoxP3 staining buffers kit) 
Cells were resuspen e  in 50 µL of  ntibo ies Mi  with Fo P3 Fi  tion/Perme biliz tion 
solution (eBioscience, ThermoFisher, Waltham, USA) and incubated 60 minutes at RT while 
sh king in the   rk. Wells were fille  up to 200 µL with 1  Perme biliz tion buffer  n  
centrifuged at 1300 rpm, 4 
o
C for 5 minutes. Cells were washed once with PBS and analyzed on 




Table 11. Staining panel for plasma cells, germinal center, and memory B cells. 
Antibody Color Clone Provider 
CD138 PE 281-2 Biolegend, San Diego, USA 
GL7 PerCP/Cy5.5 GL7 Biolegend, San Diego, USA 
CD19 PE-Cy7 ID3 ThermoFisher, Waltham, USA 
FAS APC 15A7 ThermoFisher, Waltham, USA 
CD38 Alexa 700 90 ThermoFisher, Waltham, USA 
IgD Pacific Blue 11-26 c.2a Biolegend, San Diego, USA 
B220 BV510 RA3-6B2 Biolegend, San Diego, USA 
 
Table 12. Staining panel for T follicular helper cells (Tfh) and memory T cells 
Antibody Color Clone Provider 
ICOS FITC 7E.17G9 ThermoFisher, Waltham, USA 
*CXCR5-Bio  L138D7 Biolegend, San Diego, USA 
Streptavidin PE  Biolegend, San Diego, USA 
PD-1 PerCP-eFluor 710 J43 ThermoFisher, Waltham, USA 
CD62L APC MEL14 Biolegend, San Diego, USA 
CD3e Alexa 700 
eBio500A2 
(500A2) 
ThermoFisher, Waltham, USA 
CD44 eFluor 450 IM7 ThermoFisher, Waltham, USA 
CD4 BV510 RM4.5 Biolegend, San Diego, USA 
*CXCR5-Bio+SA-PE: secondary antibody staining 
Table 13. Staining panel for T helper cells (Th1 and Tfh)  
Antibody Color Clone Provider 
**Bcl-6 PerCP-eFluor 710 BCL-DWN ThermoFisher, Waltham, USA 
*IFN-g PE-Cy7 XMG1.2 Biolegend, San Diego, USA 
*IL-21 Alexa 647 K112-91 Biolegend, San Diego, USA 
CD3e Alexa 700 
eBio500A2 
(500A2) 
ThermoFisher, Waltham, USA 
CD4 Pacific Blue RM4.5 Biolegend, San Diego, USA 
*IFN-g and IL-21: Intracellular cytokine         




Spleen samples were fixed in 4% buffere  form lin, embe  e  in p r ffin,  n  cut into 2 μm 
thick sections. The staining was performed and evaluated by the Department of Veterinary 
Pathology, Freie Universitaet Berlin.  
2.7.5.1 Hematoxylin and Eosin (HE) staining 
Hematoxylin staining was performed by dedicated staining machine with following steps: tissues 
were immersed three times in xylene (Chemsolute Xylol Technisch, Th. Geyer, Germany) for 2 
min, 2 min, and 3 min and then in a series of Ethanol solutions (Berkel, Germany) of decreasing 
concentrations (96%, 80%, and 70%) for 30 seconds. Samples were washed in water, stained 
with hematoxylin (Roth, Germany) for 8 mins, washes in water for 5 minutes and dyed in eosin 
(Waldeck, Germany) for 30 seconds. Spleens were immersed in increasing ethanol concentration 
(70%, 80%, 96%, and 100%) to eradicate the water. Finally, samples were absorbed four times 
in xylene immersions for 1 minute to replace the ethanol with xylene. Scanning of HE-stained 
slides was performed by Aperio CS2 slide Scanner (Leica Biosystems Imaging Ins., CA, USA). 
2.7.5.2 Immunohistochemistry 
Spleen samples were dewaxed in xylene (2 x 10 min), rehydrated in decreasing ethanol 
concentrations (2 x 100%, 2 x 96%, 1 x 70%; 3 min each) and the antigens were retrieved by 
heat (microwave 600 W) in 10 mM citric acid (pH 6.0). Tissue was incubated with anti-GL7 rat 
monoclon l  ntibo y (Invitrogen, C rlsb  , US ) in 1:100  ilution, overnight  t 4 °C. Neg tive 
controls were incubated with an irrelevant rat antibody (Biogenex rat, Innovative Diagnostic-
Systeme, Germany) at the same dilution and conditions. Next, the samples were incubated with 
biotinylated goat anti-rat secondary antibody (Vector Laboratories, Germany), in 1:200 dilution, 
30 min following incubation with HRP-coupled avidin-biotin complex (ABS-kit, Vector 
Laboratories, Germany) for 30 min. The color was developed by incubation with 
diaminobenzidine (DAB) for 8 min (ABS-kit, Vector Laboratories, Germany). The spleen 
samples were counterstained with hematoxylin (1 min) and dehydrated through graded ethanols 
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(70%, 2 x 96%, 2 x 100%, 3 min each) and immersed two times in xylene for 3 min before 
applying coverslip slides. The digital analysis of the samples was performed by Aperio nuclear 




2.8  Pigs as a large animal model 
2.8.1 Immunization 
Thirty healthy, six-week-old, 20 kg weight female pigs (German landrace Sus domesticus) 
purch se  from BHZP (BHZP GmbH;  n  er W ssermühle 8; 21368 D hlenburg-Ellringen) 
were kept at the animal facility of Friedrich-Loeffler-Institut, Bun esforschungsinstitut für 
Tiergesundheit Federal Research Institute for Animal Health Greifswald Insel Riems. 
Pigs (n = 6) were immunized according to the schedule presented in Table 14 with following 
vaccines: (1) ST3-tetrasaccharide CRM197 conjugate, (2) ST3-tetrasaccharide Pneumolysin 
conjugate, (3) Prevnar13
®
 as a positive control, (4) Alum only as a negative control. For the 
groups containing ST3-tetrasaccharide an amount of conjugate equ l to 2.2 µg of synthetic 
oligos cch ri e w s use .  ntigen w s   sorbe  onto 125 µg of  lum ( luminium Hy ro i e, 
Alhydrogel).  






10 Bleeding + 2
nd
 immunization 
15 Bleeding  
20 Bleeding + final immunization 
25 Bleeding 
35/36 Bleeding + dissections 
2.8.2 Antibody response  
Blood was collected on day -1, 10, 15, 20, 25 by the V. cava cranialis punctuation and on day 
35/36 by heart punctuation. Antibody titer and their subclasses were analyzed by glycan array 
and ELISA (as described previously in 2.4.3 and 2.4.4 respectively). Protective activity of the 
antibodies was evaluated by OPKA (described in 2.4.5). The neutralizing activity of anti-Ply 
antibodies was analyzed by RBC lysis assay (explained in 2.5.1.7) 
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2.8.3 FACS – T cells analysis 
Blood after first (day 20) and second boost (day 35) was collected into Li-Heparin tubes. 
Peripheral blood mononuclear cells were isolated according to the following protocol. Blood 
samples were diluted twice in NaCl and carefully overlaid on 3 mL of Pancoll, without mixing 
phases. Samples were centrifuged at 800 x g for 20 minutes, room temperature and the 
lymphocytes, together with monocytes and platelets, were harvested from the white cells layer 
between the plasma samples and the Pancoll. The separated cells were washed twice with RPMI, 
diluted to the concentration of 12.5 x 10
6
 cells per mL. Cells were stored overnight at 4°C. 
Cells were seeded in the volume of 200 µL PBMC/well in triplic tes  n  stimul ted accordingly 
to the primary immunization either with CRM197 (40 µg/mL), n tive Pneumolysin (40 µg/mL), 
ST3-tetrasaccharide CRM197 conjugate (40 µg/mL) or ST3-tetrasaccharide Pneumolysin 
conjugate (40 µg/mL).  fter 2h, Brefeldin A was added in 1:1000 dilution and incubated for 
another 4h. The cell was stained accordingly to the panel described in Table 15 and analyzed by 
FACS CantoII. 
Table 15. Staining panel for T-cell. 
 
Antibody Concentration Color Provider 
DCE 1:500 506 ThermoFisher, Waltham, USA 
Anti-CD14 1:50 Viogreen 
Abcam, Cambridge, United 
Kingdom 
Anti-CD3 1:200 PerCp-Cy5.5 Biolegend, San Diego, USA 
Anti-CD8 1:100 FITC Biolegend, San Diego, USA 
Anti-CD4 1:100 Alexa 647 Biolegend, San Diego, USA 
Anti-CD154 1:10 Pe-Vio770 Biolegend, San Diego, USA 
IFNγ 1:400 PE Biolegend, San Diego, USA, 





3 Results and Discussion 
3.1 The ST3-tetrasaccharide Glycoconjugate Adsorbs Significantly Better Onto 
Aluminium Hydroxide Particles.  
Synthetic ST3-tetrasaccharide CRM197 conjugate was obtained by coupling the ST3-
tetrasaccharide through the primary amine side chains of lysine residues and N-terminus of the 
Cross-Reactive-Material-197, called CRM197, using bis(4-nitrophenyl) adipate linker. CRM197 
is a non-toxic mutant of a diphtheria toxin, where the single amino acid exchange of a glycine in 
position 52 to a glutamic acid reduces the protein toxicity (161), widely used as a carrier protein 
for polysaccharide conjugated vaccines. The resulting glycoconjugate was characterized by SDS-
polyacrylamide gel electrophoresis shift assay (10% SDS-PAGE), and MALDI-TOF mass 
spectrometry to measure the average molecular size of the conjugate and the loading ratio ( 
Figure 18).  
The proper conjugation and presentation of carbohydrate epitopes on a carrier protein regulate 
the glycoconjugate uptake and presentation that is crucial for the vaccine immunogenicity as it 
might influence the interaction of both carbohydrates – antigen-presenting cells and the MHCII – 
CD4 T-cell. CRM197 contains 39 lysines with a heterogeneous reactivity to conjugation 
reactions (e.g. steric accessibility or the individual pKa of the respective lysine residues). 
Reaction conditions and conjugate size might also influence the conjugation efficacy of 
individual sites (161). The average loading of the glycan epitopes on each CRM197 protein was 
calculated based on the average mass of the conjugate (64494 Da), a carrier protein (58000 Da) 
and ST3-tetrasaccharide (864.75 Da) (an exemplary calculation is shown in Figure 18a). 





Figure 18. Characterization of the ST3-tetrasaccharide CRM197 conjugate by MALDI-
TOF-MS and SDS-PAGE.  
a) MALDI-TOF MS spectra of the glycoconjugate and CRM197 carrier protein. b) The 2 µg of 
CRM197 protein (line 2) and 2 µg of ST3-tetrasaccharide CRM197 glycoconjugate (line 3) were 
resolved on 10% SDS-PAGE and stained with PageBlue protein staining solution. The 
PageRuler Plus Prestained Protein Ladder was used as a molecular weight marker (line 1). 
 
The choice of proper adjuvant is one of the most crucial steps in vaccine preparation. Aluminum-
based adjuvants are common adjuvants used in marketed vaccines (e.g. Prevnar13
®.
, Hepatitis A 
(Havrix) and B (Engerix-B) vaccine, Meningococcal group B MenB vaccine (Bexsero, 
Trumenba), etc.) The Alum-adjuvants are available in two different forms as aluminium 
hydroxide (Alhydrogel) and aluminium phosphate (Adju-Phos). During the formulation of the 
vaccine antigen adsorbed onto pre-formed Al(OH)3 or AlPO4 based on electrostatic attraction 
depending on the charge of both antigen and Alum-adjuvant type. Aluminum adjuvants have a 
large adsorptive capacity and usually, only a small dose is necessary to adsorb vaccine antigens. 
Nevertheless, sometimes a dose larger than required for maximal adsorption is necessary to 
achieve an optimal immune response (162, 163). The maximum amount of aluminum per dose in 
hum n v ccines in the Unite  St tes is 0.85 mg  l
3+
 (162). To evaluate the best formulation of 
ST3-tetrasaccharide conjugated vaccine, different doses of glycoconjugate were used in 
combination with 0.125 mg of both aluminium hydroxide and aluminium phosphate. The chosen 





The vaccines were prepared as described in Method 2.4.1. Samples were centrifuged and 
supernatants were transferred to new Eppendorf tubes. The amount of non-adsorbed conjugate 
was evaluated by the BCA assay (previously described in 2.4.2). The adsorption level of the 
glycoconjugate onto aluminium hydroxide is significantly higher than onto aluminium phosphate 
(percentage values varying depend on antigen amount, (Table 16)). The highest possible 
adsorption ratio is important for controlling the quality of the vaccine by the amount of antigen 
delivered and taken up by immune cells. Therefore, I want to ensure that the proper adjuvant 
choice results in the same adsorption level and no significant variation will be observed in 
vaccine success rate. The result of the experiment clearly indicated that aluminium hydroxide 
(Alhydrogel) is a better choice of adjuvant for the ST3-tetrasaccharide CRM197 conjugate 
vaccine. 
Table 16. Adsorption level of ST3-tetrasaccharide CRM197 conjugate onto Alum particles 
in Aluminium-based adjuvants formulation with Al(OH)3 and AlPO4.  
The adsorption percentage of the glycoconjugates were calculated as a recovery of protein in the 
non-adsorbed supernatants relative to controls without adjuvant. Glycoconjugate was incubated 
with adjuvant overnight (O/N) at 4°C while rotating. Protein concentration was measured by 
BCA assay. Data are shown as the average of free measurements. 
Vaccine formulation  
(0.125 µg of Aluminium) 
Adsorption level  
(% of adsorption) 
Aluminium phosphate + 0.4ug of glycan 50 
Aluminium phosphate + 2.2ug of glycan ~25 
Aluminum phosphate + 4.4ug of glycan 55-60 
Aluminium hydroxide + 0.4ug of glycan 85-90 
Aluminium hydroxide + 2.2ug of glycan 95 




3.2 Immunization With Different Doses Of Synthetic ST3-tetrasaccharide CRM197 
Glycoconjugate Evokes the Production Of Anti-ST3 Capsular Polysaccharide 
Antibodies That Show In-Vitro Opsonophagocytic Activity 
No general information regarding the optimal dosage of oligosaccharide antigen is available. However, to 
achieve the best immune response following vaccination, the proper dosage of antigen with 
respect to the purity of the product as well as an animal model, has to be established. Hence, six 
to eight-week-old C57BL/6 mice purchased from Charles River were divided into six groups 
(five animals per group) and immunized with an amount of ST3-tetrasaccharide CRM197 
conjugate corresponding to a particular amount of ST3-tetrasaccharide antigen per injection (2.2 
µg, 0.4 µg, 0.1 µg. 0.05 µg and 0.01 µg). Vaccines were formulated with aluminium hydroxide 
as described in 2.4.1. Immunization followed the standard prime-boost-boost-final boost regime 
(Table 17). 
 Table 17. Immunization regime for dose-finding study 
Day Action 












180 Final boost; bleeding 
190 Bleeding 
 
Serum collected at different time points was used to evaluate the S.pneumoniae serotype 3 
capsular polysaccharide- and CRM197 carrier protein-specific antibody titer. ELISA assay 
shows that immunization with synthetic ST3-tetrasaccharide glycoconjugate elicits long term 
anti-carrier protein (CRM197-specific) antibody production on a similar level regardless of 
glycoconjugate dose. However, the higher doses of vaccine (2.2 µg and 0.4 µg) triggered a great 
antibody response already after the first immunization (day 10). The response to lower doses (0.1 
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µg, 0.05 µg, and 0.01µg) showed a slight delay (around 1 a.u. IgG titer after a first or second 
boost on day 31 or 35). The antibody level does not change significantly during the resting 
period (day 53 – 180) as well as after additional injections (final boost) of the vaccines (Figure 
19). As protein antigens are in general stronger immunogens than glycans, especially in mice 
model the results are mostly used as an indication of successful immunization.  

































































































Figure 19. IgG antibody responses against CRM197 measured by ELISA. 
Mice were s.c. immunized with glycoconjugate vaccines containing various doses of ST3-
tetrasaccharide CRM197 conjugate corresponding to a 2.2 µg, 0.4 µg, 0.1 µg. 0.05 µg and 0.01 
µg of ST3-tetrasaccharide. Blood was collected at different time points, and total serum IgG 
level was analyzed. The blue arrows indicate the immunization. Data are measurements of single 
animal antibodies titer on specified time points; n = 6 animal per group. 
The aim of immunization with synthetic glycoconjugate is to trigger the production of antibodies 
against native capsular polysaccharide of S.pneumonie serotype 3. The anti-CPS antibody titer 
was monitored over the time of the study. In comparison to anti-protein response, the production 
of anti-CPS IgG was delayed in time (measurable response after the first boost on day 31). The 
response was unpredictable diverse both within the groups (not all animals produce anti-CPS 
antibodies) and between different vaccine doses. Anti-CPS antibody titer in a group 1 and group 
2 immunized with the highest doses of synthetic tetrasaccharide (2.2 µg and 0.4 µg) was 
comp r ble to the group 6 injecte  with the lowest  ose of 0.01 µg. Surprisingly, the group 5 
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(0.05 µg) shows the worst response. Only one out of five animals produce CPS-specific 
antibodies, while based on anti-CRM197 antibody level immunization by itself worked well 
(Figure 20 and Figure 21). 













































































































Figure 20. S.pneumoniae serotype 3 capsular polysaccharide specific antibody responses in 
groups immunized with different doses of ST3-tetrasaccharide measured by ELISA.  
Mice were immunized with glycoconjugate vaccines containing various doses of ST3-
tetrasaccharide. Blood was collected at different time points, and total IgG titer was analyzed in 
serum. The blue arrows indicate the immunization. Data are measurements of single animal 
antibody titers on specified time points; n = 6 animal per group. 
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day 0 day 10 day 21 day 31 day 42 day 53
 
Figure 21. Comparison of the capsular polysaccharide of S.pneumoniae serotype 3 specific 
antibody titer between groups immunized with different doses of ST3-tetrasaccharide.  
Mice were immunized with glycoconjugate vaccines containing various doses of ST3-
tetrasacchari e; 2.2 µg (Group 1), 0.4 µg (Group 2), 0.1 µg (Group 3), 0.1 µg ( ifferent v ccine 
prep r tion, Group 4), 0.05 µg (Group 5)  n  0.01 µg (Group 6). Bloo  w s collecte   t 
different time points, and total IgG titer was analyzed in serum. The blue arrows indicate the 
immuniz tion. D t   re shown  s me n ±SEM of e ch group  t specifie  time points; n = 6 
animal per group.  
To evaluate the long term immune response, animals were rested for 18 weeks and received the 
final boost of ST3-tetrasaccharide CRM197 conjugated vaccine on day 180. No effect following 
the final immunization was observed (Figure 22). According to the regulation of the Office for 
Health and Social Affairs Berlin, the maximum allowed a length of the study was 209 days. We 
hypothesized that due to the time limitation, the relevant decrease in anti-CPS antibody titer 
could not be observed and the last boost did not cause an increase in the specific antibody level. 
Another assumption regarding the failure of final boosting might be caused by “overlo  e ”  n  
unsensitized animals with the antigen, so it was not recognized as foreign anymore. The study 
conducted in infants says that previous or simultaneous exposure to an epitope or antigens may 
limit the immune response. The competition during antigen processing, presentation, or 
























































































































Figure 22. Long term IgG responses against native capsular polysaccharide of 
S.pneumoniae serotype 3 measured by ELISA. 
Mice were immunized with glycoconjugate vaccines containing various doses of ST3-
tetrasaccharide. Blood was collected at different time points, and total IgG titer was analyzed in 
serum. Late time points were plotted to show an immune response after final boosting in 
comparison to antibody level after priming Data are measurements of single animal antibodies 
titer on specified time points; n = 6 animal per group. 
However, the study conducted by Eskola et al. has shown that lower antibody response is neither 
associated with impaired antibodies function nor with the induction of immune memory (165). 
Since antibodies to pneumococcal CPS protect the host against bacterial infection by opsonizing 
pneumococci and inducing phagocytosis, the opsonophagocytic killing assay (OPKA) has been 
widely accepted as the reference method for measuring the protective capacity of pneumococcal 
antibodies. The OPKA was performed to evaluate the variances in protective properties of serum 
from mice immunized with different doses of ST3-tetrasaccharide in glycoconjugate vaccines (as 
described in 2.4.5). Pooled sera of mice immunized with 2.2 µg (Group 1), 0.4 µg (Group 2), 0.1 
µg (Group 3), 0.1 µg different vaccine preparation (Group 4), 0.05 µg (Group 5) and 0.01 µg 
(Group 6) of ST3-tetrasaccharide were used. Before the assay, sera were heat-inactivated to 
avoid any dissimilarities in the level of complement (24). The OPKA results confirm that the 
synthetic glycoconjugate vaccines elicit opsonic antibodies that can kill S.pneumoniae serotype 
3. The dilutions of WHO 007sp typing serum necessary for 50% bacterial killing between 128 - 
512 are considered biologically significant for successful vaccines and served as a control. The 
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serum dilution responsible for 50% of bacteria-killing varies from group to group (Figure 23). 
No significant differences were observed (p > 0.05), however, 0.4 µg of ST3-tetrasaccharide 
synthetic glycan conjugated to carrier protein CRM197 is the dose of the vaccine inducing 
antibodies with the best opsonophagocytic activity (the highest serum dilution responsible for the 
killing of 50% bacteria, IC50 = 4767). Interestingly, the second-best dose contains the lowest 
 ntigen  mount (0.01 µg of synthetic glycan, IC50 = 3784,5). No correlation between antibody 
titer and opsonophagocytic protective activity was detected (p values > 0.05 and very low r
2 
) 
(Figure 24) so quantitative characteristics of antibodies (antibody level) do not contribute to 
OPA and the estimation of antibody activity. 








































































Figure 23. The in-vitro opsonophagocytic activity of sera from mice immunized with 
glycoconjugate vaccine containing different doses of ST3-tetrasaccharide.  
a) A comparison of OPKA activity of pooled sera from mice immunized with 0.2 µg (Group 1), 
0.4 µg (Group 2), 0.1 µg (Group 3), 0.1 µg ( ifferent v ccine prep r tion, Group 4), 0.05 µg 
(Group 5) and 0.01 µg (Group 6) doses of ST3-tetrasaccharide. Serum from blood collected on 
day 45 was used. Data are me ns ± SD of CFU re uction rel tive to neg tive control wells 
(samples lacking either antibody or complement) of three independent experiments. (b). The 
serum dilution responsible for 50% killing of S.pneumoniae serotype 3 was estimated through 
non-linear interpolation of the dilution-killing OPKA data. Data are mean ± SD of 50% killing 
values from OPKA using blood collected on day 53 and 190. Results were analyzed by the two 
























































Figure 24. Correlation between specific antibody titer and serum dilution responsible for 
the killing of 50% bacteria. 
Relationship between S.pneumoniae serotype 3 CPS specific antibody titer from group 
immunized with different amount of ST3-tetrasaccharide CRM197 conjugate corresponding to a 
particular amount of ST3-tetrasaccharide antigen (measured by ELISA) and serum dilution 
responsible for the killing of 50% bacteria (measured by OPKA). Plots show Pearson's 
correlations (r
2
 value coefficient), a P v lue of  ≤ 0.05 w s consi ere  signific nt. 
 
In summary, the CPSs isolated from bacterial culture usually contain many impurities which 
influence the activity of vaccine and the overall antigen dose cannot be dramatically decreased. 
Chemical synthesis of the highly pure and active antigen is the biggest advantage of the ST3-
tetrasaccharide semisynthetic conjugated vaccine. With this study, I proved that immunization 
with a significantly reduced amount of synthetic antigen does not decrease the protective activity 
of serum. Compared to the dose used in the commercial vaccine (2.2 µg), the lowest dose of 0.01 
µg gives still better IgG titer responsible for 50% of the killing of bacteria.  
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As establishing the best dosage is a crucial step for vaccine development, for subsequent study, I 
decided to follow the results and use 0.4 µg of ST3-tetrasaccharide synthetic glycan conjugated 
to carrier protein CRM197, which gave the best protective effect. The data is relevant for the 
mouse model and has to be evaluated in clinical studies for human use.   
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3.3 Immunization With ST3-Pneumolysin Glycoconjugate Triggers Production of 
Protective Anti-Carbohydrate and Anti-Pneumolysin Antibodies 
The bacterial capsule is the first target for the immune system and anti-CPS antibodies are highly 
protective. Therefore, commercial vaccines against S.pneumoniae contain capsular 
polysaccharides conjugated to the CRM197 carrier protein. However, each serotype of 
S.pneumoniae diverges based on differences in the polysaccharide structure and the replacement 
of serotypes included in vaccines with previously less prevalent pneumococcal serotypes occur. 
The serotype replacement problem has been a major reason for intensive research in the direction 
of  eveloping   ‘univers l’ bro  ly cross-protective pneumococcal vaccine. Targeting multiple 
membrane proteins based on their roles in bacterial pathogenicity and physiology seems to be a 
promising approach to achieve additive protection against pneumococci in mice. It has been well 
documented that protein carriers in glycoconjugate vaccines additionally induce an immune 
response against themselves, so-called "additional valency". Therefore, conjugation of synthetic 
oligosaccharides from the capsules of the most prevalent serotypes to conserved bacterial protein 
was the goal of this study. 
Pneumolysin is a cholesterol-binding toxin and one of the major virulence factors of 
S.pneumonie. The detoxified version of the protein has been chosen as a proof of concept for 
broadening the protection of ST3-tetrasaccharide conjugated vaccine.  
The plasmid expression vectors for the S. pneumoniae pneumolysin mutants (PlyW433E) were 
transformed into BL21 competent E.coli, and the recombinant pneumolysin proteins containing 
His-tagged were purified using the Ni-NTA column (Figure 25). The synthetic ST3-
tetrasaccharide was conjugated to the PlyW433E by the bifunctional linker, and the ST3-
tetrasaccharide pneumolysin conjugate (Ply-ST3-tetrasaccharide) was characterized by MALDI-
TOF and SDS-PAGE gel electrophoresis (Figure 25) with the average loading ratio of seven 




Figure 25. Characterization of purified pneumolysin PlyW433E by SDS-PAGE gel and 
ST3-tetrasaccharide pneumolysin conjugate by MALDI-TOF-MS.  
a) Characterization of the fractions from the pneumolysin purification process. Flow-through 
(line 2), washing steps (line 3 and 4) as well as elutions (line 5 and 6) were separated by 10% 
SDS-PAGE electrophoresis and stained with PageBlue protein staining solution The PageRuler 
Prestained Protein Ladder was used as a molecular weight marker (line 1). b) Matrix-assisted 
laser desorption/ionization (MALDI) analysis was carried out to measure the average molecular 
size of the ST3 tetrasaccharide Pneumolysin conjugate and the Pneumolysin carrier protein as a 
standard. 
Six to eight week old female C57Bl/6 mice were immunized s.c with the dose of 0.4 μg of ST3-
tetrasaccharide conjugated to pneumolysin carrier protein adsorbed onto aluminium hydroxide 
following the schedule prime-boost-boost. Serum for analysis of the immune response to the 
vaccination was collected (Table 18).  
Table 18. Immunization regime for a vaccination with ST3-pneumolysin glycoconjugate.  
day action 








 boosting; bleeding 
35 Bleeding 
 
The presence of the IgG antibodies against the synthetic ST3-tetrasaccharide on day 0, 21, and 
35 were measured by glycan array (Figure 26a). Sera containing antibodies that are cross-
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reactive with native CPS of S.pneumoniae serotype 3 and antibodies recognizing native 
pneumolysin was evaluated by ELISA (Figure 26b). The antibodies show protective activity 
against serotype 3 by in vitro opsonophagocytic killing assay (OPKA). No cross-protection with 
unrelated serotypes was proven, which leads to the conclusion that only glycan-specific 
antibodies can bind the complement and cause the killing of bacteria (Figure 26c). Nevertheless, 
the conjugation procedure does not influence the antigenic properties of the pneumolysin protein. 







Figure 26. Mice immunized with ST3-tetrasaccharide pneumolysin conjugate vaccine 
produce protective ST3-tetrasaccharide and pneumolysin specific antibodies  
a) Representative picture of glycan array analysis of serum from mice immunized with the ST3-
tetrasaccharide pneumolysin conjugate. The dots marked with the frame showed the binding of 
the antibody to ST3-tetrasaccharide printed on a glass slide. The anti-mouse IgG Alexa594 in a 
dilution 1:400 was used as a secondary antibody. b) Evaluation of ST3-tetrasaccharide and 
pneumolysin specific antibody level by ELISA in mice sera collected on day 35. The plate was 
coated with both S.pneumoniae serotype 3 CPS (10 µg/mL) and native pneumolysin protein (10 
µg/mL). c) The in-vitro opsonophagocytic activity of serum from mice immunized with ST3-
tetrasaccharide pneumolysin conjugated. Blood was collected on day 35. Pooled sera from mice 
vaccinated with glycoconjugate vaccine as well as control WHO 007sp typing serum were used 
against S.pneumoniae serotype 2 (ST2), serotype 3 (ST3), and serotype 5 (ST5). Data are means 




3.4 Anti-Pneumolysin Antibodies Inhibit the Hemolysis of Human Red Blood Cells 
by Whole Bacterial Cell Lysate and Prevent Alveolar Epithelial Cell 
Permeability In-Vitro 
It has been shown in many studies that anti-pneumolysin antibodies reduce the cytotoxic effects 
of Pneumolysin and delay the onset of disease caused by S.pneumoanie (166, 167). As 
demonstrated by Salha et al., the anti-pneumolysin monoclonal antibody known to inhibit the 
hemolytic activity of the toxin in vitro was also able to confer protection in vivo by reducing 
tissue damage, proinflammatory IL-6 response, or neutrophil infiltration in lungs (166). 
To prove that the anti-toxin antibody in serum collected from mice immunized with ST3-
tetrasaccharide pneumolysin conjugated vaccine can reduce the cytotoxic effect of the protein, 
the in vitro human red blood cells hemolysis assay was performed. Briefly, a polyclonal mice 
sera (collected on day 35) containing anti-pneumolysin antibody was incubated with 25 ng of 
native pneumolysin in the presence of human red blood cells (hRBCs). The hemoglobin release 
measure at the absorbance A540nm.indicates the damage of the red blood cell membrane by the 
toxin (erythrocytes lysis). Serum collected on day 35 shows strong toxin neutralizing activity. 
Anti-pneumolysin antibodies were able to completely inhibit the lysis of hRBCs compared to 
serum withdrawn on day 0. The neutralizing effect was visible up to 80 x serum dilution (Figure 
27a,b). The assay was performed with pooled serum. Therefore, statistical analysis was not 
performed.  
Pneumolysin is a conserved multi-functions membrane protein among all S.pneumoniae 
serotypes. To demonstrate that use of the detoxified pneumolysin as a carrier protein for 
synthetic carbohydrate vaccines can extend the cross-serotype protection by reducing the 
symptoms of the infection with a serotypes not included in a vaccine or during co-infection with 
non-related bacteria, hRBCs were incubated with the mice serum collected on day 35 and 
bacterial lysate of three different S.pneumoniae serotypes: serotype 2, 3 and 8. Significant 
reduction of hemoglobin released was observed independent on serotype used in the assay 
(Figure 27c) with probability values accordingly fo ST2 p = 0.0065, ST3 p = 0.0008 and ST8  
p = 0.0261. As the bacteria cell lysate contains different toxins and lytic components; minor 
hemolysis was still noted. The most significant reduction in cytotoxicity was seen with lysate of 
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serotype 3 which might suggest the additional neutralizing effect of specific anti-glycan 
antibodies.  
Epithelial cells are one of the targets for S.pneumoniae. They contribute to maintaining the 
barrier function in the lung as well as in the brain. The disruption of epithelial cell integrity of 
the lungs causes acute pneumonia and in a brain leads to meningitis. Hence, the effects of 
pneumolysin on epithelial barrier function was analyzed in-vitro. The human alveolar basal 
epithelial cell line A549 was exposed to cell lysate of S.pneumoniae serotype 2, 3 and 8 pre-
incubated with and without the serum from mice immunized with the ST3-tetrasaccharide 
pneumolysin conjugated vaccine (blood was collected on day 35). Changes in transcellular 
electrical resistance of cell monolayers were analyzed by Electric Cell-substrate Impedance 
Sensing (ECIS). Serum containing anti-pneumolysin antibody significantly inhibit the effect of 
the toxin on the cells monolayer electrical resistance (Figure 27d), indicated as a lower decrease 
in A549 monolayer permeability compares to a cell with bacterial lysate only (p-value > 0.0001).  
The above results indicate that mice immunized with the ST3-tetrasaccharide pneumolysin 
conjugated vaccine produce high levels of pneumolysin-neutralizing antibody, which may block 
acute lung injury in the early course of pneumococcal pneumonia and following respiratory 
failure. The antibodies against pneumolysin produce after immunization with the semi-synthetic 
ST3-tetrasaccharide pneumolysin conjugated vaccine, therefore have additional beneficial effects 





Figure 27. Inhibition of serotype independent pneumolysin induced lysis of human red 
blood cells by anti-pneumolysin antibodies from mice immunized with ST3-tetrasaccharide 
pneumolysin conjugated vaccine. 
a) Inhibition of hemolytic activities of native pneumolysin by antibodies from mice immunized 
with ST3-tetrasaccharide pneumolysin conjugate. Hemoglobin release is expressed as the A540 of 
 ss y supern t nts (me n ± SD). b) Representative picture of the results of hRBC hemolysis 
assay. c) The inhibition of hemolytic activities of the whole bacteria cells lysates of 
S.pneumoniae serotype 2, 3 and 8 by antibodies from mice immunized with ST3-tetrasaccharide 
pneumolysin conjugated vaccine. Hemoglobin release is expressed as the A540 of assay 
supern t nts (me n ± SD). The st tistic l signific nce was calculated by paired t-test. d) Serum 
from mice immunized with ST3-tetrasaccharide pneumolysin conjugate protects pneumolysin-
induced endothelial barrier disruption. A549 cells were treated with the whole cell lysate of 
S.pneumoniae serotype 2, 3 and 8 with and without serum from mice immunized with ST3-
pneumolysin (blood collected on day 35). Transcellular electrical resistance was continuously 
monitored and normalized to baseline resistance. Statistical significance was calculated by 





3.5 Immunization With ST3-Tetrasaccharide Pneumolysin and CRM197 Conjugates 
Decreases the Bacterial Load in Blood and Lungs as well as Reduces Disease 
Severity in Mice Challenged With S.Pneumoniae Serotype 3 Bacteria  
To determine whether ST3-tetrasaccharide pneumolysin and CRM197 conjugated vaccines are 
functional in a disease setting, mice were immunized with a dose of glycoconjugates 
corresponding to a 0.4 µg of ST3-tetrasaccharide antigen following the prime + boost + boost 
regime (Table 19) and intranasally infected with S. pneumoniae serotype 3 as described in 2.6.2. 
To evaluate the serotype-independent protection by anti-pneumolysin antibodies, an additional 
group of animals was challenged with S. pneumoniae serotype 2, (after the same immunization 
regime). Control mice received Prevnar13
®
 and PBS. Clinical signs, body weight, and rectal 
temperature were monitored every 12 hours following a clinical score. The pulmonary bacterial 
outgrowth and blood bacterial load were examined after animals were sacrificed 36 and 48 hours 
post-infection. ST3-tetrasaccharide and carrier proteins specific antibody level was analyzed by 
glycan microarray and correlated with disease severity. 
Table 19. Immunization and infection regime for S.pneumoniae serotype 2 and serotype 3 
challenge study.  
day action 








 boosting; bleeding 
35 Bleeding 
42 Bleeding 




Immunization with ST3-tetrasaccharide CRM197 conjugate and commercial vaccine Prevnar13
®
 
significantly alleviated the disease severity (no decrease in body weight and absence of 
hypothermia) when compared to the control PBS treated mice (Figure 28a and b). Clinical 
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manifestation of the diseases correlates with a bacterial burden in lungs and blood (Figure 28c 
and d) as well as specific antibody levels (Figure 29 and Figure 30). Immunization with ST3-
tetrasaccharide pneumolysin conjugate also showed a substantial positive effect on mice infected 
with S.pneumoniae serotype 3 but lack of statistical significance was observed. Nevertheless, the 






Figure 28. Evaluation of the protective effect of ST3-tetrasaccharide pneumolysin (ST3-
Ply) conjugate, ST3-tetrasaccharide CRM197 (ST3-CRM) conjugate, and Prevnar13
®
 
vaccines in a mice challenge model of S.pneumoniae serotype 3. 
a) The percentage decrease in body weight 48 h after transnasal infection with live S.pneumoniae 
serotype 3 in mice immunized with ST3-tetrasaccharide pneumolysin and CRM197 conjugates, 
as well as Prevnar13
®
 vaccines. Control group received PBS only. b) Body temperature changes 
in mice receiving different vaccines 48h after challenge with bacteria. Healthy animals maintain 
the bo y temper ture  roun  37°C  n  control PBS group shows hypothermi  (below 36°C). 
Bacterial burden in lungs (c) and blood (d) collected 48h after infection with S.pneumonie 
serotype 3 after immunization with different vaccines candidates. Colony-forming units (CFU) 
were calculated for single animals, and values were transformed to a logarithm scale. Two 
animals from group vaccinated with ST3-tetrasaccharide pneumolysin conjugate were excluded 
as immunization did not work correctly (lack of specific antibodies). Data are individual values 
from n=8 mice (n=6 for ST3-tetrasaccharide pneumolysin conjugate group) with mean 


























Figure 29. Evaluation of S.pneumoniae serotype 3 capsular polysaccharide specific 
antibody response in mice immunized with ST3-tetrasaccharide pneumolysin and 
CRM197conjugated vaccines, as well as Prevnar13
®
. 
Antibodies from mice injected with semisynthetic ST3-pneumolysin (blue) and CRM197 
(orange) conjugates recognize CPS of S.pneumoniae serotype 3. Animals immunized with 
Prevnar13
®
 (red) were used as a control. Samples were analyzed by ELISA. Graphs show mean 
adsorption level (arbitrary units)  ± SD value and individual points indicate a value for a single 





Figure 30. Evaluation of ST3-tetrasaccharide specific antibody response in mice 




Recognition of ST3-tetrasaccharide by antibodies from mice immunized with ST3-
tetrasaccharide pneumolysin conjugate (blue), ST3-tetrasaccharide CRM197 conjugate (orange) 
and commercial vaccine Prevnar13
®
 (red). Samples were analyzed by glycan array. Graphs show 
me n fluorescence intensity ± SD value, and individual points indicate a fluorescence intensity 
for a single animal (n = 16) in triplicate.  
To elucidate a potential systemic serotype independent effect of anti-pneumolysin antibodies in 
the in vivo model, mice were immunized with ST3-tetrasaccharide pneumolysin, and CRM197 
conjugated vaccines, Prevnar13
® 
as well as PBS control followed by intranasal infection with S. 
pneumoniae serotype 2. Clinical signs (body weight and temperature decrease), as well as 
bacteremia and pulmonary bacterial load, were evaluated (Figure 31). The data obtained from the 
experiment did not show any significant differences between treatment groups. Even control 
animals injected with PBS only did not demonstrate expected clinical symptoms. Therefore, we 




Figure 31. Assessment of the cross-serotype protective effect of ST3-tetrasaccharide 
pneumolysin, ST3-tetrasaccharide CRM197, and Prevnar13
®
 vaccines in a mouse challenge 
model of S.pneumoniae serotype 2. 
a) The percentage reduction of body weight in mice 36h after transnasal infection with live 
S.pneumoniae serotype 2 followed the immunization with ST3-tetrasaccharide pneumolysin and 
CRM197 conjugates, as well as Prevnar13
®
 vaccines. Control group received PBS only. b) Body 
temperature changes in mice receiving different vaccines 36h after challenge with bacteria. 
Bacterial burden in lungs (c) and blood (d) collected 36h after infection with S.pneumoniae 
serotype 2 after immunization with different ST3 vaccine candidates and Prevnar13
®.
 Colony-
forming units (CFU) were calculated for single animals, and values were transformed to a 
logarithm scale. Data are individual values from n = 8 mice and the mean was presented. 





3.6 Nasal Immunization With ST3-Tetrasaccharide and ST2-Hexasaccharide 
Conjugated to Pneumolysin and PspA Inhibits Colonization of the Nasopharynx 
After Challenge With S.pneumoniae Serotype 2. 
One of the most critical steps in the development of pneumococcal infections is nasopharyngeal 
colonization by the bacteria (168). It has been proved that S.pneumoniae virulence factors such 
as pneumolysin (Ply) and pneumococcal surface antigen A (PspA) play a crucial role in 
establishing the initial step and the subsequent spreading of the pathogen (32, 38, 169),  therefore 
they are considered as a promising protein vaccine candidates. To evaluated the potential of 
pneumolysin and PspA as both carrier and an additional antigen for glycoconjugate vaccine, the 
proteins were conjugated to both synthetic ST3-tetrasaccharide and ST2-hexasaccharide. 
CRM197 carrier protein was used as a control. Glycoconjugates were characterized by SDS-
PAGE (Figure 32) and MALDI-TOF-MS (Figure 33). The glycoconjugate conjugation ratios are 
shown in Table 20. 
 
Figure 32. Characterization of ST3-tetrasaccharide and ST2-hexasaccharide conjugated to 
pneumolysin and PspA by SDS-PAGE electrophoresis. 
Line 1: 1µg of ST3-tetrasaccharide PspA conjugate; Line 2: 1 µg of SP3-tetrasaccharide 
pneumolysin conjugate; Line 3: 1µg of SP3-tetrasaccharide CRM197 conjugate; Line 4: 1µg of 
SP2-hexasaccharide PspA conjugate; Line 5: 1µg of SP2- hexasaccharide pneumolysin 
conjugate; Line 6: 1µg of SP2- hexasaccharide CRM197 conjugate; Line 7: 1µg of Psp ; Line 8: 
1µg of pneumolysin; Line 9: 1µg of CRM197. PageRuler Plus Prestained Protein Ladder was 




Figure 33. MALDI-TOF analysis of ST3-tetrasaccharide and ST2-hexasaccharide 
conjugated to pneumolysin and PspA carrier proteins. 
The analysis was carried out to measure the average molecular size of conjugate and the loading 




Table 20. Glycoconjugates used for the nasal immunization of mice before challenge with 
S.pneumoniae serotype 2. 
 
Construct name Loading 
Concentration  
(mg/ml) 
SP2-hexasaccharide CRM197 9.7 2.26 
SP2-hexasaccharide pneumolysin 12.2 2.34 
SP2-hexasaccharide PspA 12.6 1.4 B 
SP3-tetrasaccharide CRM197 11.0 2.56 
SP3-tetrasaccharide pneumolysin 12.9 1.88 
SP3-tetrasaccharide PspA 12.5 2.02  
 
The pneumococcal colonization model is characterized by the bacteria present in the lower 
airways with an accompanying inflammatory cell response for at least 14 days post-infection 
without acute disease symptoms. S.pneumoniae D39 serotype 2 is one of the most suitable 
serotypes used for pneumococcal mouse colonization study (167) and was chosen as a bacteria 
challenge model.  
Six to eight week old female inbred C57BL/6 mice were immunized intranasally three times in a 
two-week interval with ST3-tetrasaccharide and ST2-hexasaccharide conjugated to pneumolysin, 
PspA as well as a mixture of both glycoconjugates (Table 21). Animals received the dose of 
glycoconjugate equal to 2.5 µg of protein, corresponding to approximately 0.5 µg synthetic 
oligosaccharide antigen (the amount of glycan slightly varies based on a loading ratio). 
Vaccination dosage was chosen according to a published study. In work conducted by Wu et.al., 
PspA was used as an intranasal antigen in dosages varying from 150 ng up to 2.5 µg (170). In 
studies published by Csordas et al. and Santamaria et. al. mice were intraperitoneally injected 
with 2.5 µg to 5 µg of polysaccharide conjugated to the PspA which was sufficient to trigger an 
effective immune response (171, 172).  
The glycoconjugates were formulated with Cholera Toxin subunit B (CTB) as an adjuvant in 10 
µL total volume ST3-tetrasaccharide pneumolysin and PspA conjugates were used to prove the 
independent serotype protection against pathogen colonization. ST3-tetrasaccharide CRM197 










1 ST2-PLY 12 
2 ST2-PspA 12 
3 ST2-PLY + ST2-PspA 12 
4 ST3-PLY 12 
5 ST3-PspA 12 
6 ST3-PspA + ST3-PLY 12 
7 ST3-CRM (negative control) 12 
8 PBS (negative control) 12 
  Ʃ = 96 
 
Humoral immune responses following intranasal immunization were evaluated. Post-immune 
sera two weeks after the third immunization were collected, and total antigen-specific IgG titer 
was measured by ELISA. Intranasal immunization triggered a systemic immune response in all 
tested mice. Both pneumolysin, as well as PspA protein and S.pneumoniae serotype 3 capsular 
polysaccharide specific antibodies, were produced respectively to the vaccine received (Figure 
34). However, mice injected with ST2-hexasaccharide glycoconjugate vaccine did not show any 
antibody response cross-reactive to the S.pneumoniae serotype 2 CPS. 
The systemic antigen-specific IgG titer after intranasal immunization was comparable to the 
subcutaneous way of immunization and in conclusion, could be possibly exchanged in human as 
this non-invasive method is less painful and stressful especially for young children. Among 
many advantages, intranasal vaccination may trigger protection against infections at other 
mucosal sites, e.g., lungs, intestines or genital tract, and deliver cross-protection against different 
bacterial strains through mucosal antibody secretion (173).  
In addition to preventing pathogen entry as one potential mechanism by which antibodies may 
confer protection (i.e., neutralization), antibodies can also control and help clear infections 
through non-neutralizing immune effector functions. Based on our previous results, the CPS-
specific systemic serum antibodies correlate with the opsonophagocytic killing of pneumococci 
so the intranasal immunization can not only inhibit the local bacteria colonization but also 





Figure 34. Pneumolysin, PspA, S.pneumoniae serotype 2 and serotype 3 capsular 
polysaccharide specific IgG titer in post-immune and final bleeding serum from mice 
intranasally immunized with ST3-tetrasaccharide, and ST2-hexasaccharide conjugated to 
Ply, PspA as well as a mixture of both. 
Immune response to the ST2-hexasaccharide pneumolysin (ST2-Ply), ST2-hexasaccharide PspA 
(ST2-PspA), ST2-hexasaccharide pneumolysin + ST2-hexasaccharide PspA (ST2-Ply + ST2-
PspA), ST3-tetrasaccharide pneumolysin (ST3-Ply), ST3-tetrasaccharide PspA (ST3-PspA), 
ST3-tetrasaccharide pneumolysin + ST3-tetrasaccharide PspA (ST3 Ply + PspA, ST3-
tetrasaccharide CR197 (ST3-CRM) and PBS control vaccines in mice post- serum (n = 6 for 
post-immune, n=12 for final bleeding). Pneumolysin, PspA, S.pneumoniae serotype 2 (ST2-CPS) 
and serotype 3 (ST3-CPS) polysaccharide specific antibody levels were evaluated. Each dot 
represents an individual mouse immune response. Me n ± SD values were analyzed. 
 
Three weeks after receiving the final dose of vaccine, mice were intranasally infected with a non-
lethal dose of S. pneumoniae serotype 2. Three days later, animals were euthanized and live 
pneumococci were recovered from their nasal tissues. Mucosal immunity was evaluated. IgA and 
whole IgG both protein (pneumolysin and PspA) and glycan (CPS of S.pneumoniae serotype 2, 
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CPS of S.pneumoniae serotype 3, ST2-hexasaccharide and ST3-tetrasaccharide) specific 








Figure 35. Evaluation of mucosal IgG and IgA response to CPS of S.pneumoniae serotype 
3, CPS of S.pneumoniae serotype 2, ST3-tetrasaccharide and ST2-hexasaccharide in nasal 
tissue of mice intranasally immunized with ST3-tetrasaccharide, and ST2-hexasaccharide 
conjugated to Ply, PspA as well as a mixture of both.  
IgG and IgA immune response to the ST2-hexasaccharide Pneumolysin (ST2-Ply), ST2-
hexasaccharide PspA (ST2-PspA), ST2-hexasaccharide Pneumolysin + ST2-hexasaccharide 
PspA (ST2-Ply + ST2-PspA), ST3-tetrasaccharide Pneumolysin (ST3-Ply), ST3-tetrasaccharide 
PspA (ST3-PspA), ST3-tetrasaccharide Pneumolysin + ST3-tetrasaccharide PspA (ST3 Ply + 
PspA, ST3-tetrasaccharide CR197 (ST3-CRM) and PBS control vaccines. Antibody level was 
evaluated in homogenized nasal tissue collected from mice. CPS of S.pneumoniae serotype 3, 
ST2-hexasaccharide and ST3-tetrasaccharide specific antibody levels were evaluated by glycan 
array. Each dot represents an individual mouse immune response (n = 12). Me n ± SD  values 
were analyzed. 
 
Mice intranasally immunized with the above-mentioned vaccines show a relatively hight local 
immune response (both IgA and IgG) to CPS of S.pneumoniae serotype 3, synthetic ST3-
tetrasaccharide and synthetic ST2-hexasaccharide However, mice injected with ST2-
hexasaccharide glycoconjugate vaccine did not show a local antibody response cross-reactive to 
the S.pneumoniae serotype 2 CPS. Both pneumolysin, as well as PspA protein and S.pneumoniae 
serotype 3 capsular polysaccharide specific mucosal IgA and IgG, were also produced 
respectively to the vaccine received (Figure 34). This proved that the vaccine is immunogenic 







Figure 36. Evaluation of mucosal IgG and IgA response to Pneumolysin and PspA carrier 
proteins in nasal tissue of mice intranasally immunized with ST3-tetrasaccharide, and ST2-
hexasaccharide conjugated to Ply, PspA as well as a mixture of both  
IgG and IgA immune response to the ST2-hexasaccharide Pneumolysin (ST2-Ply), ST2-
hexasaccharide PspA (ST2-PspA), ST2-hexasaccharide Pneumolysin + ST2-hexasaccharide 
PspA (ST2-Ply + ST2-PspA), ST3-tetrasaccharide Pneumolysin (ST3-Ply), ST3-tetrasaccharide 
PspA (ST3-PspA), ST3-tetrasaccharide Pneumolysin + ST3-tetrasaccharide PspA (ST3 Ply + 
PspA, ST3-tetrasaccharide CR197 (ST3-CRM) and PBS control vaccines. Antibody level was 
evaluated in homogenized nasal tissue collected from mice. CPS of S.pneumoniae serotype 3, 
ST2-hexasaccharide and ST3-tetrasaccharide specific antibody levels were evaluated by glycan 
array. Each dot represents an individual mouse immune response (n = 12). Me n ± SD  v lues 
were analyzed. 
 
The mucosal immune response (both IgG and IgA antibodies) is responsible for inhibition of 
bacteria in the nasopharynx. Indeed, the intranasal vaccination with ST2-hexasaccharide 
pneumolysin conjugate, ST2-hexasaccharide PspA conjugate, ST2-hexasaccharide pneumolysin 
+ ST2-hexasaccharide PspA conjugates mixture, ST3-tetrasaccharide pneumolysin conjugate, 
ST3-tetrasaccharide PspA conjugate, and ST3-tetrasaccharide pneumolysin + ST3-
tetrasaccharide PspA conjugates mixture induced a significant reduction of bacterial load in the 
nasal cavity compared to the bacterial load in mice injected with PBS only (Figure 37). 
The carrier proteins used in vaccines play the most important role in the reduction of 
pneumococci colonization in the nasopharynx within three days post-infection regardless the use 
of either homologous (ST2-hexasaccharide) or heterologous (ST3-tetrasaccharide) glycan. 
Previous studies have already proven that a highly conserved pneumolysin and PsaA, provides 
cross-protection in a mouse model of colonization following intranasal immunization. My study 
adds additional value, as the proteins could be combined with synthetic oligosaccharide antigens 
that are protective epitopes in an S.pneumoniae infection model (decrease the bacteria load in 
blood and lungs as well as reduce the disease severity in mice challenged with S.pneumoniae 
serotype 3 bacteria, see 3.5). 
As mentioned before, the carrier proteins originate from the same pathogen, induce an additional 
response, so-c lle  “   ition l v lency”. Conserved among all S.pneumoniae serotypes 
pneumolysin and PspA were chosen as a proof of concept to broaden the spectrum of protection 
of the pneumococcal vaccine. I was able to prove for the first time that conjugation of the 
synthetic oligosaccharide to conservative carrier proteins pneumolysin and PspA gives both local 
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protection against bacterial colonization, the first step for pneumococcal infection but also a 
systemic defense by antibody-mediated opsonophagocytic clearance of the bacteria, clearing of 
the bacteria during the infection.  
 
 
Figure 37. Intranasal vaccinations with the ST2-hexasaccharide (homologous glycan) and 
ST3-tetrasaccharide (heterologous glycan) Pneumolysin or PspA conjugated vaccines 
reduce pneumococcal colonization in mice. 
Bacterial recovery of S. pneumoniae serotype 2 (D39) from nasal tissue 3 days after the 
intranasal challenge of C57BL/6 mice (n = 12) with 3.5 × 10
6
 CFU. Each dots represent single 
animal and bars show the group median ±SD. The dotted line indicates the lower limit of the 
infection model. Data were analyzed using a one-way ANOVA multi comparison test; *p < 




3.7 Formulation of ST3-tetrasaccharide CRM197 Conjugate Vaccine Depends on 
Adjuvant Properties 
The adjuvant is a crucial portion of a vaccine and, as has been shown in many studies, 
significantly changes the immune response induced by the vaccination (129). Alum-based 
adjuvants are currently the most popular type of adjuvants used in commercial vaccines. 
Unfortunately, very often Alum adjuvants do not allow to reveal the maximum capability of the 
antigen as the mechanism, by which they improve the immune response, is still not fully 
understood. The importance of adjuvant formulation has been realized, and the number of 
approved adjuvants is gradually increasing. 
Given that carbohydrate antigens are weaker immunogens than proteins, the proper choice of the 
adjuvant formulation is the major challenge during the carbohydrate vaccine development 
process. Developing adjuvant formulations with improved potency and safety will be of great 
value. To maximize the immunogenic and protective potential of the ST3-tetrasaccharide 
CRM197 conjugate, we formulate the vaccines with various adjuvants (Table 21). 
The ST3-tetrasaccharide was conjugated to the CRM197 carrier protein by a bifunctional linker. 
The conjugate was characterized by MALDI-TOF and by a gel shift assay (Figure 38). The 
average loading ratio of four glycans per protein was obtained. The loading ration can vary from 
batch to batch depending on, e.g., the amount of glycan used in the particular reaction. 
Nevertheless, based on previous studies from the Seeberger group, it was known that the loading 
ratio between three to twelve glycans is sufficient for the protection (174). The conjugation 
procedure conducted in a small batch for the research purpose varies a lot and has to be 
optimized for the large scale production according to guidelines that are related to good 






Figure 38. Characterization of ST3-tetrasaccharide CRM197conjugat. 
a) MALDI-TOF analysis was carried out to measure the average molecular size of conjugate and 
the loading ratio of the glycan on the carrier protein. The recombinant CRM197 was used as 
standard. b) The conjugate visualization by gel shift assay (10% SDS-PAGE) 
Given the long-term success of “gol  st n  r ”  luminum   juv nt, all new adjuvants 
formulations have to be compared to Alum (162). As investigated before (see 3.1) the adsorption 
of the ST3-tetrasaccharide CRM197 conjugate onto Aluminum hydroxide particles is 
significantly better than onto aluminium phosphate. Therefore, the ST3-tetrasaccharide CRM197 
conjugated formulated with aluminium hydroxide was the first group used in the study. The 
 ntigen w s   sorbe  onto 125 µg Alum (Al(OH)3) as an aluminum source (Alhydrogel, 
Brenntag, Denmark).  
The particular vaccine formulation was decided according to the chemical and biological 
properties of the adjuvant (Table 23).  ll groups cont in the s me  ose of  ntigen equ l 0.4 µg 
of synthetic ST3-tetrasaccharide conjugated to the CRM197 and amount of adjuvant decided 
base on commercially available vaccine formulation or published data.  
Emulsions have been used as adjuvants for both human and animal vaccines for many years. 
Traditional oil-b se  emulsion   juv nts, such  s complete or incomplete Freun ’s   juv nt, 
have been reported with many side post-immunization reactions (175). MF59
TM
 is a squalene-
based oil-in-water emulsion, currently licensed as part of an influenza vaccine by Novartis, 
mostly acting by enhancing recruitment of antigen-presenting cells. Therefore, the second group 
to be formulated with the ST3-tetrasaccharide CRM197 conjugate formulated was MF59
TM
. The 
ST3-tetrasaccharide CRM197 conjugate was adjuvanted with MF59
TM
 and an emulsion was 
prep re  by “two-syringes” metho  in 1:1 volume r tion of  ntigen  n    juv nt. 
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It has been well known that the majority of microbial components, referred to as pathogen-
associated molecular patterns (PAMPs) stimulate the innate immune response through pattern 
recognition receptors such as Toll-like receptors (TLRs) (176). Vaccines containing TLR ligand-
based adjuvants activate and trigger the innate immune response and enhance the protection 
induced by vaccines. A derivative of lipopolysaccharide, monophosphoryl lipid A (MPLA) 
already approved in many commercial vaccines (177), a powerful immunostimulator for the 
treatment of cutaneous cancers in various clinical trials Resiquimod (R-848) (178) and one of the 
oldest but very potent components of attenuated vaccines – bacterial RNA (179), were chosen as 
adjuvants for the synthetic ST3-tetrasaccharide CRM197 conjugated vaccine. The way of 
vaccine formulation depends on the chemical properties of the adjuvant. As all of the above-
mentioned adjuvants can not be chemically attached to the antigen, nanoparticles were selected 
as a delivery system. Many studies showed that using nanostructures functionalized with antigen 
and adjuvant might augment the immunogenicity of the vaccine by enhancing the activation of 
antigen-presenting cells (158, 180). Polylactic acid (PLA) particles made of biodegradable 
approved for human-used polyester are broadly described as a co-delivery system of vaccine 
components (181). The use of PLA particles in the formulation of ST3-tetrasaccharide – 
CRM197 conjugate with TLRs ligands (MPLA, Resiquimod, and RNA) offers the possibility to 
delivery the antigen and immunostimulatory molecules to the immune cells in more natural 
spherical structures and help to overcome the problem the adjuvant formulation. Particles were 
prepared by a water/oil/water (W1/O/W2) double emulsion solvent evaporation technique 
(2.7.2). One of the greatest benefits of particulate antigen delivery systems is their ability to co-
deliver antigens and immunostimulatory molecules simultaneously to the same APCs (137). 
MPLA and Resiquimod (TLR4 and TLR7/8 activators) were chosen as a prove of synergistic 
effects that may result in a more effective or longer-lasting immune response (162). For groups 3 
to 6, the ST3-tetrasaccharide CRM197 conjugate together with adjuvant were encapsulated into 
biodegradable PLGA particles (as described in Particle preparation 2.7.2.). In addition, the 




Table 22. The experimental group used in the evaluation of adjuvant formulation on the 
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human dose 
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8 Empty 
particles 




Particle characterization is a crucial step before further development for applications. The 
presence of the adjuvant and antigen, size and distribution of the particles were determined. The 
flow-through solutions after washing steps were monitored by Nano-Drop and BCA assay for the 
presence of the non-encapsulated conjugate. The ST3-tetrasaccharide CRM197 conjugate was 
not detected at any point, so the encapsulation efficiency was assumed to be complete.  
The encapsulation and localization of the antigen on the particles were confirmed by flow 
cytometry and confocal microscopy analysis. ST3-tetrasaccharide CRM197 conjugate 
encapsulated particles were incubated with the ST3 and CRM197 specific monoclonal antibodies 
followed by detection using a FITC conjugated secondary antibody. Confocal microscopy 
analysis revealed the specific surface localization of ST3-tetrasaccharide CRM197 on the 
particles (Figure 39a). The changes in fluorescence intensity according to the control with 
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secondary antibodies only were measured by flow cytometry. The shift of the signal to the right 
indicates the presence of both carbohydrate and protein components on the particles (Figure 
39b). Surface localization of the ST3-tetrasaccharide antigen is an important feature considering 
that polysaccharide specific immune responses are primarily mediated by cross-linking of the B 
cell receptor. 
The parameters for nano- (<500 nm) and micro- (2-8 μm) particle fabrication are well 
established. The dimension of particles loaded with antigen and adjuvant was analyzed by 
dynamic light scattering (DLS) measurement and scanning electron microscopy (SEM). The size 
distribution by intensity and number shows the average magnitude of the ST3-tetrasaccharide 
CRM197 and adjuvant encapsulated particles between 300 – 500 nm depending on the 
formulation (Figure 39c and d). Inconsistent results provide no definite answer as to which 
PLGA particles size is the most effective for vaccine delivery. Some studies have shown that 
particles less than 450 – 600 nm induced the most robust immune response after s.c. injection 
(activation of CD8+ cells) (182). In regards to IgG production, the 200 nm and 500 nm particles 
elicited similar antibody titer (183). Microparticles of 0.5 – 5 µm  re embrace via phagocytosis 






Figure 39. Exemplary characterization of PLA particles.  
a) The picture of ST3-tetrasaccharide CRM197 conjugate and RQ loaded particles observed 
under the Transmission Electron Microscope (TEM). Scale bars indicated in the pictures. b) 
Encapsulation of ST3-tetrasaccharide CRM197 conjugate into PLA particles analyzed by Flow 
Cytometry. The shift in the intensity of the fluorescence signal (x-axis) indicates the presence of 
the glycan (monoclonal IgG antibodies against ST3-tetrasaccharide in green) and protein 
(monoclonal IgM antibodies against CRM197 in red) part of the conjugate compare to the 
control of secondary antibodies only (anti-IgG-FITC and anti-IgM-FITC). The same number of 
events was recorded for all measurements. c) Particle size and polydispersity measured by 
Dynamic Light Scattering (DLS). Representative pictures of ST3-tetrasaccharide CRM197 
conjugate and RQ loaded particles. Graphs show the particle size by number and intensity. 
Measurement was repeated three times.  
123 
 
3.8 The Immune Response Following Immunization with ST3-Tetrasaccharide 
CRM197 Conjugate Depends on the Choice of Adjuvant and Vaccine 
Formulation 
Six to eight-week-old C57BL/6 mice were s.c immunized with an amount of ST3-tetrasaccharide 
CRM197 conjugate corresponding to a dose of 0.4 µg of ST3-tetrasaccharide antigen per 
injection in different vaccine formulations. Animals were vaccinated according to the long-term 
immunization regime prime + boost + boost + final boost (Table 23). Blood was collected, and 
the antibody response was analyzed.  
Table 23. Immunization regime for adjuvant formulation study 
days procedure 











49-140 Resting period 
140 Bleeding 




Based on broad knowledge about T-cell differentiation and a role of pathogen-associated 
molecular patterns (PAMPs) in the induction of immune responses, in theory, it is possible to 
selectively induce cell-mediated or humoral and T-helper 1 or T-helper 2 (Th1/Th2) responses by 
adjustment of vaccine adjuvant formulations. In a mouse model, the IgG subclasses induced after 
immunization are an indirect measurement of Th2-type versus Th1-type immune response. The 
production of IgG1-type antibodies is principally induced by Th2-type cytokines, whereas the 
IgG2 and IgG3 reflect the involvement of Th1-type cytokines (186). A specific IgG subclass can 
contribute to the clearance of encapsulated bacteria by particular mechanisms. Murine IgG3 is 
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highly protective, while the IgG2a, IgG2b, and IgG1 isotypes are poorly or non-protective and 
have a significantly lower affinity. Mice IgG2 display the strongest binding to Fc receptors and 
together with IgG3 can activate the complement better than IgG1 (IgG3>IgG2b>IgG2a>IgG1) 
(187, 188). Therefore, an immune response with a broad subclass distribution may be beneficial 
against encapsulated bacteria. In human IgG3 and IgG1 are the best complement activators (189).  
The effect of adjuvant formulation on the Th1 and Th2 profile of humoral immune responses was 
analyzed by determining the level of IgG1, IgG2, and IgG3 antibodies recognizing a carrier 
protein as well as synthetic ST3-tetrasaccharide and native CPS of S.pneumoniae serotype 3. The 
blood from a single animal was screen by glycan arrays using IgG1, IgG2 and IgG3 secondary 
antibodies conjugated to different fluorescent dyes.  
The influence of the adjuvant formulation on the magnitude within a time course and functional 
activity of the antibody response upon vaccination with ST3-tetrasaccharide CRM197 conjugate 
vaccine was also tested. It was presented that the use of different adjuvants correlates with 
antibody response kinetic as they differ in mode of action. MF59
TM
 promptly stimulate an early 
immune response while Alum entraps the antigen and slows down antibody production two 
weeks after priming (129). The analysis revealed that the kinetic of the humoral response 
induced by ST3-tetrasaccharide CRM197 conjugate strongly depends on the adjuvant 
formulation in the mouse model (Figure 40). However, neither special pattern nor correlation 
was perceived. 
Immune memory is one of the critical features of a successful vaccine. Effector memory for 
short-incubation diseases and central memory for long-incubation diseases must be formed after 
boosting immunization. Animals immunized with ST3-tetrasaccharide CRM197 conjugate in 
combination with Th1 adjuvants (MPLA, RQ-848, bacterial RNA as well as a combination of 
MPLA and RQ-848) showed high anti-ST3-tetrasaccharide IgG2 and IgG3 titer. The same groups 
demonstrate an excellent IgG2 response just after the final boost. The quick and specific 
recognition of the previously encountered antigen and a corresponding high immune response is 
indirect evidence for the presence of oligosaccharide specific memory B-cells. Using the TLR 
ligands as adjuvants (MPLA, RQ-848, RNA) substantially shifted the immune response toward a 
Th1 phenotype.  
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The profile of S.pneumoniae serotype 3 CPS-specific IgG subclasses (IgG1, IgG2, and IgG3) 
differs from the ST3-tetrasaccharide-specific IgG subclass antibody response. The vaccine 
formulated with Alum and MF59
TM
 (o/w squalene) evoked a prevalence of the IgG1 subclass, 
(indicative of a Th2-biased response), while the MPLA, RQ-848, and RNA strongly indicated the 
Th1 cell profile by induction of IgG2 and IgG3 subclasses. Improved production of IgG2 
antibodies was similarly observed for the formulation of ST3-tetrasaccharide CRM197 conjugate 
with MF59
TM 
even though the adjuvant is considered more Th2. Nonetheless, the in vitro results 
have to be interpreted very carefully as the immune system is very complex, and the response in 
the murine model differs. In summary, the choice of adjuvant plays a significant role in the level 








Figure 40. Immune response analysis of mice immunized with the ST3-tetrasaccharide 
CRM197 conjugate in the different adjuvant formulations. 
a) Representative picture of glycan array analysis of serum from mice immunized with the ST3-
tetrasaccharide CRM197 conjugate and RQ encapsulated PLA particles. Serum was collected 






after final bleeding (day 168). The IgG1, IgG2, and IgG3 were labeled with different fluorescent 
dyes, and intensity was measured at 300 PMT. b) The printing pattern of glycan array used for 
screening of serum samples. All glycans were structures spotted onto a glass slide in the 
concentr tion of 200 µM  n  were p rt of the MPS glyc n libr ry. c) Kinetic of ST3-
tetrasaccharide specific antibody response in mice immunized with different formulations of 
ST3-tetrasaccharide CRM197 conjugate seven days after the second boost, during the resting 
period and seven days after the final boost evaluated by glycan array analysis. d) Cross-reactivity 
and kinetics of antibody response against native CPS of S.pneumoniae serotype 3 from mice 
vaccinated with ST3-tetrasaccharide CRM197 conjugate in various adjuvant formulations. Mean 




Figure 41. Glycan array evaluation of IgG1, IgG2, and IgG3 antibody response to CRM197 
in mice immunized with ST3-tetrasaccharide CRM197 conjugate vaccine using different 
adjuvant formulations. 
Data are measurements of single animal antibodies titer on day 35 (after 2
nd
 boost), day 148 
(during the resting period) and day 168 (after final boost). Graphs show mean fluorescence 




Figure 42. Glycan arrays evaluation of IgG1, IgG2, and IgG3 antibody response to ST3-
tetrasaccharide in mice immunized with ST3-tetrasaccharide CRM197 conjugate using 
different adjuvant formulations. 
Data are measurements of single animal antibodies titer on day 35 (after 2
nd
 boost), day 148 
(during the resting period) and day 168 (after final boost). Graphs show mean fluorescence 




Figure 43. Glycan array evaluation of IgG1, IgG2, and IgG3 antibody response to native 
CPS of S.pneumoanie serotype 3 in mice immunized with ST3-tetrasaccharide CRM197 
conjugate using different adjuvant formulations. 
Data are measurements of single animal antibodies titer on day 35 (after the second boost), day 
148 (during the resting period) and day 168 (after final boost). Graphs show mean fluorescence 
intensity ± SD, n = 8. 
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Polysaccharide specific antibodies are the primary protective mechanism against pneumococcal 
bacteria. To determine antibody-mediated bacterial killing in-vitro, an opsonophagocytic killing 
assay (OPKA) was performed. This very well-established method evaluates the vaccine-induced 
immunoprotection by measuring the reduction of viable bacteria in the presence of phagocytes, 
antibodies, and complement (160, 190). 




are the best candidates for the 
formulation of the ST3-tetrasaccharide CRM197 conjugate vaccine with the highest serum 
dilutions responsible for 50% killing of bacteria (IC50), respectively 1236 and 998 (Figure 44). 
The IC50 for a control Prevnar13
®
 vaccinated group equaled 357. The group containing 
aluminium hydroxide showed IC50 = 360; MPLA IC50 = 341; the combination of MPLA and RQ-
848 IC50 =; 260 and RNA IC50 = 203. No statistical significance was calculated (p > 0.05).  
It has been claimed that quantitative characteristics of antibodies (= antibody levels) contribute 
to OPA and the estimation of immunity, those correlations between the measured concentrations 
of IgG and opsonophagocytic activity have been required (191, 192). Unfortunately, no 
correlation between antibody titer and opsonophagocytic protective activity in groups 
immunized with ST3-tetrasaccharide CRM197 conjugate and the different adjuvant formulation 
was observed (p values > 0.05 and very low r
2 
 value) (Figure 45).  
However, it is a controversial question of whether the quality or quantity of antibodies is mostly 
responsible for vaccine efficacy. An antibody may be highly correlated with protection or 
synergistic with other functions. Antigen-binding antibodies mediate effector functions through 
interactions between their Fc domains and Fc receptors (FcR) found either on all innate immune 
cells or components of the complement system. The outcome of Fc/FcR interaction might be 
phagocytosis, induction of cell lysis or degranulation. Antibodies can also recruit complement to 
directly kill pathogens or use additional innate immune clearing activities via complement 
receptors (193).  
Based on the results, I strongly believe that functional activity plays a crucial role in protection, 
not the number of antibodies induced by vaccination (OPK activity). It has been described that 
modifications of the Fc domain, as well as changes in Ab isotype/subclass and glycosylation, 
may have a profound impact on antigen-antibody complex delivery and can improve affinity for 
particular Fc receptors (194). A detailed investigation of the antibody generated after 
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immunization with ST3-tetrasaccharide CRM197 conjugate vaccine with different adjuvant 
formulations has to be performed. Knowing the avidity and character of immunocomplexes helps 
to fully understand the vaccine formulation effect.  




































































































































Figure 44. Comparison of the in-vitro opsonophagocytic activity of sera from mice 
immunized with ST3-tetrasaccharide CRM197 conjugate using different adjuvant 
formulations  
a) A comparison of OPKA activity of pooled sera from mice immunized with ST3-
tetrasaccharide CRM197 conjugate in different adjuvants formulation. The commercial vaccine 
Prevnar13
®
 and WHO human reference serum 007sp were used as controls. Data are me ns ± 
SD of CFU reduction relative to negative control wells (samples lacking either antibody or 
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complement) of two independent experiments. b) Evaluation of serum dilution responsible for 
the killing of 50% bacteria by the in-vitro opsonophagocytic killing assay. Graph shows mean 
±SD of results from two independent experiment estimated through non-linear interpolation of 
the dilution-killing OPKA data. Data were analyzed by the two way ANOVA, and p-v lue of  ≤ 
0.05 was considered significant. Human reference serum 007sp was used as a control. 
 

































































































Figure 45. Correlation between specific antibody titer and serum dilution responsible for 
the killing of 50% bacteria. 
Relationship between (a) S.pneumoniae serotype 3 CPS and (b) ST3-tetrasaccharide specific IgG 
subclasses titer from group immunized with ST3-tetrasaccharide CRM197 conjugate in the 
different adjuvant formulation (measured by ELISA) and serum dilution responsible for the 
killing of 50% bacteria (measured by OPKA). Plots show Pearson's correlations (r
2
 value 






To evaluate the composition of the immune cells from animals immunized with various 
formulations of ST3-tetrasaccharide CRM197 conjugate vaccine, flow cytometric analysis of 
spleen cells and bone marrow was conducted. The experiment provides detailed information 
about the numbers and phenotypes of the immune cells.  
The spleen cells obtained from immunized animals were first differentiated based on B220 
epitope (one of the epitopes of  CD45 protein, which is expressed on all murine B cells) and 




) cell subsets were further analyzed by the presence of CD138 (a marker of plasma cells) 










was identified as long-lived plasma cells, mainly responsible for maintaining the 
level of serum antibodies. Follicular B (FO B cells) cells live in the well-established lymphoid 
follicles of spleen and lymph nodes and present T-dependent antigen to activated T cells. FO B 
cells were characterized by the presence of IgD, high level of B220 as well as CD19 and CD38 









). Memory B cells are other subpopulations of B cells. They are 
responsible for a quick and robust antibody-mediated immune response in the case of re-











 staining. The Fas receptor responsible for maintaining homeostasis in the peripheral 












). GL7 serves as a marker for germinal centers in the immunized 
spleen. Activated GL7
+
 B cells have a very high functional activity for producing antibodies and 
presenting antigens (196) (Figure 46). No significant differences were observed between specific 
B cell subsets in groups immunized with ST3-tetrasaccharide CRM197 conjugate vaccine in the 
different adjuvant formulation (Figure 47). A similar analysis was performed for bone marrow 
immune cells (Figure 48). The level of B cell subset does not differ depending on the adjuvant 
used. A lack of variance might be due to the analysis of the whole B cells population and not 
ST3-tetrasaccharide specific cells. The population of carbohydrate-specific B cells is very low 





Figure 46. Gating strategy for flow cytometry assay of B-cells from the spleen.  
Spleen cells were divided into different B-cells subclasses base on B220 and IgD staining. 











cells among the whole spleen cells lymphocytes. b) Germinal 



























Figure 47. Flow cytometry analysis of B-cells in the spleen from mice immunized with ST3-
tetrasaccharide-CRM197 conjugate using different adjuvant formulations. 
The percentage of different B cell subsets from spleens, such as follicular B cells, germinal 
center B cells, memory B cells, and plasma cells were analyzed by FACS staining. Mice were 
immunized with: (1) Prevnar13®, ST3-tetrasaccharide-CRM197 conjugate adjuvanted with (2) 
aluminum hydroxide, (3) MF59, (4) MPLA, (5) Resiquimod (RQ), (6) MPLA + RQ, (7) bacterial 
RNA and (8) negative control, empty particles. The values for a single animal per each group 




Figure 48. Flow cytometry analysis of B-cells in bone marrow from mice immunized with 
ST3-tetrasaccharide-CRM197 conjugate using different adjuvant formulations. 
The percentage of follicular B cells, germinal center B cells, memory B cells, and plasma cells in 
bone marrow were analyzed by FACS staining. Mice were immunized with: (1) Prevnar13
®
, 
ST3-tetrasaccharide-CRM197 conjugate adjuvanted with (2) aluminum hydroxide, (3) MF59, (4) 
MPLA, (5) Resiquimod (RQ), (6) MPLA + RQ, (7) bacterial RNA and (8) negative control, H2O 
Particles only. The values for a single animal per each group were plotted, and the mean of n = 8 
(and n = 4 for the control group) was calculated.  
Carbohydrates conjugated to the carrier protein are considered T-cell dependent antigens. The T 
cell subpopul tion, such  s n ïve T cells, T follicul r helper cells,  n  centr l memory T cells 
from spleen and bone marrow, were analyzed by flow cytometry. CD3 antigen appears at all 
stages of T cell development, which makes it an ideal T cell marker and CD4 molecule help to 
recognize T helper (197). T cells c n be further  ivi e  into n ïve  n  memory cells b se  on 
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 and additionally, the high level of the programmed cell death-1 (PD-1) 
and distinctive for them CXCR5 marker (Figure 49). Similar to B cells, no significant 
differences were observed for both spleen and bone marrow cells (Figure 50) as the whole T 
cells, not ST3-tetrasaccharide T cells, were analyzed. The presence of T carbs has still been 
doubted as their identification is very challenging. 
 
Figure 49. Gating strategy for flow cytometry assay of T-cells from the spleen. 
Spleen cells were divided into different T-cells subsets base on CD3 and CD4 staining. 
Aggregates were excluded by FSC-H vs. FSC-A gating. a) N ïve T cells were  escribe   s 
CD3+CD4+CD62L+ CD44low/- population among whole spleen T-cells. b) Central Memory T-
cells subclass were CD62L+CD44+ among CD3+CD4+ lymphocytes. c) T-follicular Helper 




Figure 50. Flow cytometry analysis of T-cells in spleen and bone marrow from mice 
immunized with ST3-tetrasaccharide-CRM197 conjugate in the different adjuvant 
formulations. 
The percent ge of T follicul r helper cells, centr l memory T cells,  n  n ïve T cells in (a) 
spleen and (b) bone marrow were analyzed by FACS staining. Mice were immunized with: (1) 
Prevnar13
®
, ST3-tetrasaccharide-CRM197 conjugate adjuvanted with (2) Aluminum Hydroxide, 
(3) MF59, (4) MPLA, (5) Resiquimod (RQ), (6) MPLA + RQ, (7) bacterial RNA and (8) 
negative control, H2O Particles only. The values for a single animal per each group were plotted, 
and the mean of n = 8 (and n = 4 for the control group) was calculated. 
Due to the presence of B and T lymphocytes, the spleen is one of the recommended organs to 
evaluate for enhanced histopathology of the immune system. Functionally, two major zones of 
the organ can be distinguished: hematogenous red pulp and the lymphoid white pulp composed 
of the periarteriolar lymphoid sheath (T-cell area), the adjacent follicles (B-cell area), and 
marginal zone (B-cell area) (198). The lymphoi  follicles  re very rich in n ïve B cells  n  serve 
as a filter for antigen, allowing B cells to make contact with the antigen (an activation of B cells 
and germinal center reaction). Histological analysis of spleen provides a deeper insight into the 
immune response to antigenic stimuli by observation of area and size of follicles with prominent 
germinal centers (Figure 51). Activated B cells express the GL7 epitope serving as a marker for 





significant difference in overall histopathology of spleen from mice immunized with the various 
formulation of ST3-tetrasaccharide CRM197 conjugated vaccine was observed (Figure 54).  
 
 
Figure 51. Representative picture of hematoxylin and eosin (HE) staining of a spleen. 
Spleen was cut into 2 μm thick sections, and HE-stained. a) The whole section of a spleen b) 
Follicle area and follicle diameter. 
Figure 52. Exemplary picture of immunohistochemistry staining of GL7+ follicle centers in 
a spleen. 
A number of lymphoid follicles per mm
2
, a number of GL7+ follicles centers per mm
2
, mean 
area of GL7+ follicle centers (mm
2





Figure 53. Representative image of spleen immunofluorescent staining for germinal 
centers. 
Spleen was stained with (a) anti-GL7 antibodies, (b) anti-CD3. The merged image of (c) 







Figure 54. Histopathological analysis of spleens from mice immunized with the various 
formulation of ST3-tetrasaccharide CRM197 conjugated vaccine. 
A number of follicles center per mm
2 
(a) and percentage of follicles area per whole spleen area 
(b) calculated based on HE staining. A number of GL7+ cells per mm
2
 (c) and a number of 





3.9 ST3-tetrasaccharide CRM197 And Pneumolysin Conjugated Vaccines Are 
Immunogenic In The Swine Model  
Despite many essential differences in terms of immunology and physiology between mice and 
humans, the murine model still has been the gold standard for early pre-clinical studies (199). In 
many respects, mouse models reflect human diseases very poorly. The complexity of the human 
disease, the inherent nature of the mouse model, sterile housing conditions, significant 
differences in cellular composition between mouse and human tissues, differences in the 
molecular as well as immune response make mouse models unsuitable (200). Domestic pigs are 
very similar to humans in terms of anatomy, immunology, and physiology. Moreover, porcine 
immune responses are similar to human responses with >80% of studied parameters, whereas in 
mice the response has <10% of overlap (201). Additionally, several pathogens such as Gram-
positive Staphylococcus aureus (202) and Gram-negative Bordetella pertussis (203); viruses like 
influenza virus (204), infect both humans and pigs, the latter has been described as a very 
suitable model for the studying human immunology and response to infectious diseases (205). 
The size of the animal also allows for repeated measurements in time without killing it (206, 
207). Therefore, the swine model is considered a highly relevant model for vaccine development. 
Herein, six-week-old healthy, female domestic pigs (German landrace Sus scrofa were s.c. or 
intramuscular (i.m) immunized with 2.2 µg of ST3-tetrasaccharide conjugated to CRM197 or 
pneumolysin and formulated with 0.125 mg of aluminium hydroxide. The control groups were 
Prevnar13
® 
(positive control) and Alum only (negative control). Conjugates were prepared and 
characterized as previously described in section 2.3.1 and 2.3.2. An immunization was conducted 
according to the prime + boost + boost regime (Table 24). Blood was collected on day 0, 10, 20, 
and final bleeding on day 35/36 and use for antibody response analysis.  
Table 24. Immunization regime for pigs 
 
days Procedure 
0 Immunization, bleeding 
10 1
st
 boost, bleeding 
20 2
nd
 boost, bleeding 




Since the immune response to protein antigens is much stronger than to carbohydrate antigens, 
the anti-carrier protein antibody response was measured to estimate whether the immunization 
by itself was successful and the vaccine was immunogenic in a pig model. A high level of 
pneumolysin-specific antibodies was measured in the group immunized with ST3-tetrasaccharide 
pneumolysin conjugate. Animals injected with vaccines containing CRM197 as a carrier protein 
(ST3-tetrasaccharide CRM197 conjugate and Prevnar13
®
) show significantly elevated titer of 
anti-CRM197 IgG (Figure 55). The expected anti-protein response was observed in the 
immunized group, therefore semi-synthetic ST3-tetrasaccharide CRM197 and pneumolysin 
conjugated vaccines were immunogenic in the swine model. However, a detectable level of a 
specific protein response was observed in unrelated groups due to nonsterile housing and 
breeding of the animals. Those conditions are in fact preferable, as they reflect the human 
situation such as differences in genetic background, diverse microbiota from food and 





































































































































































































Figure 55. The evaluation of IgG response to (a) CRM197 and (b) Pneumolysin carrier 
proteins measured by ELISA. 
Carrier protein-specific antibody levels were analyzed at day 0, day 10 (first boost), day 20 
(second boost), and day 35-36 (final bleeding). Data are measurements of single animal 
antibodies titer on specified time points; n = 6 animal per group.  
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The presence of ST3-tetrasaccharide and S.pneumoniae serotype 3 CPS cross-specific IgG1 and 
IgG2 were examined by glycan arrays. The arrays contain synthetic and native structures spotted 
on the glass slides (printing pattern shown in Figure 40b). Antibody isotype distribution of anti-
carrier protein antibodies was checked as well. Both CRM197 and Ply specific IgG1, and IgG2 
were identified in groups immunized respectively with Prevnar13
®
 and ST3-tetrasaccharide 
CRM197 glycoconjugate as well as ST3-tetrasaccharide pneumolysin conjugate. For groups 
immunized with semisynthetic ST3-tetrasaccharide CRM197 and pneumolysin conjugated 
carbohydrate vaccines, ST3-tetrasaccharide specific IgG1 titer is significantly higher than IgG2 
(IgG1: IgG2 ratio 2.8 and 2.7 respectively). The vaccines were adjuvanted with aluminium 
hydroxide that has Th2 properties (mostly IgG1 production) (Figure 56a). S.pneumoniae serotype 
3 CPS-cross reactive antibody level was significantly elevated in a group immunized with 
Prevnar13
®
 as the vaccine contain isolated CPS. Groups immunized with semi-synthetic vaccine 
show 3.5 x increase in CPS-specific IgG1 titer and twice higher IgG2 levels compared to a 
negative control immunized with Alum only. The study provides the first evidence for the 
immunogenicity of the ST3-tetrasaccharide CRM197 and pneumolysin conjugated 
glycoconjugate vaccine in a swine model. The positive results of the semi-synthetic 
glycoconjugate vaccine candidate in two different animal models might considerably help in 
advancing the vaccine to clinical trials. 
Furthermore, the first success of semi-synthetic glycoconjugates in pigs might open new 
opportunities in the field of synthetic carbohydrate vaccines for veterinary use. Piglets can 
develop severe diseases such as sepsis, meningitis, pneumonia, endocarditis as well as arthritis 
upon infection with Streptococcus suis (208). Infected animals are treated individually with a 
mixture of antibiotics which are very expensive and difficult to control. This leads to a high level 
of antimicrobial resistance (99.61% of multidrug resistance bacteria were found in pigs) (209). 
Infection caused by this bacteria can be also transmitted from animal to humans (outbreak in 
2005, Sichuan Province in China – 640 pigs and 39 people died from S. suis infection) (210). 
Therefore, a lot of effort has been invested in developing the S. suis vaccine for pigs.  
To confirm the protective activity of ST3-tetrasaccharide specific antibodies, a standard OPKA 
was performed using S. pneumoniae serotype 3 and HL-60 cells. Human reference serum WHO 
007sp served as standardized control to prove that assay was performed within an acceptable 
range. The results demonstrated that serum from animals immunized with ST3-tetrasaccharide 
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CRM197 (serum dilution responsible for 50% killing of bacteria, IC50 = 528) and pneumolysin 
(IC50 = 240) conjugated vaccines have significantly higher antibody titer responsible for 50% 
killing of the bacteria than group injected with Prevnar13
® 
(IC50 = 122) (Figure 57). In-vitro 
opsonophagocytic killing assay, the gold standard to measure the efficacy of pneumococcal 
vaccines proved that antibody raised in pigs immunized with semi-synthetic vaccines have 





Figure 56. Evaluation of IgG immune response of pigs immunized with ST3-
tetrasaccharide CRM197 and pneumolysin conjugates in blood collected at the final time 
point.  
Antibody response against (a) synthetic ST3-tetrasaccharide, (b) native CPS of S.pneumoniae 
serotype 3, (c) CRM197 and (d) native pneumolysin, measured in serum obtained from mice 
vaccinated with Alum only, Prevnar13
®
, ST3-tetrasaccharide CRM197 conjugate, and ST3-
tetrasaccharide Plneumolysin conjugate. Mean fluorescence intensity (MFI) of six animals 
measured in triplicates were plotted. Data were analyzed by t-test,  





Figure 57. In-vitro opsonophagocytic killing activity of antibodies from pigs immunized 
with ST3-tetrasaccharide CRM197 and pneumolysin conjugates. 
a) A comparison of OPKA activity of pooled sera from pigs immunized with ST3-
tetrasaccharide CRM197 and ST3-tetrasaccharide pneumolysin conjugates. The commercial 
vaccine Prevnar13
®
 and Alum only were used as a positive and negative control, respectively. 
D t   re me ns ± SD of CFU re uction rel tive to neg tive control wells (samples lacking either 
antibody or complement) of two independent experiments. b) Evaluation of antibody titer of 
pooled serum responsible for 50% killing of bacteria in the opsonophagocytic killing assay. IgG 
titers are expressed as the reciprocal serum dilution mediating 50% bacterial killing, estimated 
through non-linear interpolation of the dilution-killing OPKA data. Human reference serum 
007sp was used as a control. 
Antibodies from group immunized with ST3-tetrasaccharide pneumolysin conjugated vaccine 
showed toxin neutralization activity. These antibodies are able to inhibit the hemolysis of red 
blood cells by Pneumolysin in-vitro (Figure 58). As animals are kept in non-sterile conditions, 
some of them acquired neutralizing antibodies cross-reactive with pneumolysin. Nevertheless, 
the group that was immunized with ST3-tetrasaccharide pneumolysin conjugate showed a 
statistically significant decrease of hemoglobin release compared to Prevnar13
® 
vaccinated 
animals (p = 0.0185) and a substantial reduction with regards to ST3-tetrasaccharide CRM197 (p 
= 0.15) and Alum injected groups (p =. 0.29) 
Piglets are the natural host for Streptococcus suis which share many similarities in pathogenesis 
with S. pneumoniae infection in humans. Piglets could develop severe disease upon infection 
with S. suis like sepsis, meningitis, pneumonia, endocarditis as well as arthritis (208). Therefore, 
establishing the infection model of S. pneumoniae and exploring the protective ability of the 




Figure 58. Inhibition of pneumolysin induced lysis of human red blood cells by anti-
pneumolysin antibodies from the blood of pigs immunized with ST3-tetrasaccharide 
Pneumolysin glycoconjugate collected during final bleeding. 
a) Inhibition of hemolytic activities of native pneumolysin by antibodies from pigs immunized 
with ST3-tetrasaccharide Pneumolysin conjugate. Blood was collected during final bleeding on 
day 35-36. Hemoglobin release is expressed as the A540 of  ss y supern t nts (me n ± SD). b) 
Comparison of the toxin neutralization activities of antibodies from mice immunized with ST3-
tetrasaccharide CRM197 and ST3-tetrasaccharide pneumolysin conjugates, as well as 
Prevnar13
®
 and Alum control at the fivefold serum dilution. Data points are shown for single 
animals in each group (n = 6). Hemoglobin release is expressed as the A540 of assay supernatants. 





The magnitude of an immune response to a glycoconjugate vaccine depends not only on 
antibodies producing B cells but also on a relatively small population of antigen-specific T 
lymphocytes which helps B cells as well as control the inflammation and protection in response 
to the pathogen. Therefore, understanding the role of antigen-specific T cells in the host immune 
response is essential for developing effective T cell-dependent vaccines (211). A population of 
antigen-specific T cells in the absence of infection is very tiny (around 1 in 10
−6
 within a n ïve 
and 1–100 in 10
−5
 within the memory of conventional T cells) what makes the analysis of the 
cell population very difficult (207). The abundance of carbohydrate specific T-cell (Tcarbs) is 
even smaller and more challenging to visualize; thus, this subclass is often neglected. It was 
shown that the expression of the marker CD154 (expressed by conventional CD4 T cells after 
TCR stimulation), on pig CD4
+





 cells coexpress cytokines such TNFα (207). 
The CD154 expression on swine CD4
+
 T cells (from immunized animals) restimulated either 
with a carrier protein included in the semisynthetic ST3-tetrasaccharide glycoconjugate vaccine 
(CRM197 or pneumolysin) and commercial Prevnar13
®
 (CRM197) or entire glycoconjugates 
were analyzed. The frequencies of TNFα producing CD154+CD4+ T cells were evaluated 
according to gating strategy (Figure 59). PBMCs stimulated with medium alone served as a 
control. The swine study was performed to understand if antigen-specific CD4+ T cells can be 
monitored at different time-points and detected across all immunized animals. 
By restimulation of PBMC obtained from animals immunized with semi-synthetic carbohydrate 
vaccines, both ST3-tetrasaccharide pneumolysin and ST3-tetrasaccharide CRM197 conjugates, 
with carrier protein pneumolysin and CRM197 accordingly, I was able to prove the presence of 
vaccine-specific CD4+T cells in the blood of animals after the third boost. The same PBMC 
samples re-stimulated with ST3-tetrasaccharide pneumolysin and ST3-tetrasaccharide CRM197 
conjugate instead of carriers protein only, showed even higher frequencies of cytokine-producing 
specific T cells, statistically significant compared to unstimulated PBMC (p < 0.001 for ST3-
tetrasaccharide CRM197 conjugate and p < 0.01 for ST3-tetrasaccharide pneumolysin conjugate) 
as well as to CRM197 restimulation only (p < 0.01) (Figure 60). This observation might suggest 
the involvement of carbohydrate specific T cells (Tcarbs). However, it needs further investigation 




The above results strongly prove the involvement of T cells in response to the semi-synthetic 
carbohydrate conjugated vaccine (without the infection present) used in an outbred animal model 
from conventional husbandry.  
 
 
Figure 59. Gating strategy for the CD154+ and TNFα+CD154+ cells from ex-vivo PBMC 
gated on CD4
+
 T cells that were either unstimulated (w/o) or stimulated with carrier 
proteins used for vaccination. 
Spleen cells were divided into different T-cells subsets base on CD3+ and CD4+ staining. 
Aggregates were excluded by FSC-H vs. FSC-A gating. a) N ïve T cells were  escribe   s 
CD3+CD4+CD62L+ CD44low/- population among whole spleen T-cells. b) Central Memory T-
cells subclass were CD62L+CD44+ among CD3+CD4+ lymphocytes. c) T- follicular Helper 






Figure 60. Restimulation of swine PBMCs accordingly to the primary immunization with 
carrier protein CRM197 or pneumolysin and glycoconjugates ST3-tetrasaccharide 
CRM197 or ST3-tetrasaccharide pneumolysin shows increased levels of CD154+ and 
TNFα+CD154+ antigen-specific CD4+ cells. 
To detect antigen-reactive T cells, PBMCs collected during final bleeding (day 35-36) were ex 
vivo restimulated with carrier proteins or glycoconjugates and unstimulated cells. The percentage 
of CD154+ and TNFα+CD154+ antigen-specific cells among the CD4+ population was analyzed 
by FACS. Comparison of antigen-specific CD154+ and TNFα+CD154+ cells after restimulation 
of PBMC from animals immunized with (a) ST3-tetrasaccharide Pneumolysin glycoconjugate 
vaccine and Alum control group with Pneumolysin (40 µg/mL) and ST3-tetrasaccharide 
Pneumolysin conjugated (40 µg/mL) as well as unstimulated group; (b) pigs vaccinated with 
ST3-tetrasaccharide CRM197 glycoconjugate vaccine and Alum control group with CRM197 
(40 µg/mL) and ST3-tetrasaccharide CRM197 conjugated (40 µg/mL) as well as unstimulated 
group; (c) animals injected with Prevnar13
® 
and Alum control group with CRM197 (40 µg/mL) 
as well as unstimulated group. The values for a single animal per each group were plotted, and 
the mean ±SD of n = 6 (and n = 3 for the second batch of Alum control group) was calculated. 







4 Conclusions and Outlook 
Streptococcus pneumoniae remains a deadly disease in small children and the elderly, even 
though polysaccharide and conjugate vaccines based on isolated capsular polysaccharides (CPS) 
are relatively successful. The most common serotypes that cause infections are used in vaccines 
around the world, but differences in geographic and demographic serotype distribution 
compromise protection by leading vaccines. The isolation of CPS from cultured bacteria for 
obtaining polysaccharides for conjugate-vaccine production is operationally challenging. Thus, 
we use the chemical synthesis approach to produce the minimal protective epitope of diverse 
oligosaccharides resembling the CPS of different serotypes. S.pneumoniae serotype 3, although 
included in the commercial vaccines, has shown atypical immunogenicity. It is attributed to the 
high CPS expression by the bacteria and to a weakened booster response leading to the 
incapability of vaccinated individuals to mount an immune response after booster immunization 
(212). Thus, serotype 3 has still been one of the most prevalent serotypes. To improve the 
immunogenic properties of ST3, synthetic antigenic structures based on antibody binding 
specificities were designed and synthesized (104). The medicinal chemistry approach for 
creating glycoconjugate vaccines has helped to improve the stability and immunogenicity of 
synthetic vaccine candidates for several serotypes and has increased the production of specific 
protective antibodies against different pathogens (90, 98, 213).  
Synthetic tetrasaccharide based on S.pneumoniae serotype 3 (ST3) CPS repeating units have 
been conjugated to a CRM197 carrier protein and characterized as immunogenic in a mouse 
model. However, the protection had to be improved (104). Serotype 3 was chosen to illustrate 
the principle of proper optimization of variable aspects of vaccine formulation, such as dosage, 
adjuvant, and carrier protein. Understanding the most important aspects of vaccine preparation 
helps to obtain a better immune response to semi-synthetic vaccine candidates and protection 
against pneumococcal disease.  
No information on the optimal dosage of oligosaccharide antigen was available previously, I 
starte  my work by est blishing the best v ccine qu ntity. The  mount of 2.2 µg of n ïve CPS is 
used in commercial Prevnar13
®
 vaccine. However, taking into account the impurities of the 
isolated CPS and the size of the mouse model the amount of synthetic oligosaccharide for animal 
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study can be reduced. I proved that the amount of synthetic antigen can be significantly 
decreased while maintaining sufficient protection shown by in-vitro opsonophagocytic killing 
 ss y. In  efi nce of the gener l notion “the more, the better”, the higher  ose  i  not improve 
the protective effect of immunization but could even diminish the final success of the 
vaccination. However, with the very low amount of antigen, the immune response was delayed 
and an additional boost was needed. For my subsequent study, I decided to follow the best dose 
of the ST3-tetrasaccharide CRM197 conjugate equal to 0.4 µg of synthetic ST3-tetrasaccharide. 
The data is relevant only for the mouse model and it has to be evaluated in clinical studies for 
human use. Nevertheless, utilizing highly pure synthetic oligosaccharides in precisely optimized 
dosages is one of the fundamental aspects for successful vaccination. 
Serotype replacement is a major issue in the case of glycoconjugate vaccines, that has prompted 
big efforts to develop a universal vaccine. The usage of conserved membrane proteins has been 
investigated. Unfortunately, as a bacteria capsule is the first target for the immune system, 
bacterial proteins cannot provide sufficient protection against infection. Therefore, combining 
the approach of using the synthetic oligosaccharide from the capsules of the most prevalent 
serotypes in conjugation to conserve bacterial protein has been a goal of my study. The carrier 
protein derived from S.pneumoanie c n serve  s “ ouble- ction bullet”, being both   c rrier 
essential for glycan presentation and an additional vaccine antigen providing broader protection, 
so-called "additional valency". Hence, ST3-tetrasaccharide was conjugated to pneumolysin and 
PspA protein. Immunization with ST3-pneumolysin glycoconjugate triggered the production of 
protective anti-pneumolysin and anti-carbohydrate antibodies. Neutralizing antibodies against 
protein inhibited the hemolysis of human red blood cell by whole bacteria cell lysate and 
prevented alveolar epithelial cell permeability in vitro. The in-vivo model showed that ST3-
tetrasaccharide Pneumolysin conjugates decrease the bacteria load in blood and lungs as well as 
reduce the disease severity in mice challenged with S.pneumoniae serotype 3. Additionally, nasal 
immunization with ST3-tetrasaccharide and ST2-hexasaccharide conjugated to pneumolysin and 
PspA inhibited colonization of the nasopharynx after infection with S.pneumoniae serotype 2. I 
was able to prove for the first time that the semi-synthetic oligosaccharide vaccine, utilizing 
conserved proteins pneumolysin and PspA, acts as a double-action bullet by triggering both local 
protection against bacteria colonization and systemic defense by the antibody-mediated 
opsonophagocytic killing of the bacteria during the infection. 
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The use of conservative protein needs to be further investigated. Combining different bacteria 
serotypes and various carrier proteins to extend vaccine protection will be the next step. 
Employing a chimeric protein, e.g. a combination of PspA and PspC for glycoconjugate vaccine 
seems to be also very attractive approach towards broadening a vaccine spectrum. Furthermore, 
investigating the differences in antigen recognition and presentation based on the carrier protein 
will be the question to answer.  
An adjuvant is employed in vaccines to help to create a stronger and more efficient immune 
response and provide the protection from the disease. Therefore, the adjuvant is an essential part 
of a vaccine. Several adjuvants characterized by various mechanisms and different immune 
profile (cell-mediated or humoral and T-helper 1 or T-helper 2 (Th1/Th2) immune responses) are 
currently used (113, 214). The adjuvant formulation influence the magnitude of the immune 
response within the time course and the functional activity of the antibody response upon 
vaccination with ST3-tetrasaccharide CRM197 conjugate vaccine was tested. In order to 
improve the immunogenicity of semi-synthetic ST3-glycoconjugates, I used several 
commercially available adjuvants and incorporated them into biodegradable poly-lactic-acid 
(PLA) microparticles. This approach allowed for the physical combination of adjuvants and 
antigens, and it ensured the targeted uptake of the vaccine by professional phagocytes. Screening 
experiments in mice yielded promising results for agonists of TLR7/8, namely resimiquimod 
(R848) and bacterial RNA, as well as MPLA, a TRIF-biased TLR4 agonist used in several 
commercial vaccines. However, the OPKA results indicated that the RQ-848 and MF59
TM 
are 
the best candidates for the formulation of the ST3-tetrasaccharide CRM197 conjugated vaccine. 
No correlation was observed between antibody titer and opsonophagocytic protective activity in 
groups immunized with ST3-tetrasaccharide CRM197 conjugate and the different adjuvant 
formulation. A detailed investigation of the antibody has to be performed to fully understand the 
vaccine formulation effect generated after immunization as their avidity and character of 
immunocomplexes formed.  
Antibody repertoires displayed by mice differ from other mammals, including humans (215), and 
species-specific variations of the immune response to glycan antigen have been observed (67). 
Pigs are very similar to humans in terms of anatomy, immunology, and physiology, and have 
been described as suitable models for different human infectious disease (206) as well as vaccine 
development (199). Thus, piglets were chosen as an animal model to evaluate the 
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immunogenicity of semi-synthetic ST3-tetrasaccharide CRM197 and pneumolysin conjugated 
vaccines. The study provides the first evidence for the immunogenicity of the synthetic 
glycoconjugate vaccine in a swine model. The generated antibodies were able to kill 
pneumococci and neutralize the toxic effect of pneumolysin in-vitro. However, the protective 
activity of the glycoconjugate vaccines in the swine in-vivo infection model has to be further 
investigated. I was also able to prove the involvement of T cells in response to semi-synthetic 
carbohydrate conjugated vaccine as well as the specific carbohydrate T cells subpopulation, 
namely Tcarbs. The successful outcome of the study facilitates the possibility of advancing the 
ST3-tetrasaccharide conjugate vaccine for human clinical trial and opens new opportunities in a 
field of synthetic carbohydrate vaccine research for veterinary purposes.  
In summary, I combined a series of innovations, which will not only enhance the efficacy and 
applicability of glycoconjugate vaccines but will also help to further clarify the principles of 
anti-carbohydrate- and anti-bacterial immunity. Therefore, my thesis work will open the road for 
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